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General introduction
The concept of the Developmental Origins of Health and Disease postulates that early de-
velopmental events shape our future health and well-being because our organs and its func-
tions undergo programming during embryonic and fetal life 1. The brain is one of the organs 
that starts developing soon after conception. Brain development is complexly regulated by 
neurotransmitters and hormones, such as thyroid hormone, which is produced by the thyroid 
gland positioned in the front of the neck 2. The fetus is highly dependent on the placental 
transfer of thyroid hormone from the mother before mid-gestation, because the fetus is not 
able to produce sufficient amounts of thyroid hormone itself yet 3. Before the fetal thyroid 
gland is fully functional, the brain is already expressing nuclear thyroid hormone receptors, 
which suggests a prominent role of thyroid hormone for brain development 2. Exposure of 
the fetus to insufficient concentrations of thyroid hormone may disturb brain developmental 
processes such as the migration, the proliferation, and the differentiation of neuronal cells 4,5. 
An impressive example of the importance of thyroid hormone for fetal brain development is 
cretinism. Individuals with this severe condition suffered from intellectual disability, hearing 
and speech problems, disorders of stance and gait, hypothyroidism, and/or stunted growth. 
A high rate of mothers that gave birth to cretins also had abnormal thyroid enlargement, so 
called goiter, which made it likely that these women had a malfunctioning thyroid gland 6.
“Goiter is a disease which, when once acquired and not cured, can be transmitted 
even to the third and fourth generation of posterity, therefore people with this disease 
should not be permitted to indulge in parenthood” – Quote from the Boston Medical 
Surgical Journal from 1918 7.
Diffuse goiter can develop when the thyroid hormone concentration in the circulation is too 
low. This low concentration is “sensed” by the hypothalamus, which subsequently increases 
the thyroid-releasing hormone (TRH) production. TRH acts on the thyrotrophic cells of the 
anterior lobe of the pituitary gland and stimulates the secretion of thyroid stimulating hor-
mone (TSH). High stimulation of the thyroid by TSH can cause the thyroid to grow with the 
goal to restore normal concentrations of thyroid hormone in the circulation. When TSH binds 
to the TSH receptor on thyroid follicular cells, the thyroid gland will synthesize and secrete 
two types of thyroid hormones: thyroxine (T4) and the biologically active triiodothyronine 
(T3). T4 and T3 circulate around in serum either bound to thyroid transport proteins or in 
free form (FT4 and FT3) and T3 exerts thyroid hormone action by further binding to nuclear 
receptors in target organs. Once the thyroid hormone concentration in the circulation reaches 
normal values, the release of both TRH and TSH will be inhibited. This way, a homeostatic 
balance of thyroid hormone concentrations in serum is reached in healthy persons.
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Research from the 19th and 20th century revealed that iodine is an important trace element 
required for the production of thyroid hormones 8. Historically, goiter was more prevalent in 
areas where drinking water had a low concentration of iodine. Hence, low iodine intake was 
identified as the cause of goiter. Because of this relationship, the role of iodine deficiency in 
the etiology of endemic cretinism was investigated. For example, a double blinded controlled 
trial, in which families were randomized either to a placebo or iodine treatment, found that 
the prevalence of goiter and cretinism was lower in those families that received an injection 
of iodized oil 9. However, timing of treatment mattered. Some women that were treated in the 
third trimester gave birth to a cretin, while no cretins were born to mothers treated before or 
in early pregnancy. Thyroid dysfunction in children with cretinism could also be reversed by 
iodine supplementation 10. The hypothesis therefore is that endemic cretinism is caused by 
an inadequate thyroid hormone transfer from mother to fetus during pregnancy, that iodine 
deficiency is an important risk factor, and that timely iodine intervention can prevent severe 
iodine deficiency disorders in the child 11. For this reason, thyroid function tests are performed 
in early pregnancy and recommendations were made for higher iodine intake in pregnancy, 
and for routinely checking the thyroid axis in all newborns.
“On a worldwide basis, iodine deficiency is the single most important preventable 
cause of brain damage” – ICCIDD/UNICEF/WHO 12
Thyroid dysfunction in pregnancy is relatively common due to a change in thyroid physiol-
ogy, especially in case of iodine deficiency 13. The current guidelines recommend treating 
pregnant women with overt hypothyroidism, which is characterized by a high TSH and a low 
FT4 concentration, with levothyroxine 14. This recommendation is based on evidence from 
observational studies that revealed associations of overt hypothyroidism with severe preg-
nancy complications 15,16, including fetal death. Untreated overt hypothyroidism has also been 
associated with a 7-point lower IQ score in the offspring 17. Universal screening and treatment 
of women with milder forms of thyroid dysfunction is, however, not routinely performed. 
Subclinical hypothyroidism, characterized by high TSH and a normal FT4 concentration, has 
been associated with adverse pregnancy outcomes in thyroid peroxidase positive women; see 
an overview of studies elsewhere 14. Depending on the TSH concentration and/or the thyroid 
peroxidase antibody (TPOAb) status, treatment is considered 14,18. The evidence for an as-
sociation of subclinical hypothyroidism with child neurodevelopmental outcomes is inconsis-
tent. By contrast, isolated hypothyroxinemia, characterized by a low FT4 and a normal TSH 
concentration, has been associated with a variety of adverse neurodevelopmental outcomes, 
such as lower IQ or a delay in cognitive functioning 19–23, worse psychomotor development 
21,24, schizophrenia 25, autism spectrum disorder or autistic traits 26–28, and attention-deficit 
hyperactivity disorder (ADHD) or related symptoms 17,28–30. Despite the evidence from ob-
servational studies, universal screening to detect low FT4 concentrations in pregnant women 
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and treatment is not recommended 14, because the existing randomized controlled trials failed 
to show beneficial effects of levothyroxine treatment of women with hypothyroxinemia on 
cognitive development of the offspring 31,32. An observational study embedded in the Gen-
eration R cohort, which involves an iodine-sufficient population, showed in addition to a 
low maternal FT4 concentration, that also a high FT4 concentration during pregnancy was 
associated with a lower child IQ score and lower gray matter volume and cortex volume in the 
offspring 19. Though this is in line with findings from animal studies 33–38, it has not yet been 
replicated in other cohort studies and it is not known whether associations differ in countries 
with a different iodine status.
Reference ranges of thyroid function tests are established to identify women with ab-
normal thyroid function. The international thyroid guidelines advise that reference ranges 
should be based on the 2.5th and 97.5th percentile of the population with an optimal iodine 
intake 14. However, there is insufficient evidence to determine whether these reference ranges 
are affected by iodine status. Iodine nutrition in populations is most frequently assessed by 
a measurement of the urinary iodine concentration (UIC) in a single spot urine sample. Ac-
cording to the classification of the World Health Organization, a population with a median 
UIC below 150 µg/L is considered iodine deficient. Mild-to-moderate iodine deficiency 
during pregnancy is still a common problem 39,40 and has been associated with lower scores 
of verbal IQ, reading accuracy, and reading comprehension 41, poorer spelling 42,43, reduced 
receptive and expressive language skills 44, worse executive function 45, internalizing and 
externalizing problems 46, poorer fine mother skills 46, and higher ADHD symptom scores 47. 
However, not all prospective birth cohort studies show an association between UIC and child 
neurodevelopmental outcomes 48–50. Differences in results between studies might be related 
to methodological differences (e.g., selected reference group and available data on confound-
ers), the age of assessment of the neurodevelopmental outcome of interest, the timing of the 
iodine measurements, and the severity of iodine deficiency in the population. What remains 
unknown is whether the association of maternal iodine status with child neurodevelopmental 
outcomes varies during different periods of gestation and what the consequences of iodine 
excess are for child neurodevelopment.
Objectives
The aims of this thesis are:
1. To explore the determinants of iodine status during early pregnancy in populations of 
differing iodine status.
2. To assess the association between maternal iodine status and maternal thyroid function 
during pregnancy in a mild-to-moderate iodine deficient population and to determine 
variation in thyroid function reference ranges according to iodine status.
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3. To assess the association maternal iodine status with childhood IQ, autistic traits, and 
ADHD symptoms in populations of differing iodine status.
4. To assess the association of maternal thyroid function with childhood IQ, autistic traits, 
and ADHD symptoms in populations of differing iodine status.
Setting
Most studies presented in this thesis are embedded within the EUthyroid project entitled 
“Towards the elimination of iodine deficiency and preventable thyroid-related diseases in 
Europe”. For this three-year Horizon 2020 project, which started in June 2015, data were 
harmonized and combined from three major European prospective birth cohort studies: 
INfancia y Medio Ambiente (INMA, Spain), Generation R (the Netherlands), and Avon Lon-
gitudinal Study of Parents and Children (ALSPAC, United Kingdom). These cohort studies 
had detailed information on maternal iodine status, thyroid function during pregnancy, and 
child neurodevelopmental outcomes and were selected because of the differing iodine status 
in these populations, ranging from iodine sufficiency to mild-to-moderate iodine deficiency. 
Not part of the EUthyroid project was the Swedish Environmental Longitudinal, Mother and 
child, Asthma and allergy (SELMA) cohort. This cohort study had information on maternal 
iodine status and more extensive data on thyroid function tests during pregnancy (e.g., TSH, 
(F)T4, (F)T3, and markers of thyroid autoimmunity) than INMA, Generation R, or ALSPAC. 
Data on child neurodevelopmental outcomes in SELMA could however not be used. These 
four cohort studies were designed to study the role of early environmental or genetic causes of 
normal and abnormal development from fetal life onwards. Combining individual-participant 
data of multiple cohorts permits hypothesis testing on a larger scale, may overcome difficul-
ties associated with individual studies (e.g., low statistical power, range restriction), and may 
increase our confidence in the generalization of the results when it replicates the findings of 
individual studies. Hence, this thesis may provide an opportunity to generate a trustworthy 
foundation for conclusions and scientific progress.
INMA
INMA is a network of birth cohorts in Spain of which three birth cohorts were included in 
this thesis: Valencia, Sabadell, and Gipuzkoa 51. Pregnant women were recruited in Valencia 
between November 2003 to June 2005, in Sabadell from July 2004 to July 2006, and in 
Gipuzkoa from April 2006 to January 2008 during the first pre-natal visit. INMA was used 
for the analysis of the first, third, and fourth aim of this thesis.
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Generation R
The Generation R study is a population-based birth cohort study in Rotterdam, the Neth-
erlands 52. Pregnant women with a delivery date from April 2002 until January 2006 were 
eligible for participation. Enrollment was possible throughout gestation. Generation R was 
used for the analysis of the first, third, and fourth aim of this thesis.
ALSPAC
ALSPAC is a population-based birth cohort in Avon, United Kingdom 53,54. Pregnant women 
with an expected date of delivery between April 1991 and December 1992 were eligible for 
inclusion (phase I). After pregnancy, additional recruitment phases (II and III) took place to 
enroll those who would have fitted the original eligibility criteria. All mother-child pairs that 
were recruited during pregnancy were used for the analysis of the first, third, and fourth aim 
of this thesis.
SELMA
The SELMA study is a population-based longitudinal prospective cohort study in the county 
of Värmland, Sweden 55. Pregnant women were recruited from September 2007 to March 
2010 during the first prenatal visit at an antenatal care center around week 10 of pregnancy. 
Women beyond week 22 in their pregnancy were excluded from the SELMA study. This 
study was only used for the second aim of this thesis.
Outline
Chapter 2 explores the determinants of iodine status in populations of differing iodine status. 
Chapter 3 focuses on the association between maternal iodine status and maternal thyroid 
hormone concentrations in a mild-to-moderate iodine deficient pregnant population from the 
SELMA study and variation in reference ranges by iodine status is investigated. In chapter 4, 
we study the associations of maternal iodine status during pregnancy with child neurodevel-
opmental outcomes. Chapter 4.1 describes the association of maternal iodine status with child 
IQ, while chapter 4.2 evaluates the association of maternal iodine status with child ADHD 
and autistic traits. Chapter 5 evaluates the association of maternal thyroid function with child 
neurodevelopmental outcomes. In chapter 5.1, we examine the association of maternal thyroid 
function with child IQ and autistic traits. In chapter 5.2, the association of maternal thyroid 
function with child ADHD is assessed. In chapter 6, the main findings are summarized, and 
the clinical implications and direction for future research are described. Finally, a summary 
of this thesis is included in chapter 7.
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Abstract
Purpose: As a component of thyroid hormones, adequate iodine intake is essential during 
pregnancy for fetal neurodevelopment. Across Europe, iodine deficiency is common in preg-
nancy, but data are lacking on the predictors of iodine status at this life stage. We, therefore, 
aimed to explore determinants of iodine status during pregnancy in three European popula-
tions of differing iodine status.
Methods: Data were from 6566 pregnant women from three prospective population-based 
birth cohorts from the United Kingdom (ALSPAC, n=2852), Spain (INMA, n=1460), and 
the Netherlands (Generation R, n=2254). Urinary iodine-to-creatinine ratio (UI/Creat, µg/g) 
was measured in spot-urine samples in pregnancy (≤18-weeks gestation). Maternal dietary 
intake, categorised by food groups (g/day), was estimated from food-frequency question-
naires (FFQs). Multivariable regression models used dietary variables (energy-adjusted) and 
maternal characteristics as predictors of iodine status.
Results: Median UI/Creat in pregnant women of ALSPAC, INMA, and Generation R was 
121, 151, and 210 µg/g, respectively. Maternal age was positively associated with UI/Creat in 
all cohorts (P<0.001), while UI/Creat varied by ethnicity only in Generation R (P<0.05). Of 
the dietary predictors, intake of milk and dairy products (per 100 g/day) was positively asso-
ciated with UI/Creat in all cohorts [ALSPAC (B=3.73, P<0.0001); INMA (B=6.92, P=0.002); 
Generation R (B=2.34, P=0.001)]. Cohort-specific dietary determinants positively associated 
with UI/Creat included fish and shellfish in ALSPAC and INMA, and eggs and cereal/cereal 
products in Generation R.
Conclusions: The cohort-specific dietary determinants probably reflect not only dietary 
habits but iodine-fortification policies; hence public-health interventions to improve iodine 
intake in pregnancy need to be country-specific.
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Introduction
Iodine is an essential component of the thyroid hormones which are important for optimal 
fetal and early postnatal neurodevelopment 1,2. Mild-to-moderate maternal iodine deficiency 
in early pregnancy has been associated with suboptimal offspring cognitive outcomes 3–7. The 
early stages of pregnancy mark the beginning of crucial fetal brain development processes 
such as neuron proliferation, migration, and differentiation 8. Though these early processes 
are thyroid hormone-dependent, the fetal thyroid gland is not fully functional until 18-20 
weeks, highlighting the importance of thyroid hormone supply from the mother. In this critical 
early period, the mother, therefore, needs sufficient iodine intake to maintain optimal thyroid 
function 1. As a result of the increased demand for thyroid hormones and other physiological 
changes associated with pregnancy, pregnant women have a higher iodine requirement than 
the general population, putting them at greater risk of deficiency 9,10.
As more than 90% of the dietary iodine absorbed is excreted by the kidneys, urinary iodine 
concentration (UIC) is considered to be a good estimate of recent iodine intake at the popula-
tion level 11. In pregnant populations, iodine sufficiency is defined by a median UIC in the 
range of 150-249 µg/L, corresponding to the iodine intake of 250 µg/day recommended by 
the World Health Organisation (WHO) 12.
Determining the main food sources of iodine in pregnancy is essential, so that pregnant 
women can be given information on how to achieve adequate iodine nutrition. Although 
good food sources of iodine, such as milk, eggs, fish, and, in some countries, iodised salt, are 
well-known, the consumption patterns of these foods vary between and within populations, 
as does their iodine content (i.e., as a result of seasonal variation, agricultural practices, and 
differences in iodine content of soil and water) 13,14. Consequently, some variation in the 
importance of different iodine food sources to population iodine status is expected between 
countries; hence universal dietary recommendations to increase iodine intake are unlikely to 
be appropriate.
Considering the negative consequences of iodine deficiency in pregnancy and the fact that 
many pregnant women worldwide are still iodine-deficient 15, achieving adequate iodine status 
in the pregnant population is of public-health importance. Data are, however, lacking on the 
determinants of iodine status in pregnancy in both deficient and sufficient areas; knowledge 
of such factors would help to identify women likely to have low iodine status.
This study aimed to explore the determinants of iodine status during early pregnancy 
in three European populations of differing iodine status. The objectives of the study were: 
(i) to establish whether iodine status during early pregnancy is associated with maternal 
socio-demographic, anthropometric, lifestyle factors, and pregnancy characteristics; (ii) to 
determine how maternal iodine status is influenced by dietary intake during pregnancy; (iii) 
to identify similarities and differences in the main determinants of iodine status between 
deficient and sufficient pregnant populations.
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Methods
Study population
Data from three prospective population-based birth cohorts were used: (i) the Avon Lon-
gitudinal Study of Parents and Children (ALSPAC) in the United Kingdom (UK) 16,17; (ii) 
Generation R in the Netherlands 18; and (iii) INfancia y Medio Ambiente (INMA) in Spain 
19. In ALSPAC, 14541 pregnant women living in the former Avon area in the South West of 
England, with an expected delivery date between 1st April 1991 and 31st December 1992, 
were recruited. The study website contains details of all the data that are available through a 
fully searchable data dictionary and variable search tool 20. In Generation R, 9778 mothers 
residing in Rotterdam with an expected delivery date from April 2002 to January 2006 were 
enrolled in the study. In total, 2150 pregnant women were recruited as part of the INMA 
Project from three regions in Spain (Valencia, Sabadell, and Gipuzkoa), in the period of 
November 2003 to January 2008.
Ethics
Ethical approval was obtained prior to recruitment from a number of bodies: the ALSPAC 
Ethics and Law Committee and the Local Research Ethics Committees (ALSPAC), the Medi-
cal Ethical Committee of the Erasmus Medical Centre (Generation R), the Ethical Committee 
of the Municipal Institute of Medical Investigation and the ethical committees of the hospitals 
involved in the studies (INMA). All participating women provided informed consent.
Selection criteria for the current study
Women were selected for the current study if they had at least one pre-existing measure of 
urinary iodine concentration in pregnancy 4,21,22 or urine samples available for iodine measure-
ment, provided that the child had a measure of intelligence quotient (IQ) for ALSPAC and 
Generation R. In INMA, iodine was measured in all women with additional urine samples 
available, irrespective of child-IQ data.
Women with multiple pregnancies, in-vitro fertilisation, known thyroid disease, and/or use 
of thyroid-related medication were excluded (Fig. 1). We restricted analyses to measures 
from early pregnancy, the most critical time for iodine-dependent brain development 2,23; 
hence, for this study, only samples collected ≤ 18 weeks’ gestation were included.
Iodine measurements
Urinary iodine concentration (UIC, µg/L) was measured in spot-urine samples collected 
at a median (25-75th percentile) gestational age of 11.0 (8.0-15.0) weeks in ALSPAC, 13.1 
(12.1-14.6) weeks in Generation R, and 13.0 (12.4-13.9) weeks in INMA. Gestational week 
was established using ultrasound examination (Generation R and INMA) or the date of the 
last menstrual period (ALSPAC). To adjust for variation in intra- and inter-individual daily 
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hydration status 24–27, iodine concentration was corrected by dividing by urinary creatinine 
concentration to give the iodine-to-creatinine ratio (UI/Creat, µg/g). Correcting UIC by use 
of urinary creatinine concentration reduces intra-individual variation 25, especially in cohorts 
of the same sex and age-range [i.e., our cohorts were all women of childbearing age (15-44 
years)]. The iodine-to-creatinine ratio has previously been used in all three cohorts 4,7,21.
 
 
Enrolled during 
pregnancy
Total N=25571
ALSPAC (n=14541)
Generation R (n=8880)
INMA (n=2150)
Data unavailable: 
Urinary iodine and creatinine concentration data 
unavailable
Total N=17762
ALSPAC (n=11036)
Generation R (n=6468)
INMA (n=258)
UI/Creat measured
Total N=7809
ALSPAC (n=3505)
Generation R (n=2412)
INMA (n=1892)
UI/Creat ≤ 18 weeks
Total N=6566
ALSPAC (n=2852)
Generation R (n=2254)
INMA (n=1460)
UI/Creat ≤ 18 weeks 
+ FFQ data
Total N=5736
ALSPAC (n=2710)
Generation R (n=1580)
INMA (n=1446)
Exclusions: 
IVF Total N=12
(ALSPAC, n=0; Generation R, n=12; INMA, n=0)
Multiple pregnancy Total N=29
(ALSPAC, n=0; Generation R, n=29; INMA, n=0)
Thyroid disease and/or thyroid-related medication 
use Total N=140
(ALSPAC, n=21; Generation R, n=34; INMA, n=85)
Contaminated samples1 Total N=362
(ALSPAC: UIC > 500 µg/L or UI/Creat > 700 µg/g, 
n=362; Generation R, N/A; INMA, N/A)
UI/Creat available
Total N=7269
ALSPAC (n=3122)
Generation R (n=2340)
INMA (n=1807)
Fig. 1 Flow chart of the study population selection.
a  Urine samples with UIC > 500 µg/L or UI/Creat > 700 µg/g were excluded only from the ALSPAC cohort, 
as there was a concern about contamination by the use of iodine-containing test strips (see methods). There 
was no such concern in Generation R and INMA; therefore, the exclusion criteria were not applicable to 
urine samples from these two cohorts. FFQ, food frequency questionnaire; IVF, in-vitro fertilisation; N/A, 
not applicable; UI/Creat, urinary iodine-to-creatinine ratio; UIC, urinary iodine concentration.
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In each cohort, we reported both the median (25-75th percentile) UIC (µg/L) and UI/Creat 
(µg/g). The percentage with UI/Creat <150 µg/g was also reported; this cut-off was informed 
by the WHO threshold for adequacy in pregnancy (a median UIC ≥150 µg/L) 12 and, when 
corrected for creatinine concentration, has been used in previous research 4,6,7.
Laboratory analysis
Urinary creatinine concentration was determined by the Jaffe rate method in all cohorts. Uri-
nary iodine concentration was determined as previously described in detail 4,22; a brief 
description follows.
ALSPAC: urinary iodine concentration was measured as 127I at the Trace Element Unit, 
Southampton General Hospital, on a dynamic reaction cell inductively coupled plasma 
mass spectrometer (NexION 300D Perkin-Elmer, Beaconsfield). The accuracy of the results 
was verified using the certified reference material (CRM) Seronorm urine Levels 1 and 2 
(Nycomed, Norway), and accuracy was also monitored by measurement of EQUIP samples 
at regular intervals throughout the analysis. Within-run precision gave a relative standard 
deviation (RSD) of 0.8% at 42 µg/L, 2.5% at 84 µg/L, 0.6% at 149 µg/L, and 2.0% at 297 
µg/L. Between-run precision was 8.7% RSD at 42 µg/L, 6.5% at 84 µg/L, 7.2% at 149 µg/L, 
and 6.8% at 297 µg/L.
Generation R: urinary iodine concentration was measured in Radboud University Medical 
Centre, Nijmegen, the Netherlands, by the Sandell-Kolthoff method. Iodine calibration was 
performed using the CRM Seronorm urine Levels 1 and 2 (Nycomed, Norway) and four 
EQUIP samples that were certified for urinary iodine concentration (Centers for Disease 
Control and Prevention, USA). At a level of 216 µg/L, the within-assay precision was 5.1% 
RSD and the between-assay precision was 14.3% RSD (n= 30).
INMA: urinary iodine concentration was measured at the Public Health Laboratory Stan-
dards, Basque Government Department of Health, Spain (Acreditation LE/1108 with ISO 
15189 for Clinical Laboratories, National Acreditation Entity), using a paired-ion reversed-
phase, high-performance liquid chromatography with electrochemical detection at a silver-
working electrode (Waters Chromatography, Milford, MA). The accuracy of the results was 
verified using the CRM Seronorm urine Levels 1 and 2 (Nycomed, Norway) and internal 
quality control samples. Within-run precision was 4.5% RSD at 50 μg/L, 3.2% at 100 μg/L, 
and 2.0% at 300 μg/L. Between-run precision was 7.9% RSD at 50 μg/L, 3.5% at 100 μg/L, 
and 2.5 % at 300 μg/L.
In ALSPAC, there was concern that some urine samples had been contaminated by the use 
of iodine-containing test strips 28, and therefore, samples with UIC >500 µg/L and/or UI/Creat 
>700 µg/g were excluded (n=412, 11.8%). These cut-offs were based on previous information 
from ALSPAC and from other studies of UK pregnant women 4,29,30. Some ALSPAC women 
had multiple urine samples and in cases, where one sample was contaminated, the results 
from the next available uncontaminated sample were used (n=50).
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Dietary assessment
Maternal diet in all cohorts was assessed using a food-frequency questionnaire (FFQ). This 
was administered in late pregnancy in ALSPAC (at 32 weeks) and in early pregnancy in 
Generation R and INMA (at the same time as urine sampling). The FFQ was unquantified 
in ALSPAC, but was semi-quantitative (SFFQ) in Generation R and INMA. The FFQ was 
self-administered in ALSPAC and Generation R, and administered by trained interviewers in 
INMA.
ALSPAC: Detailed information about the design of the questionnaire can be found else-
where 31,32. Briefly, women were asked to indicate how frequently “nowadays” they consumed 
43 food groups and individual foods with five predefined frequency categories, ranging from 
“never or rarely” to “more than once a day”. Portion sizes were not included in the question-
naire.
Generation R: SFFQ in Generation R represented an adapted version of a validated SFFQ 
in elderly subjects 33. In summary, it contained a list of 293 foods and asked about frequency 
of consumption in the past three months, mostly, therefore, reflecting the first trimester. Ques-
tions about portion size, estimated using food photographs or Dutch household measures, 
methods of preparation, and additions to foods were also included 3,34. The food list had 
previously been reduced to 17 main food groups 35, based on the European Prospective Inves-
tigation into Cancer and Nutrition SOFT classification (EPIC-SOFT) 36.
INMA: SFFQ was based on an expanded adaptation of a 61-item SFFQ by Willet and 
colleagues 37 that was developed and validated 38,39. To summarise, women were asked how 
often, on average, they had consumed a specified standard portion of 100 food items in early 
pregnancy (since their last menstrual period until the time of the interview at ~12 weeks), 
using nine frequency categories, ranging from “never or less than once a month” to “six or 
more times per day”.
For the current study, in each cohort, food intake (g/day) was calculated by multiplying 
the frequency of consumption by an average standard portion (for the ALSPAC FFQ) or 
a specified portion (for the SFFQ in Generation R and INMA) of that food. Foods were 
then classified into food groups and the amounts of individual food items consumed were 
summed accordingly. To facilitate comparison between cohorts, the classification of food 
groups used in Generation 36 was used as a template. This required the formation of new 
food groups in ALSPAC, while the pre-existing food groups were used in Generation R and 
INMA, with some minor modifications to make them comparable. The definitions of food 
groups in the individual cohorts are shown in Supplemental Table 1. Separate information 
about the consumption of table salt and use of iodine-fortified table salt was collected only 
in the INMA cohort.
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Iodine supplement use
Detailed data on the use of potassium iodide and/or iodine-containing multivitamin/mineral 
supplements during pregnancy were collected only in INMA. For this analysis, we used 
data on iodine supplements from pre-pregnancy until the end of the first trimester, expressed 
as mean iodine intake from supplements. In our ALSPAC sample, only two women took a 
kelp supplement and one took a potassium-iodide supplement; they were excluded from the 
analysis. Data on the use of iodine-containing multivitamin supplements from preconception 
until enrolment (at time of urine sample collection) were available only for a sub-set of our 
Generation R sample (n=381); women who took an iodine-containing supplement (n=345) 
were excluded in sensitivity analyses.
Maternal and pregnancy characteristics
Information on pregnancy characteristics, anthropometrics, socio-demographic, and environ-
mental exposures was collected by means of questionnaires or extracted from obstetric medi-
cal records. Discrete variables were re-categorised, where possible, to facilitate comparisons 
between cohorts. Exposure factors in these analyses can be classified into three groups: (i) 
maternal factors: maternal age (ALSPAC: at last menstrual period; Generation R, INMA: at 
urine collection); pre-pregnancy body mass index (BMI, kg/m2); ethnicity (ALSPAC: White/
non-white; Generation R: Dutch/non-Dutch, where non-Dutch = Indonesian, Cape Verdean, 
Moroccan, Dutch Antilles, Surinamese, Turkish, other non-Western, Asian, other Western; 
INMA: Spanish/non-Spanish, where non-Spanish = Latin American, European, others); 
parity (zero, one, two or more); smoking status (never smoked, smoked initially or until 
pregnancy was known, continued smoking); and alcohol consumption during pregnancy (yes/
no); (ii) markers of socio-economic status: education level (ALSPAC: low = no qualification, 
certificate of secondary education, or vocational; medium = O level or A level; high = a 
degree; Generation R: low = no education or primary; medium = secondary phase 1 and 2; 
high = higher phase 1 and 2; INMA: low = no education, unfinished primary, or primary; 
medium = secondary; high = university degree); monthly net household income (Generation 
R: low <€1200, medium = €1200-2200, high >€2200); home ownership (ALSPAC: owned/
mortgaged, private/other rented, council rented); crowding index (ALSPAC: ≤1 person per 
room, +1 person per room); family adversity index [ALSPAC: 18-item measure of hardships 
during pregnancy 40, categorised into: no adversities, mild (0-2), severe (≥3) 41]; life event 
score (ALSPAC: exposure to stressful situations during pregnancy); marital status (ALSPAC: 
never married, married, other; Generation R: unmarried/married); and living with father’s 
child/partner (ALSPAC, INMA: yes/no); and (iii) child factors: child’s sex (male/female).
Statistical analyses
To study the associations of maternal characteristics and diet with iodine status, we used 
UI/Creat as a measure of individual iodine status. UI/Creat was not normally distributed 
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but right-skewed. To meet parametric-test assumptions, UI/Creat was transformed using the 
natural logarithm. Outliers were assessed by visual inspection of box-plots. We assessed non-
linearity of the associations of each continuous independent variable with UI/Creat by adding 
their squared term to the regression models, and also by plotting each potential determinant 
variable against UI/Creat and comparing the fit (R2) of a linear vs. quadratic function through 
the data points.
Multiple linear regression models with log-transformed UI/Creat as the dependent variable 
were performed for each cohort using two models: Model 1 included maternal and pregnancy 
factors, markers of socio-economic status and child’s sex as independent variables; Model 2 
included variables from Model 1 plus dietary intake of food groups.
Analyses of the dietary influences on UI/Creat (Model 2) were also adjusted for estimated 
energy intake (kcal/day). Effect estimates (unstandardised B coefficients) for food groups 
were expressed per 100 g and also per portion (g). The increase in the geometric mean of UI/
Creat per 100 g and per portion increase in intake and its 95% confidence interval (CI) were 
calculated by back-transformation [exponentiation (EXP)] of the effect estimates and 95% 
CIs from logarithmic scale. The following formulae were used for the back-transformations: 
effect estimate per 100 g = EXP (intercept + B * 100) – EXP (intercept); lower 95% CI = EXP 
[intercept + (B * 100) – (1.96 * standard error of estimate (SEE) *100)] – EXP (intercept); 
and upper 95% CI = EXP [intercept + (B * 100) + (1.96 * SEE * 100)] – EXP (intercept). 
For calculations per portion size, the multiplication by 100 in the formulae is replaced with 
the portion size (g) for each food group accordingly. When calculating the effect estimates 
from Model 2, all categorical covariates were set to their reference group and the continuous 
covariates gestational week, maternal age, BMI, and energy intake were centered to their 
means.
We conducted four types of sensitivity analyses: (i) under-reporting: to account for poten-
tial under-reporting of energy intake in Model 2, in all cohorts, we excluded women with 
energy intakes below the 5th percentile; (ii) iodine supplements: we adjusted Model 2 for 
iodine-supplement use in INMA (as the only cohort with complete iodine-supplement data) 
and excluded iodine-supplement-users in Generation R (as data were available only for a 
sub-set of the sample); (iii) gestational age: as the median gestational week at urine sampling 
was later in INMA and Generation R than in ALSPAC, we performed sensitivity analyses 
to test the associations with iodine status in the first trimester, using samples collected up to 
13 weeks; and (iv) covariate creatinine-adjustment method: since age, BMI, and ethnicity 
are known predictors of urinary creatinine concentration 42 and urinary creatinine can also 
vary during gestation 43, this could result in spurious associations of these variables with the 
ratio of UI/Creat; we, therefore, performed sensitivity analyses for these variables (BMI, age, 
ethnicity, and gestational age) using Model 1 and 2 with the (natural) log-transformed UIC 
(µg/L) unadjusted for creatinine as our dependent variable and added creatinine concentration 
as a separate independent variable to the models. This method has been recommended previ-
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ously 42 and ensures that UIC is adjusted for dilution by creatinine concentration, while the 
associations of the other variables with UIC are independent of urinary creatinine.
All analyses were conducted using multiply-imputed data to account for missing data 
on socio-demographic variables. Multiple imputation was performed using the automatic 
method in SPSS. A total of 20 datasets were generated and analysed using standard multiple 
imputation procedures 44. Detailed information about the imputed variables is provided in the 
Electronic Supplementary Material. Missing FFQ data were not imputed, as diet has a wide 
inter-person variability hence imputation of dietary data would not be sufficiently accurate. 
All statistical analyses were performed with IBM SPSS Statistics version 24.0 (IBM Corp., 
Armonk, NY, USA). Values were considered statistically significant at P<0.05.
Results
Sample characteristics
After exclusions, the final study population comprised 6566 pregnant women: 2852 from 
ALSPAC, 2254 from Generation R, and 1460 from INMA (Fig. 1). Descriptive statistics of 
mothers by cohort are shown in Table 1. Maternal age varied across cohorts, with women in 
ALSPAC having a lower mean ± standard deviation (SD) age than women in INMA [28.7 
(±4.5) vs. 31.4 (±4.1) years, respectively]. Median BMI was within the healthy range in all 
cohorts (Table 1). The majority of mothers defined themselves as White in ALSPAC (98.2%), 
Spanish in INMA (91.8%), while slightly more than half of the women in Generation R said 
they were non-Dutch (51.4%). Most women were nulliparous and non-smokers, with similar 
proportions between cohorts.
Iodine status
The median UI/Creat (25-75th percentile) was 121 (81-193) µg/g in women from the UK 
(62.8% <150 µg/g), 151 (96-255) µg/g in women from Spain (49.5% <150 µg/g), and 210 
(140-303) µg/g in women from the Netherlands (28.8% <150 µg/g) (Table 2).
Association with socio-demographic and lifestyle factors
In multivariable models (adjusted Models 1 and 2), gestational week of urine sample, ma-
ternal age, and BMI were associated with UI/Creat in all three cohorts. Gestational week at 
urine sampling (≤18 weeks) was positively associated with UI/Creat in ALSPAC (B=0.051, 
P<0.0001) but not in the other two cohorts (Table 3). However, in sensitivity analyses re-
stricted to samples collected up to 13 weeks, there was an association of gestational week 
with UI/Creat in all three cohorts (ALSPAC: B=0.029, P<0.001, n=1951; Generation R: 
B=0.031, P=0.049, n=1094; INMA: B=0.079, P=0.045, n=747) with a larger effect size in 
Generation R and INMA than in the analyses up to 18 weeks. In the sensitivity analysis 
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using covariate creatinine-adjustment, the results for the association of gestational week up 
to 18 weeks with UIC did not substantially differ from those with UI/Creat in ALSPAC and 
INMA, while in Generation R, the effect size was higher, reaching statistical significance 
(Supplemental Table 3).
There was a positive association of maternal age with UI/Creat (ALSPAC: B=0.014, 
P<0.0001; Generation R: B=0.018, P<0.0001; INMA: B=0.020, P=0.0001). After further 
adjusting for maternal diet and energy intake estimated from the FFQs (Model 2), the effect 
size of age was attenuated by 16-30% across cohorts, but remained statistically significant 
(Table 3). The positive association with age remained in all cohorts, except in Model 2 for 
ALSPAC, when using the covariate creatinine-adjustment method of UIC (Supplemental 
Table 3).
There was a negative association of BMI with UI/Creat (ALSPAC: B= -0.013, P=0.0001; 
Generation R: B= -0.011, P<0.0001; INMA: B= -0.013, P=0.005), which, after adjustment 
for maternal diet and energy intake remained statistically significant (Table 3, Model 2). 
However, BMI was not associated with UIC (µg/L) with the covariate creatinine-adjustment 
method in Generation R and INMA but remained negatively associated with UIC in ALSPAC, 
though with a lower effect size (Supplemental Table 3).
Cohort-specific socio-demographic and lifestyle factors were identified as determinants 
of iodine status. In Generation R, maternal ethnicity and smoking were associated with UI/
Creat (Table 3). Compared to the Dutch women, Moroccan, Turkish and other non-Western 
women had a higher UI/Creat, whereas Surinamese and those from the Dutch Antilles had a 
lower UI/Creat. Some of these effects were attenuated after accounting for maternal diet in 
Model 2 (Table 3). Similarly to UI/Creat, UIC (with covariate creatinine-adjustment) also dif-
fered by ethnicity; Moroccan, Turkish and other non-Western women still had a significantly 
higher UIC than the Dutch, while the UICs of Surinamese and Dutch Antilles women did 
not significantly differ from those of the Dutch women (Supplemental Table 3). Generation 
R women who reported smoking vs. those who never smoked had a lower UI/Creat, which 
remained statistically significant after adjustment for maternal diet (Table 3, Model 1 and 2). 
In ALSPAC, family adversity index (severe vs. none; B= -0.100, P=0.016), and marital status 
(married vs. never-married; B=0.095, P=0.015) were associated with UI/Creat, even after 
adjusting for maternal diet (Table 3). Results for all predictors included in the multivariable 
models are presented in Supplemental Table 2.
Dietary influences on iodine status
As not all women with urinary iodine measurements before 18 weeks had also completed 
an FFQ, numbers for these analyses were lower for all cohorts (Fig. 1): ALSPAC (n=2710), 
Generation R (n=1580), INMA (n=1446). Descriptive statistics of dietary intakes of food 
groups for pregnant women in each cohort are presented in Supplemental Table 4.
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Table 1 Descriptive statistics a of the study population by cohort.
Sample characteristics ALSPAC(n=2852)
Generation R
(n=2254)
INMA
(n=1460)
Maternal factors
Age b,c (years), mean (±SD) 28.7 (±4.5) 29.9 (±5.0) 31.4 (±4.1)
Pre-pregnancy BMI (kg/m2), median (IQRs) c 22.3 (20.5 - 24.6) 23.5 (21.5 - 26.4) 22.5 (20.8 - 25.0)
Ethnicity d, n (%)
Reference group 2800 (98.2) 1095 (48.6) 1340 (91.8)
Non-white 52 (1.8) N/A N/A
Non-Dutch N/A 1159 (51.4) e N/A
Non-Spanish N/A N/A 120 (8.2)
Parity c, n (%)
0 1354 (47.5) 1279 (56.7) 806 (55.2)
1 965 (33.8) 665 (29.5) 544 (37.3)
≥ 2 533 (18.7) 310 (13.8) 110 (7.5)
Smoking status, n (%)
Never smoked 2169 (76.1) 1671 (74.2) 1020 (69.9)
Stopped smoking 333 (11.7) 211 (9.3) 187 (12.8)
Continued smoking 350 (12.2) 372 (16.5) 253 (17.3)
Alcohol consumption, n (%)
No 1350 (47.4) 1458 (64.7) 1330 (91.1)
Yes 1502 (52.6) 796 (35.3) 130 (8.9)
Markers of socio-economic status
Education level, n (%)
Low 576 (20.2) 247 (11.0) 337 (23.1)
Medium 1780 (62.4) 995 (44.1) 581(39.8)
High 496 (17.4) 1012 (44.9) 542 (37.1)
Net household income (€ per month), n (%)
Low < €1200 N/A 492 (21.8) N/A
Medium €1200-2200 N/A 597 (26.5) N/A
High > €2200 N/A 1165 (51.7) N/A
Home ownership, n (%)
Owned/mortgaged 2425 (85.0) N/A N/A
Private/other rented 236 (8.3) N/A N/A
Council rented 191 (6.7) N/A N/A
Crowding index, n (%)
≤ 1 person per room 2747 (96.3) N/A N/A
+ 1 person per room 105 (3.7) N/A N/A
Family adversity index, n (%)
None 0 1395 (48.9) N/A N/A
Mild 1-2 1124 (39.4) N/A N/A
Severe > 3 333 (11.7) N/A N/A
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Table 1 Descriptive statistics a of the study population by cohort. (continued)
Sample characteristics ALSPAC(n=2852)
Generation R
(n=2254)
INMA
(n=1460)
Life event score, median (IQRs) 3.0 (2.0 - 5.0) N/A N/A
Marital status, n (%)
Never-married 355 (12.5) 1136 (50.4) N/A
Married 2357 (82.6) 1118 (49.6) N/A
Other f 140 (4.9) N/A N/A
Living with a partner, n (%)
Yes 2720 (95.4) N/A 1445 (99.0)
No 132 (4.6) N/A 15 (1.0)
Child factors
Child’s sex c, n (%)
Male 1405 (49.3) 1147 (50.9) 737 (50.5)
Female 1447 (50.7) 1107 (49.1) 723 (49.5)
a  Data presented as mean (±SD) for continuous normally distributed variables, median (IQRs) for continuous 
non-normally distributed variables and n (%) for categorical variables.
b  Maternal age at urine sample collection, except in ALSPAC (age at last menstrual period).
c  Data were not imputed, due to no missing values for age (in ALSPAC, Generation R), pre-pregnancy BMI 
(INMA), parity (Generation R) and child’s sex (ALSPAC). The rest of the data are shown after imputation 
of the missing values (see methods).
d  ALSPAC (Reference group=White); Generation R (Reference group=Dutch, Non-Dutch=Indonesian, Cape 
Verdean, Moroccan, Dutch Antilles, Surinamese, Turkish, Other non-Western, Asian, or other Western, see 
Table 3); INMA (Reference group=Spanish, Non-Spanish=Latin American, European, or Others).
e  Non-Dutch group in Generation R presented in detail in Table 3. 
f  ALSPAC (Other=widowed, divorced, or separated).
Abbreviations: BMI, body mass index; IQRs, interquartile ranges; N/A, data not available or not applicable; 
SD, standard deviation.
Table 2 Urinary iodine status in early pregnancy (≤ 18 gestational weeks) expressed as UIC, UI/Creat and 
proportion of mothers with UI/Creat below 150 µg/g.
ALSPAC
(n=2852)
Generation R
(n=2254)
INMA
(n=1460)
Gestational age at urine sampling, weeks a 11.0 (8.0 - 15.0) 13.1 (12.1 - 14.6) 13.0 (12.4 - 13.9)
Urinary iodine concentration (UIC), µg/L a 95 (56 - 151) 165 (94 - 277) 130 (76 - 219)
Iodine-to-creatinine ratio (UI/Creat), µg/g a 121 (81 - 193) 210 (140 - 303) 151 (96 - 255)
UI/Creat < 150 µg/g, n (%) 1792 (62.8) 650 (28.8) 723 (49.5)
Abbreviations: UI/Creat, urinary iodine-to-creatinine ratio; UIC, urinary iodine concentration.
a Data presented as median (25th - 75th percentiles).
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“Milk and dairy products” was the only food group positively associated with UI/Creat in 
all three cohorts: ALSPAC (B=3.73, P<0.0001); Generation R (B=2.34, P=0.001); INMA 
(B=6.92, P=0.002) (Supplemental Table 5). Based on the fully-adjusted models, one-portion 
increase in consumption of milk and dairy products (e.g., a glass of milk, 200 g) 45 was associ-
ated with a 5-14 µg/g increase in the geometric mean of UI/Creat (Table 4). Intake of “fish 
and shellfish” was positively associated with UI/Creat in pregnant women in Spain (INMA) 
and the UK (ALSPAC), though the effect size per 100 g was more than five times larger in 
INMA women (B=28.04, P=0.029 vs. B=5.10, P=0.017).
Cohort-specific dietary determinants were also identified (Table 4). In ALSPAC, consump-
tion of fruit (P=0.012), cakes and confectionery (P=0.028) were positively associated with 
UI/Creat. Intake of cereals and cereal products (P<0.0001), eggs (P=0.0001), nuts and seeds 
(P=0.001), and added fat (P=0.022) were all positively associated with UI/Creat in Genera-
tion R. Higher salt intake (including iodised salt) (per 1 g) was associated with higher UI/
Creat (P=0.003), while increasing meat intake was associated with lower UI/Creat (P=0.002) 
in INMA.
Excluding women with extremely low energy intakes (< 5th percentile) did not considerably 
change our results, except for small changes in INMA where the association between fish 
intake and UI/Creat was borderline significant but the effect size remained relatively un-
changed (data not shown). In INMA, mean daily iodine-supplement intake was an important 
determinant of UI/Creat (Standardised B=0.235, P<0.0001). Adjusting for iodine-supplement 
use in INMA attenuated the result for maternal age (B=0.012, P=0.018), but did not change 
the rest of the results substantially (data not shown). In Generation R, the exclusion of 
iodine-supplement users resulted in higher effect estimates for some ethnic groups (e.g., 
Moroccan, Turkish and other Western); the associations between intake of non-alcoholic and 
alcoholic beverages and UI/Creat reached statistical significance but the effect sizes remained 
unchanged; the rest of the results remained relatively unchanged (data not shown).
Discussion
In this study of pregnant women, several dietary (milk and dairy products) and maternal fac-
tors (maternal age, BMI, gestational week) were associated with UI/Creat across all cohorts 
in adjusted models. Furthermore, important cohort-specific dietary determinants were identi-
fied, such as fish intake in ALSPAC (UK), egg and cereal/cereal product intake in Generation 
R (Netherlands), and fish, salt, and meat intake in INMA (Spain).
The population of pregnant women from the Netherlands was iodine-sufficient, while 
populations from the UK and Spain were mildly-to-moderately deficient. It should be noted 
that the ALSPAC median-UIC value, although from samples that are nearly 25 years old, 
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is almost identical to the UK value from the 2017 Global Scorecard for Iodine Nutrition in 
pregnant women, i.e., 95 µg/L vs. 99 µg/L 15.
The differences in iodine status between the countries may be partly explained by differing 
use of iodised salt. The iodised salt penetration rate in households and the food industry (e.g., 
bread-making) in the Netherlands has been estimated as 60% and 70%, respectively, while 
a 16% penetration rate has been reported in Spanish households 46. By contrast, iodisation 
of salt was never common in the UK 47, and even nowadays, its availability is very limited 
(21.5%); furthermore, the iodine concentration of the major UK brand is low 48.
Association with socio-demographic and lifestyle factors
Gestational week of urine samples was positively associated with a UI/Creat in ALSPAC but 
not in the other cohorts. This may be because ALSPAC samples were collected at an earlier 
gestational age than in the other cohorts; if the greatest increase in urinary iodine excretion is 
in the first weeks of pregnancy, the effect of gestational age may be attenuated in later samples 
(i.e., up to 18 weeks as in our study). Indeed, in sensitivity analyses, when we restricted 
analysis to samples collected up to 13 weeks, the effect size was higher in the other two 
cohorts. The positive association between gestational week of urine sample with UI/Creat in 
early pregnancy could be attributed to an increase in glomerular filtration rate and subsequent 
renal iodine loss in early pregnancy 49,50, though data are conflicting as studies report both 
an increase and a decrease in the UI/Creat 51–54. As urinary iodine excretion in early vs. late 
pregnancy stages might be higher as a result of increased renal clearance of iodine, using 
early measurement to assess status might overestimate true intake 55. Creatinine clearance has 
also been shown to vary during gestation 43, which could have biased our results when using 
UI/Creat. However, gestational week was also positively associated with UIC (µg/L) alone 
when including creatinine separately in the model.
In all three cohorts, BMI was negatively associated with UI/Creat. In a study in non-
pregnant adults 56, creatinine clearance was positively associated with BMI, independent of 
adiposity, and a positive association with lean thigh-tissue area was reported; this suggests 
that the association of creatinine with BMI might be explained by lean body mass. The nega-
tive association between BMI and UI/Creat that we report may therefore be partly explained 
by the use of creatinine adjustment and may highlight potential issues with the use of this 
measure of iodine status 42,57. Indeed, in sensitivity analysis, we did not find an association of 
BMI with UIC alone in two of the cohorts when we adjusted for creatinine by including it as 
a covariate in the model instead of using the ratio of UI/Creat.
There was a positive association of maternal age with UI/Creat in all cohorts. Age was still 
significantly associated with UI/Creat after adjustment for dietary intake though the effect size 
was attenuated; it was further reduced when iodine-supplement use in INMA was accounted 
for, suggesting that some of the effect of age could be explained by diet and supplement use 
in older women. Similarly to BMI, age is a known predictor of urinary creatinine 42. However, 
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in sensitivity analysis when adjusting for creatinine separately in the model, unlike BMI, age 
remained positively associated with UIC but with a lower effect size.
The iodine status of pregnant women from the Netherlands varied by ethnic origin, with 
higher iodine status in Moroccan, Turkish and other non-Western women, and lower iodine 
status in Surinamese and Dutch Antilles women, even after adjusting for socio-demographic 
factors. Variation in diet may partially explain these differences as some of the effect esti-
mates were attenuated when adjusting for dietary intake. Alternatively, there may be genetic 
variability in iodine or creatinine clearance 42,58. Indeed, we found that when using UIC and 
adjusting for urinary creatinine separately in the model, UIC varied similarly to UI/Creat 
between the ethnic groups though some of the associations were attenuated and were no 
longer significant (e.g., for Surinamese and Dutch Antilles women). It should be noted that 
numbers in some of these ethnic-group categories were relatively small (n<100). Ethnicity 
was not significantly associated with iodine status in ALSPAC or INMA, but this may reflect 
the small sample sizes of other ethnic groups in these cohorts. Ethnic differences in iodine 
status could help to identify subgroups at high-risk for iodine insufficiency; in countries with 
a large proportion of diverse ethnic groups, culturally-specific approaches to improve dietary 
adequacy may be more suitable than a single solution for the whole population.
Dietary influences on iodine status
The only food group that was positively associated with UI/Creat in all three cohorts was 
“milk and dairy products”, demonstrating their significant role as an important dietary de-
terminant of iodine status in pregnancy. This finding is consistent with the results of other 
studies in European pregnant women, i.e., Norway 59,60, Iceland 61, Italy 62, Spain 63, and the 
UK 52,64, as well as studies of pregnant women in Australia 65.
Based on our model, a portion of “milk and dairy products” equivalent to a glass of milk 
(200 g) was associated with 5 to 14 µg/g increase in UI/Creat across cohorts. The effect sizes 
for milk differed between cohorts; the highest effect size was in Spain, while the lowest was 
in the Netherlands. This is in line with the milk-iodine concentration in each country (i.e., ~26 
µg in Spain 66, ~15 µg in the Netherlands 67, and 15 µg in the UK in 1990/1991 68). The results 
might be different if repeated now as the iodine concentration in UK milk is higher than 
estimated when ALSPAC women were recruited in 1990/1991, i.e., 427 vs. 150 µg/kg 68,69.
Consumption of eggs and fish were positively associated with UI/Creat, though not consis-
tently across the cohorts; the association with egg intake was statistically significant only in 
the Netherlands, while intake of fish and shellfish was associated with UI/Creat only in Spain 
and the UK. The effect size for eggs was higher than that expected, given their iodine content, 
but similar to values reported previously 60. These higher values may reflect the consumption 
of eggs with salt in the Netherlands, which is likely to be iodised. An average portion of fish 
(120 g) was associated with some 6 to 34 µg/g increase in UI/Creat, across cohorts. Variation 
in the effect size could partly reflect the variability in average fish consumption, particularly 
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of white fish, which is a good iodine source 70 (e.g., pregnant women in Spain consumed 
a higher amount of white fish daily than did women in the UK). The wide CIs around the 
estimates probably relate to the variability in fish-iodine concentration 14 (i.e., the proportion 
of oily fish in the food group has a much lower iodine concentration 70) and to the irregular 
nature of fish consumption which may not be captured by a spot-UI/Creat.
Consumption of cereals and cereal products was a statistically significant determinant of 
UI/Creat only in the Netherlands; this association is probably driven by consumption of bread 
which is made with iodised salt in the Netherlands 71, whereas without iodised salt, bread 
has a low iodine concentration and was not found to be a predictor of iodine status in the 
UK or Spanish cohorts. Intake of iodised table salt was measured only in pregnant women 
from Spain; 1 g of salt was associated with around 32 µg/g increase in UI/Creat. Both of 
these results suggest that iodised salt consumed either discretionarily (e.g., as table salt in 
Spain), or as part of processed foods (e.g., in bread in the Netherlands) is an important dietary 
determinant of iodine status. We observed the highest UI/Creat in the Netherlands, followed 
by Spain, and the lowest in the UK, suggesting that iodised-salt use might be a key dietary 
factor with large influence on iodine status.
Surprisingly, meat intake was negatively associated with UI/Creat in the Spanish cohort, 
even after controlling for socio-demographic variables. Higher urinary creatinine concentra-
tions have been reported in individuals with a high-meat diet, which may account for the 
lower ratio 72,73.
Some of our other food-group associations are difficult to explain and may be chance find-
ings, e.g., the positive association with fruit, and cakes/confectionary in the UK. However, 
fruit intake was also associated with urinary iodine excretion in Norwegian pregnant women 
59 and the finding might warrant further investigation.
Although we have observed significant increases in UI/Creat, the effect sizes were relatively 
small and the total explained variance in UI/Creat (R2) was low. This is probably explained 
by the large day-to-day variability in iodine intake which cannot be captured in a single spot-
urine sample and the measurement errors of dietary assessment methods in capturing habitual 
iodine intake. Moreover, as a result of the physiological changes occurring during gestation 
(e.g., increased renal iodine clearance), pregnancy may not represent a steady state of iodine 
metabolism (intake vs. excretion) 10.
Strengths and limitations
Strengths of our study include the large sample size, the inclusion of pregnant women from 
three geographically and culturally different populations. Furthermore, we explored associa-
tions with the entire range of food groups, rather than focusing on a few groups or isolated 
foods as in previous studies 62,63. However, our study also has a number of limitations. Firstly, 
the use of an FFQ for measuring diet and the use of spot-urine samples for estimating indi-
vidual iodine intake have their methodological disadvantages 24–26,74. Although we only had 
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spot-urine samples which might not reflect individual iodine intake or status, we used UI/
Creat which has been shown as a valid alternative to the 24-hour urinary iodine excretion 
when used in homogenous population groups 75. Although urinary iodine concentration was 
measured in three different laboratories using different assays, each laboratory ensured accu-
racy by use of certified reference materials. Exploring associations between data from an FFQ 
and spot-UI/Creat can also be problematic, as an FFQ is designed to measure habitual diet 
76, whereas a spot-urine sample reflects iodine intake in the last 24-48 hours 11; this may be 
reflected in the more consistent association between UI/Creat and intake of daily food items 
(e.g., milk) than those infrequently consumed (e.g., fish). However, our large cohort sample 
size would have helped to overcome this limitation to some extent. Second, it should be noted 
that in ALSPAC there was a time difference in the administration of the FFQ (at 32 weeks) 
and urine-sample collection (≤18 weeks); hence the FFQ might not reflect diet during early 
pregnancy. Third, although we harmonised the classification of foods into food groups, there 
were some differences in the foods included in each group which may explain variation in 
effect sizes between cohorts (i.e., in ALSPAC the dairy food group included milk and cheese, 
while in INMA and Generation R, ice cream, yoghurt, cream were also included). Fourth, 
we had incomplete, or no, data on iodine supplement use in two of the cohorts (Generation 
R and ALSPAC), which could be an important determinant that we were unable to evaluate; 
however this is unlikely to be a limitation in ALSPAC as it is unlikely that women would 
have taken an iodine-containing supplement in the early 1990s. Finally, we measured urinary 
iodine only in women with available child IQ data in two of the cohorts which might have 
created bias.
Conclusion
Various maternal characteristics and dietary habits were associated with UI/Creat in preg-
nancy, some of which were population-specific. For that reason, universal interventions 
and dietary recommendations to improve the iodine intake of pregnant women might not 
be appropriate; a country-specific approach needs to be adopted. Between countries, but 
also within countries with a large proportion of different ethnic groups, culturally-specific 
recommendations are probably necessary. Achieving and maintaining iodine sufficiency in 
populations require monitoring dietary determinants of iodine status so that appropriate ac-
tion can be taken, where necessary.
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Supplementary material
ALSPAC
For the women in the analysis (n=2852), there were 2.6% missing values in total (n=1263) 
and 19.3% of the cases (n=550) had at least one missing value. Data were imputed for 12 
out of the 15 variables used in the analysis, including pre-pregnancy BMI (n=250), ethnicity 
(n=96), parity (n=134), smoking status (n=51, smoking status variable was made from two 
imputed smoking variables with n=102 missing values in total), alcohol consumption (n=101, 
alcohol consumption variable was made from two imputed variables with n=159 missing 
values in total), education level (n=86), home ownership (n=72), crowding index (n=94), 
family adversity index (n=30), life event score (n=96), marital status (n=47), and living with 
a partner (n=97). Data were not imputed for gestational age, maternal age and child’s sex due 
to no missing values.
Generation R
For the women in the analysis (n=2254), there were 5.5% missing values in total (n=1369) 
and 31.7% of the cases (n=715) had at least one missing value. Data were imputed for nine 
out of 11 variables, including gestational age (n=1), pre-pregnancy BMI (n=12), ethnicity 
(n=71), smoking status (n=248), alcohol consumption (n=254), education level (n=149), 
net household income (n=479), marital status (n=154), and child’s sex (n=1). Data were not 
imputed for maternal age and parity due to no missing values.
INMA
For the women in the analysis (n=1460), there were 1.1% missing values in total (n=154) 
and 5.8% of the cases (n=84) had at least one missing value. Data were imputed for nine out 
of ten variables, including gestational age (n=4), maternal age (n=4), ethnicity (n=3), parity 
(n=2), smoking status (n=44), alcohol consumption (n=56), education level (n=5), living with 
a partner (n=1), and child’s sex (n=35). Data were not imputed for pre-pregnancy BMI due 
to no missing values.
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Supplemental Table 1 Overview of the classification of foods into food groups by cohort.
Food group ALSPAC Generation R INMA
Vegetables green leafy vegetables 
(e.g., cabbage), other green 
vegetables (e.g., leeks), 
carrots, other root vegetables 
(e.g., turnip), salad vegetables 
(e.g., tomatoes)
leafy (e.g., spinach), root 
(e.g., carrots), cabbage, 
mixed salad vegetables, 
mushrooms, allium (e.g., 
onion, garlic), stems and 
sprouts (e.g., asparagus), 
fruiting (e.g., tomatoes)
leafy (e.g., spinach), root 
(e.g., carrots), cruciferous 
(e.g., broccoli), salad 
vegetables (e.g., lettuce), 
allium (e.g., onions, leek, 
garlic), fruiting (e.g., 
tomatoes, aubergines, 
peppers)
Fruit fresh fruit (e.g., apple, grapes, 
banana)
fresh fruit (e.g., apple, 
grapes, banana), olives
fresh fruit (e.g., apple, 
grapes, banana)
Nuts and seeds nuts, tahini nuts, seeds, nut spread almonds, peanuts, 
hazelnuts, pine nuts
Potatoes chips, roast potatoes, boiled/
mashed/ jacket potatoes
potatoes and other tubers 
(does not include potato 
crisps)
fried, boiled/roasted 
potatoes, potato crisps
Legumes pulses (e.g., lentils, chickpeas), 
baked beans, peas, sweetcorn, 
broad beans
dried lentils, beans and
peas
lentils, chickpeas,
beans
Cereals and cereal 
products
breakfast cereals (e.g., oats, 
cornflakes, bran cereals), 
pasta, rice, bread, crispbreads, 
pizza
breakfast cereals, pasta, rice, 
bread, pretzels, crispbreads, 
pizza, flour and thickeners
breakfast cereals, pasta, 
rice, bread, boiled corn
Cakes, confectionery 
and added sugar
cakes or buns, biscuits, 
chocolate bars (e.g., Mars), 
chocolate (e.g., dairy milk), 
sweets (e.g., toffees), pudding 
(e.g., cheesecake, mousse), 
sugar
cakes, pastries, biscuits, 
candy bars, chocolate, 
non- chocolate sweets (e.g., 
toffees) jam, honey, sugar, 
ice cream, syrups, water ice
cakes, pastries, biscuits, 
chocolate, jams, honey, 
sugar
Added fats animal fats (e.g., butter, ghee), 
vegetable oils and spreads 
(e.g., olive oil)
animal fats (e.g., 
butter),vegetable oils (e.g., 
olive oil), spreads and 
margarines
animal fats (e.g., butter), 
vegetable oils and spreads 
(e.g., olive oil)
Milk and dairy 
products
milk, cheese milk, milk drinks, 
evaporated milk, yoghurt, 
fresh cheese (e.g., cottage 
cheese), cheese, milk 
puddings (e.g., mouse, 
cream base), cream
fresh milk, condensed 
milk, yoghurt, cheese, 
custard, ice cream, cream
Meat and meat 
products
red meat, poultry, offal (e.g., 
liver), processed meat (e.g., 
sausages, burgers, bacon), pies 
and pasties (e.g., meat pies)
red meat, poultry, offal (e.g., 
liver), processed meat (e.g., 
sausage, pate)
red meat, white meat 
(e.g., chicken), offal (e.g., 
liver), processed meat 
(e.g., sausages, pate, 
bacon)
Eggs eggs, quiche eggs eggs
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Supplemental Table 1 Overview of the classification of foods into food groups by cohort. (continued)
Food group ALSPAC Generation R INMA
Fish and shellfish white fish (e.g., cod), oily fish 
(e.g., salmon), shellfish (e.g., 
prawns)
white fish (e.g., cod), oily 
fish (e.g., salmon), shellfish 
(e.g., prawns), processed 
fish (e.g., fish fingers)
boiled/fried/ grilled white 
fish (e.g., cod), boiled/
fried/ grilled oily fish 
(e.g., salmon), seafood 
and shellfish (e.g., 
oysters, clams, lobster)
Condiments and 
seasoning
N/A seasonings (e.g., salt, herbs, 
spices)
salt, including iodised salt
Processed and fried 
foods
(e.g., sauces, soups, 
fried foods, crisps)
fried food (e.g., bacon, eggs, 
egg fried fish), crisps
sauces (e.g., tomato, 
dressings, mayonnaise), 
soups, bouillons
vegetable soups, tomato 
sauce, chicken croquettes, 
pizza
Non-alcoholic 
beverages (excluding 
coffee and tea)
tinned juice (e.g., tomato 
juice), pure fruit juice, soft 
drinks
fruit and vegetable juices, 
soft drinks, isotonic drinks, 
water
fruit juice, soft drinks, 
non-alcoholic beer, tap 
water, bottled water
Alcoholic beverages N/A wine, beer, liquors and 
spirits
wine, beer, liquors and 
spirits
Miscellaneous (e.g., 
soy products, diet 
foods and sweeteners)
soy products (e.g., TVP, 
vegeburgers), bean curd (e.g., 
tofu)
diet products, soy products, 
artificial sweeteners
N/A
Abbreviations: N/A, data not available; TVP, texturised vegetable protein.
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Supplemental Table 4 Descriptives of dietary intakes of food groups (g/day) and energy intake (kcal/day) 
estimated from FFQ by cohort.
Food group (grams/day) a
ALSPAC
(n=2710)
Generation R
(n=1580)
INMA
(n=1446)
Mean (±SD) Mean (±SD) Mean (±SD)
Vegetables 117 (±64) 144 (±64) 220 (±114)
Fruit 100 (±56) 171 (±116) 320 (±200)
Nuts and seeds 3 (±7) 17 (±12) 6 (±9)
Potatoes 98 (±49) 52 (±43) 63 (±37)
Legumes 54 (±32) 4 (±7) 38 (±25)
Cereals and cereal products 195 (±79) 195 (±71) 184 (±77)
Cakes, confectionery and added sugar 80 (±55) 98 (±56) 44 (±36)
Added fats 19 (±11) 25 (±14) 23 (±15)
Milk and dairy products 391 (±155) 412 (±251) 444 (±233)
Meat and meat products 71 (±40) 78 (±43) 116 (±50)
Eggs 21 (±18) 11 (±10) 20 (±9)
Fish and shellfish 35 (±30) 14 (±13) 69 (±36)
Condiments and seasoning (e.g., salt, iodised salt) N/A 6 (±5) 0.3 (±0.4)
Processed and fried foods (e.g., sauces, soups, fried foods, crisps) 8 (±8) 100 (±90) 101 (±66)
Non-alcoholic beverages (excluding coffee and tea) b 175 (±83) 940 (±550) 1488 (±494)
Alcoholic beverages N/A 6 (±17) 3 (±13)
Miscellaneous (e.g., soy products, diet foods and sweeteners) 2 (±9) 6 (±20) N/A
Energy, kcal/day 1743 (±459) 2076 (±520) 2083 (±532)
a  Dietary intake of food groups presented as mean (±SD) grams per day, energy intake presented as mean 
(±SD) kcal per day.
b  Food group also includes water in INMA and Generation R (but not in ALSPAC).
Abbreviations: FFQ, food frequency questionnaire; N/A, data not available; SD, standard deviation.
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Abstract
Background: Severe maternal iodine deficiency can impact fetal brain development through 
effects on maternal and/or fetal thyroid hormone availability. The effects of mild-to-moderate 
iodine deficiency on thyroid function are less clear. The aim was to investigate the associa-
tion of maternal urinary iodine concentration corrected for creatinine (UI/Creat) with thyroid 
function and auto-antibodies in a mild-to-moderate iodine-deficient pregnant population.
Methods: This study was embedded within the Swedish Environmental Longitudinal, Mother 
and child, Asthma and allergy (SELMA) study. Clinical reference ranges were determined by 
the 2.5th and 97.5th population-based percentile cut-offs. The associations of UI/Creat with 
thyrotropin (TSH), free T4 (FT4), free triiodothyronine (FT3), total T4 (TT4), and total triio-
dothyronine (TT3) were studied using multivariable linear regression in thyroid peroxidase 
antibody (TPOAb)-negative women. The association of UI/Creat with TPOAb and thyro-
globulin antibody (TgAb) positivity was analyzed using multivariable logistic regression.
Results: Urinary iodine and thyroid function were measured at a median (95% range) ges-
tational age of 10 (6-14) weeks in 2009 women. The median (95% range) UI/Creat was 85 
µg/g (36-386) and the UI/Creat was below 150 µg/g in 80.1% of women. Reference ranges 
did not differ substantially by UI/Creat. A lower UI/Creat was associated with a lower TSH 
(P=0.027), a higher TT4 (P=0.032), and with a corresponding trend towards slightly higher 
FT4 (P=0.081), FT3 (P=0.079), and TT3 (P=0.10). UI/Creat was not associated with the 
FT4/FT3 (P=0.94) or TT4/TT3 ratios (P=0.63). Women with a UI/Creat of 150-249 µg/g had 
the lowest prevalence of TPOAb positivity (6.1%), while women with a UI/Creat of <150 
µg/g had a higher prevalence [11.0%, odds ratio (OR) confidence interval (95% CI) 1.84 
(1.07–3.20), P=0.029]. Women with a UI/Creat ≥500 µg/g showed the highest prevalence and 
a higher risk of TPOAb positivity, however, only a small proportion of women had such a UI/
Creat [12.5%, OR (95% CI) 2.36 (0.54–10.43), P=0.26].
Conclusions: We could not identify any meaningful differences in thyroid function reference 
ranges. Lower iodine availability was associated with a slightly lower TSH and a higher TT4. 
Women with adequate iodine intake had the lowest risk of TPOAb positivity.
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Introduction
During pregnancy there is an increased demand for maternal thyroid hormone because of 
the placental transport of thyroid hormone to the fetus, an increase in thyroxine-binding 
globulin concentrations, and a higher degradation of thyroid hormone due to placental type 
III iodothyronine deiodinase 1. Iodine is an essential component of thyroid hormone and both 
low and high iodine intakes may adversely affect thyroid function 2. A considerable increase 
in preconceptional or gestational daily iodine intake is required to meet the higher demand for 
thyroid hormone, to compensate for greater iodine losses during pregnancy, and to transfer a 
sufficient amount of iodine to the fetus 3–5. The current guidelines of the World Health Orga-
nization therefore recommend an iodine intake of 250 µg per day for pregnant and lactating 
women as opposed to 150 µg per day in an adult non-pregnant state 3. However, data on the 
effects of iodine availability on maternal thyroid function during pregnancy are inconsistent.
A large Chinese study indicated that in pregnant women, the optimal urinary iodine concen-
tration (UIC) ranged from 150 to 250 µg/L 6. Outside this range there was a higher prevalence 
of women with thyroid autoimmunity and women with a UIC above this range had a higher 
risk of subclinical hypothyroidism and isolated hypothyroxinemia 6. A few studies show that 
a lower UIC during pregnancy is associated with a higher free thyroxine (FT4) 7,8 and free 
triiodothyronine (FT3) 7–9, while a higher UIC has been associated with higher thyrotropin 
(TSH) 8,10 and higher FT3 11. On the contrary, other studies, of which several are small in size 
(N<700) 11–14, do not report any association of UIC with TSH or FT4 9,11–15 and data on (F)T3 
are often lacking. While it is recommended that pregnancy TSH and FT4 reference ranges 
should be calculated in an iodine sufficient population 4, there is insufficient evidence to 
determine whether reference ranges are affected by iodine status.
Therefore, the aim of our study was to analyze the cross-sectional association of maternal 
iodine status with maternal TSH, FT4, FT3, total T4 (TT4), total T3 (TT3), the FT4/FT3 
and TT4/TT3 ratios, thyroid peroxidase antibodies (TPOAbs), and thyroglobulin antibodies 
(TgAbs), and to determine variation in thyroid function reference ranges according to iodine 
status.
Materials and Methods
Study population
This study was embedded in the Swedish Environmental Longitudinal, Mother and child, 
Asthma and allergy (SELMA) study, which is a population-based prospective birth cohort 
study originating in the county of Värmland, Sweden 16. Sweden is a country with a voluntary 
fortification program and iodized salt since 1936 17. Pregnant women who visited an antenatal 
care center for the first time around week 10, but before week 22 of pregnancy, between 
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September 2007 and March 2010 were invited to participate in the SELMA study. Pregnant 
women provided written informed consent, and the SELMA study is approved by the regional 
ethical committee, Uppsala, Sweden (2007-05-02, Dnr: 2007/062). For the current study, 
women were included if a measure of urinary iodine and creatinine concentration, and thyroid 
function during pregnancy were available. Exclusion criteria were twin pregnancy, thyroid 
interfering medication usage, and pre-existing thyroid disease.
Laboratory measurements
Early morning void urine samples were collected at the day for enrollment and stored at 
-20°C. Urinary iodine was measured by the Sandell-Kolthoff method. Iodine calibration was 
performed using certified reference materials (CRM), Seronorm urine Levels one and two 
(Nycomed, Norway), and four EQUIP samples certified for UIC (Centers for Disease Control 
and Prevention, USA). At a level of 1.7 µmol/l iodine the within-assay coefficients of varia-
tion (CV) was 5.1% and the between-assay CV was 14.3% (N=30). The urinary creatinine 
concentration was determined by the Jaffe rate method. The UIC corrected for creatinine (UI/
Creat) was used as a marker of iodine status.
Non-fasting blood samples were collected at enrollment and were stored frozen at -80°C 
in a bio-bank at the Central Hospital in Karlstad, Sweden. Serum TSH, FT4, FT3, TT4, TT3, 
TPOAbs, and TgAbs were measured using electrochemoluminescence assay (Cobas e601 
platform; Roche Diagnostics, Mannheim, Germany) at the Department of Clinical Chemistry, 
Máxima Medical Center in Veldhoven, the Netherlands. Human chorionic gonadotropin 
(hCG) was determined in lithium-heparin plasma using electrochemoluminescence assays 
(Cobas® e601; Roche Diagnostics, Mannheim, Germany). Within-laboratory CVs were 
2.1%, 3.5%, 3.8%, 3.8%, and 7.7% for TSH, FT4, FT3, TT4, and TT3, respectively. For hCG, 
the CV was 2.5% at 4.3 U/L and 2.1% at 171 U/L. The manufacturer’s cut-offs for TPOAb 
and TgAb positivity were at the concentrations of >34 IU/mL or >115 IU/mL, respectively.
Serum cotinine was used as a marker for smoking. Briefly, aliquots of 100 μL serum were 
added with labelled internal standard and proteins were precipitated by acetonitrile and 
analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Participants 
were categorized as non-smokers if their cotinine concentrations were <0.2 ng/mL and as 
active smokers if their cotinine concentrations were ≥15 ng/mL. If their concentrations were 
in between, participants were considered to be passive smokers.
Covariates
Information on gestational age at blood and urine sampling, maternal age at enrollment, 
maternal ethnicity (Western, non-Western), and maternal educational level (low = none or 
primary education; medium = secondary education; high = higher education) was collected 
through questionnaires. The Swedish National Birth Register was used to collect data on a 
diagnosis of thyroid disease, parity, and child sex. Information on pregnancy weight and 
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height, which was used to calculate body mass index (BMI), was collected either through a 
prenatal questionnaire or the Swedish National Birth Register.
Statistical analyses
Reference ranges were defined based on the 2.5th and 97.5th percentiles after exclusion of 
TPOAb-positive women. To check whether reference ranges differed according to iodine 
status, we defined reference ranges in women subdivided by quartiles of UI/Creat – to have 
equal numbers of women per category – and by alternative categorization, which broadly 
relates to cut-off values based on the epidemiological criteria for assessing iodine nutrition 
in pregnant women (UI/Creat <50, 50-99, 100-149, 150-249, 250-499, and ≥500 µg/g) 3. As 
a sensitivity analysis, we also defined the reference ranges in women using the alternative 
categorization based on the UIC.
We studied the association of UI/Creat across the full range with TSH, FT4, FT3, TT4, 
TT3, and the FT4/FT3 and TT4/TT3 ratios using multivariable linear regression analyses in 
TPOAb-negative women. Non-linearity was tested using restricted cubic splines with three 
knots and we evaluated normality of residuals using histograms. We studied the associa-
tion of UI/Creat across the full range with TPOAb and TgAb positivity using multivariable 
logistic regression. Similar models were used for exploring the association of a UI/Creat 
of <150 (<50, 50-99, 100-149), 250-499, and ≥500 µg/g with thyroid antibody positivity 
compared with the reference group of women with a UI/Creat of 150-249 µg/g. This analysis 
was repeated using the same categorization based on the UIC. UI/Creat, TSH, and TPOAb 
concentrations were log-transformed. Back-transformed values are shown in plots for better 
interpretation. Values in the lowest and highest centile of UI/Creat and thyroid function tests 
were considered as outliers and excluded from the regression analyses when analyzed across 
the full range.
All analyses were adjusted for hCG, gestational age at blood and urine sampling, ma-
ternal age, maternal ethnicity, maternal educational level, parity, maternal BMI, smoking 
status based on the serum cotinine concentration, and child sex. We additionally adjusted 
for TPOAbs in the analysis of the association between UI/Creat and thyroid function tests. 
With ANOVA, we tested the null hypothesis that the thyroid hormone concentrations were 
similar across the full range of the natural logarithm of UI/Creat. Missing data of covariates 
were imputed using multiple imputation by chained equations, generating 25 datasets. The 
statistical analyses were performed using R statistical software version 3.4.3 (R Core team, 
Vienna, Austria; packages mice and rms).
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Results
The fi nal study population comprised 2009 pregnant women, in whom data on both UI/Creat 
and thyroid function was collected at a median (95% range) gestational age of 10 (6-14) 
weeks (Fig. 1). The median UI/Creat (95% range) was 85 (36-386) µg/g and the UI/Creat 
was below 150 µg/g in 80.1% of women. The majority of women were of Western descent 
(97.3%), non-smokers (84.9%), and had a secondary (“middle”) or higher (“high”) educa-
tional level (33.6% and 54.4%, respectively). Further study population characteristics are 
shown in Table 1.
Fig. 1 Flowchart of the selection of the study population.
Thyroid function reference ranges
Thyroid function reference ranges did not diff er substantially according to UI/Creat when 
analyzed per quartile (Table 2). The relative largest diff erence in cut-off s for thyroid function 
reference ranges was for the upper limit of TSH. However, these diff erences were small in 
absolute values and there was no clear trend across iodine status. In the lowest quartile of 
UI/Creat, the upper limit for TSH was 3.24, which is 0.16 mU/L (4.7%) lower than that in 
the total population. In the highest quartile, the upper limit was 3.26, which was 0.14 mU/L 
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(4.1%) lower than that calculated in the total population. For other cut-offs of UI/Creat or 
UIC, the number of women with more-than-adequate and excessive values was too small for 
reliable calculations (Supplementary Table 1 and 2).
Table 1 Characteristics of the study population (N=2009).
Characteristic Values
UIC, median (95% range), µg/L 90 (38-439)
UI/Creat, median (95% range), µg/g 85 (36-386)
UIC <150 µg/L, % 78.6
UI/Creat < 150 µg/g, % 80.1
TSH, median (95% range), mU/L 1.31 (0.13-4.13)
FT4, median (95% range), pmol/L 15.0 (11.4-19.4)
FT3, median (95% range), pmol/L 4.67 (3.72-5.94)
TT4, median (95% range), nmol/L 118.0 (81.1-165.5)
TT3, median (95% range), nmol/L 1.93 (1.27-2.89)
hCG, median (95% range), U/L 69937.0 (9973.2-167580.0)
TPOAb positivity, % 10.2
TgAb positivity, % 7.9
Gestational age at sampling, median (95% range), weeks 10 (4-16)
Maternal age, mean (SD), years 30 (5.2)
Maternal ethnicity, %
Western 97.3
Non-Western 2.7
Maternal educational level, %
Low 12.0
Middle 33.6
High 54.4
Parity, %
0 44.3
1 36.5
≥ 2 19.2
Maternal BMI, median (95% range), kg/m2 23.6 (18.6-35.9)
Cotinine, ng/mL, %
<0.2: non-smoker 84.9
0.2-15: passive smoker 6.2
>15: active smoker 9.0
Female sex, % 47.7
TPOAb positivity and TgAb positivity were defined as > 34 IU/ml and >115 IU/ml, respectively. Numbers of 
covariates are based on imputed data. BMI, body mass index; FT3, free triiodothyronine; FT4, free thyroxine; 
hCG: human chorionic gonadotropin; T3, triiodothyronine; T4, thyroxine; TT3, total triiodothyronine; TT4, 
total thyroxine; TgAb, thyroglobulin antibody; TPOAb, thyroid peroxidase antibody; TSH, thyrotropin; UIC, 
urinary iodine concentration; UI/Creat, UIC corrected for creatinine.
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Table 2 reference ranges (2.5th and 97.5th percentile values) of thyroid function tests in TPOAb negative wom-
en, stratified by quartiles of UI/Creat.
Total Quartile 1 Quartile 2 Quartile 3 Quartile 4 Range of differencecompared to total group
N=1802 N=443 N=446 N=449 N=464 lower limit upper limit
UI/Creat in µg/g 86 (20-1368) 50 (20-61) 72 (61-85) 103 (86-132) 191 (133-1368) NA NA
TSH in mU/L 0.11-3.40 0.11-3.24 0.15-3.39 0.17-3.77 0.07-3.26 -0.04 to +0.06 -0.16 to +0.37
FT4 in pmol/L 11.6-19.3 12.0-19.8 11.5-18.8 11.5-18.8 11.7-19.6 -0.1 to +0.4 -0.5 to +0.5
FT3 in pmol/L 3.73-5.89 3.71-5.83 3.85-5.88 3.73-5.92 3.69-6.00 -0.04 to +0.12 -0.06 to +0.17
TT4 in nmol/L 82.4-165.6 85.4-170.1 81.3-163.8 80.9-163.7 82.4-161.1 -1.5 to +3.0 -4.6 to +4.5
TT3 in nmol/L 1.29-2.88 1.35-2.84 1.29-2.88 1.28-2.92 1.27-2.88 -0.02 to +0.06 -0.04 to +0.04
TPOAb positivity defined as >34 IU/mL. The range of difference of the lower limit is calculated by compar-
ing the 2.5th percentile value of each thyroid function test in the whole study population (“Total”) to the most 
deviating 2.5th percentile value calculated in women subdivided into the four quartiles of UI/Creat. The range 
of difference of the upper limit is calculated by comparing the 97.5th percentile value of each thyroid function 
test in the whole study population (“Total”) to the most deviating 97.5th percentile value calculated in women 
subdivided into the four quartiles of UI/Creat. NA, not applicable.
Iodine status and thyroid function
A lower UI/Creat was associated with a lower TSH and a higher TT4 (Fig. 2; Supplementary 
Table 3). There was a trend towards an association of a lower UI/Creat with a higher FT4 
(P=0.081), FT3 (P=0.079), and TT3 (P=0.10). There was no association of UI/Creat with the 
TT4/TT3 and FT4/FT3 ratios (Fig. 2; Supplementary Table 3).
In the whole study population, an increase of one unit in the natural logarithm of UI/
Creat was associated with a 27% lower risk of TPOAb positivity [odds ratio (OR) 0.73, 
95% confidence interval (CI) 0.56–0.98, P=0.034)], but not with TgAb positivity (OR 0.83, 
95% CI 0.61–1.14, P=0.25, analyses per quartile in Supplementary Table 4). While TPOAb 
positivity was present in 6.1% of women with a UI/Creat of 150-249 µg/g, this was 11.0 % 
in women with a UI/Creat of <150 µg/g (OR 1.84, 95% CI 1.07–3.20, P=0.029,Table 3). 
Women with a UI/Creat of ≥500 µg/g had a higher risk of TPOAb positivity with 12.5% being 
TPOAb positive. However, only a small proportion of women entered in this category (N=24; 
OR 2.36, 95% CI 0.54–10.43, P=0.26). Analyses based on the UIC showed similar results 
(Supplementary Table 5). For TgAb positivity, there was a similar pattern as for TPOAb 
positivity but with considerably smaller percentage differences (Table 3).
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Fig. 2 Association between the natural log of UI/Creat 
and thyroid function tests in TPOAb-negative women.
Analyses were performed by multivariable linear re-
gression analyses, adjusted for TPOAb, hCG, gesta-
tional age, maternal age, maternal ethnicity, maternal 
education, parity, maternal BMI, smoking status based 
on the serum cotinine concentration, and child sex. UI/
Creat, TSH, TPOAb, and hCG were log transformed. 
Back-transformed values are shown in plots for better 
interpretation. BMI, body mass index; hCG, human 
chorionic gonadotropin; TPOAb, thyroid peroxidase 
antibody; TSH, thyrotropin; UI/Creat, urinary iodine 
concentration corrected for creatinine.
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Table 3 Association between UI/Creat and thyroid auto-antibodies.
UI/Creat, µg/ga
TPOAb positivity TgAb positivity
positive/negative (%) OR (95% CI), P positive/negative (%) OR (95% CI), P
<150b 176/1430 (11.0) 1.84 (1.07–3.20), 0.029 134/1467 (8.4) 1.60 (0.88-2.88), 0.12
150-249 15/232 (6.1) 1.00 (ref) 13/233 (5.3) 1.00 (ref)
250-499 10/119 (7.8) 1.26 (0.52–3.09), 0.61 9/120 (7.0) 1.45 (0.53–3.93), 0.47
≥ 500 3/21 (12.5) 2.36 (0.54–10.43), 0.26 2/22 (8.3) 1.61 (0.27–9.65), 0.60
Analyses were performed by multivariable logistic regression analyses, adjusted for hCG, gestational age, 
maternal age, maternal ethnicity, maternal education, parity, maternal BMI, cotinine, and child sex. TPOAb 
positivity and TgAb positivity were defined as
>34 IU/mL and >115 IU/mL, respectively.
a  The total number (%) of women with a UI/Creat <150, 150-249, 250-499, and ≥ 500 µg/g in the total study 
population is 1609 (80.1%), 247 (12.3%), 129 (6.4%), and 24 (1.2%), respectively.
b  Stratified sub-analysis TPOAb positivity: UI/Creat <50 µg/g, OR 1.70 (95% CI 0.86-3.37), P=0.13; 50-99 
µg/g, OR 1.92 (1.09-3.40), P=0.025; 100-149 µg/g, OR 1.74 (0.93-3.25), P=0.084. Stratified sub-analysis 
TgAb positivity: UI/Creat <50 µg/g, OR 1.79 (95% CI 0.85-3.78), P=0.13; 50-99 µg/g, OR 1.62 (0.87-3.01), 
P=0.13; 100-149 µg/g, OR 1.66 (0.84-3.26), P=0.14.
CI, confidence interval; OR, odds ratio.
Discussion
In this study of pregnant women from a mild-to-moderately iodine-deficient population, we 
studied the association of iodine status with a detailed profile of thyroid function and auto-
antibodies. Gestational reference ranges for thyroid function tests did not differ substantially 
by iodine status. We show that a lower UI/Creat was associated with significantly lower TSH, 
higher TT4, and a higher risk of TPOAb positivity. A lower UI/Creat was also associated 
with a higher FT4, FT3, and TT3, but these associations did not reach statistical significance 
(P≤0.10). The FT4/FT3 and TT4/TT3 ratios were stable across the full range of UI/Creat.
Low iodine intakes may trigger mechanisms to counteract any potential thyroidal conse-
quences. These include an increase in the thyroidal uptake of iodine, mainly via stimulation 
of the sodium-iodide symporter by increasing TSH concentrations 18. This typically occurs 
from a daily iodine intake of <100 μg/day and results in a lower renal iodine clearance, thus 
likely reflected by a lower UI/Creat. In the current study, a higher UI/Creat was associated 
with a higher TSH. This finding has been reported in other pregnant populations as well 6,8. 
A possible explanation would be that a lower UI/Creat also increases the risk of autonomous 
thyroid hormone production by nodules/multinodular goiters, which is associated with a 
lower TSH 19,20. Alternatively, a higher TSH at a higher range of UI/Creat values may also 
partially reflect the Wolff-Chaikoff effect caused by higher iodine intakes, especially when 
this increase occurs rapidly 15,21. In rats, a higher TSH was explained by reduced deiodinase 
type II activity due to excessive iodine intakes 22,23. The TSH reference ranges in the total 
population, however, did not deviate much from the reference ranges among groups of UI/
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Creat, ranging from iodine deficiency to iodine sufficiency, which is in line with a previous 
study from Norway 7. While it is known that reference ranges differ between populations 24, 
and that those differences may be partially explained by differences in ethnicity 25–27, there 
has been insufficient evidence that iodine status may also affect thyroid function within its 
normal range. There is a concern that reference ranges may be affected when calculated in 
populations with (mild-to-moderate) iodine deficiency. This concern could be ascribed to the 
association with thyroid autoimmunity, as there may be a higher risk of TPOAb positivity 
at lower iodine intakes. However, it has already been recommended that the calculation of 
thyroid function reference ranges should be performed in TPOAb-negative pregnant popula-
tions 4. This study therefore calls into question the relevance of the selection criterion of 
iodine sufficiency for calculating thyroid reference ranges during pregnancy in addition to the 
criterion of excluding TPOAb-positive women.
Low iodine intake can cause a shift in thyroid hormone availability from T4 to the more 
biologically active T3 via up-regulating peripheral type II deiodinase and by increasing the 
thyroidal secretion of T3 28,29. Given this knowledge, we hypothesized that a lower UI/Creat 
would be associated with lower TT4 and FT4. In contrast, our analyses show that lower UI/
Creat was associated with a higher TT4 and also a trend towards a higher FT4 with UI/Creat 
lower than roughly 100 μg/g. The results of other studies have also been contra-intuitive 
with regards to the underlying physiology. Two of those, of which one was performed in 
an iodine-replete population and the other in a mild-to-moderate iodine deficient popula-
tion, also found a negative association between UI/Creat and FT4 7,8. Others investigated the 
potential effect of iodine supplementation on FT4 7,30. One of these found that women who 
started iodine supplementation between week 13 and 20 of gestation had lower FT4 than non-
users or women who started supplementation preconceptionally 7. Another study showed that 
although the majority of women using iodine supplements had a FT4 within the normal range, 
those who had received iodine supplements in early pregnancy exhibited a faster decline in 
FT4 than those who had consumed iodized salt for at least two years before pregnancy 30. 
This could indicate that a more acute increase in iodine intake during pregnancy, rather than 
prolonged exposure to higher iodine availability, affects the association of UI/Creat with 
thyroid function, leading to a transient decrease in FT4, for example, via the Wolff-Chaikoff 
effect 21. Future studies are needed to identify thresholds from which iodine supplementation 
could affect thyroid function.
Based on the physiological adaptations in thyroid hormone physiology, we expected a priori 
that a lower UI/Creat would be associated with a higher FT3 and TT3, and possibly would 
decrease the FT4/FT3 and TT4/TT3 ratios. Our study shows a trend toward an association of 
UI/Creat - lower than roughly 100 μg/g - with an increase in FT3, but this association did not 
reach statistical significance. A similar, but statistically significant, association was identified 
in a study including a population with a slightly lower median UIC than in our population (68 
μg/L vs. 90 μg/L in SELMA) and with a larger proportion of women below the recommended 
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cut-off for defining iodine deficiency during pregnancy, i.e., UIC<150 μg/L (86% vs. 78.5% 
in SELMA) 7. Other studies show a weak but statistically significant negative correlation 
between UIC and FT4 conducted in similarly iodine-insufficient area (median UIC 89 μg/L) 
9 and a sufficient area (median UIC 328 μg/L) 8, or oppositely, a positive correlation in a 
population with a large proportion of women with excessive iodine intakes 11. However, in 
our study, there was no association of UI/Creat with the FT4/FT3 and TT4/TT3 ratios, which 
could suggest that iodine availability was not low enough to evoke preferential production of 
T3 in this population. Possibly in more chronic severe iodine-deficient populations, women 
are at a higher risk of deplete intra-thyroidal iodine storage already at the beginning or during 
the course of pregnancy, which may cause shifts in these ratios 1.
Thyroid autoantibody positivity occurs in 2% to 17% of pregnant women 4. TPOAb posi-
tivity is associated with a higher risk of miscarriage 31, preterm birth 31,32, child behavioral 
problems 33, and lower child IQ 34. In the current study, TPOAb positivity occurred more 
often in women with low or high UI/Creat. Interestingly, thyroid antibody concentrations 
tend to decline after the first trimester due to immune tolerance, and this could potentially 
affect the definition of TPOAb positivity 35–37. However, in our study, blood samples were 
collected at a median gestational age of 10 weeks, before such a decrease in TPOAb titres 
would likely occur. Women with a UI/Creat of 150-249 µg/g had the lowest prevalence of 
TPOAb positivity (6.1% vs. 11.0% and 12.5% in women with a UI/Creat of <50 and ≥ 500 
µg/g, respectively). This finding is in line with a large study from an iodine-sufficient area 
in China, showing similar differences in the prevalence of TPOAb positivity among different 
UIC groups 6. Also, a study from Norway showed a U-shaped association of iodine intake 
measured by a food frequency questionnaire with TPOAb positivity in mild-to-moderately 
iodine-deficient pregnant women 7. That association, however, did not reach statistical sig-
nificance and no association of urinary iodine with TPOAb positivity was identified 7. We 
speculate that owing to the few women in each cohort with excessive iodine intakes, both 
our study and the Norwegian study did not have sufficient statistical power to show that high 
iodine intake is also associated with a higher risk of thyroid autoimmunity. Excessive iodine 
intakes may cause a shift toward pro-inflammatory cells and a higher generation of radical 
oxygen species due to increased iodination of thyroglobulin, activating pathways promoting 
thyrocyte apoptosis and thyroiditis 38,39.
We were able to study the association of iodine status with thyroid function using an ex-
tensive dataset with multiple thyroid function tests and thyroid auto-antibodies, and with a 
large number of potential confounding variables. An important limitation for interpreting the 
results of the current study is that early morning urine void samples tend to underestimate 
daily iodine excretion 40. Furthermore, it is known that urinary iodine is highly variable from 
day-to-day and therefore not a good indicator of individual iodine status 41,42. It is important to 
note that the UI/Creat is a valid measure of iodine status of a population with the same sex and 
age 43, or large groups of individuals as those that were analyzed in the current study with a 
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standardized sampling of morning void urine, because this reduces the consequences of mea-
surement error. Another limitation is that the use of a single void urine and blood sample to 
measure iodine status and thyroid function, respectively, did not allow to study iodine status 
trajectories during pregnancy and subsequent changes in thyroid function. There was also a 
lack of data on iodine containing supplement use. It would have been relevant to investigate 
whether the associations we observed in our study would differ based on supplement use and 
timing of intake as this could subdivide more acute from chronic changes in iodine intake 
7. There are currently no national recommendations in Sweden on iodine supplementation 
during pregnancy and no data on the use of iodine containing supplements among pregnant 
women 44. However, a considerable percentage of pregnant women in Nordic countries, such 
as Norway and Denmark, use iodine containing supplements, which possibly suggests that 
the use of these supplements may also be substantial in Sweden 7,17. Lastly, the cross-sectional 
design of this study limits causal inference, and therefore, it is important to interpret these 
results while taking into account data from interventional and experimental studies.
To conclude, this study did not find any indication that differences in iodine status within 
the population had a meaningful effect on the reference ranges of thyroid function tests. Fur-
thermore, we found that suboptimal gestational iodine status is associated with lower TSH, 
and higher TT4, but we found no clear indication of preferential T3 production due to iodine 
deficiency. Both low and high gestational iodine status may be associated with a higher risk 
of TPOAb positivity.
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Supplemental material
Supplementary Table 1 Reference ranges (2.5th and 97.5th percentile values) of the various thyroid function 
tests in TPOAb-negative women according to groups of UI/Creat (µg/g).
UI/Creat (µg/g)
Total <50 50-99 100-149 150-249 250-499
N=1802 N=219 (12.2%) N=859 (47.7%) N=352 (19.5%) N=232 (12.9%) N=119 (6.6%)
TSH, mU/L 0.11-3.40 0.15-3.08 0.10-3.47 0.17-3.40 0.09-2.92 0.04-3.71
FT4, pmol/L 11.6-19.3 11.9-19.3 11.7-19.1 11.4-18.7 11.9-19.8 12.2-18.4
FT3, pmol/L 3.73-5.89 3.65-5.77 3.79-5.89 3.67-5.86 3.70-5.94 3.74-5.83
TT4, nmol/L 82.4-165.6 87.2-169.8 83.3-167.1 79.7-156.9 85.5-156.4 77.4-160.5
TT3, nmol/L 1.29-2.88 1.39-2.87 1.29-2.88 1.27-2.89 1.31-2.78 1.26-2.90
The subgroup of women with UI/Creat ≥ 500 µg/g (N=21, 1.2%) was too small for reliable calculations and 
therefore omitted. FT3, free triiodothyronine; FT4, free thyroxine; TT3, total triiodothyronine; TT4, total thyroxine; 
TSH, thyrotropin; UI/Creat, urinary iodine concentration corrected for creatinine.
Supplementary Table 2 Reference ranges (2.5th and 97.5th percentile values) of the various thyroid function 
tests in TPOAb-negative women according to groups of UIC (µg/L).
UIC (µg/L)
<50 50-99 100-149 150-249 250-499
N=176 (8.8%) N=965 (48.0%) N=421 (21.0%) N=264 (13.1%) N=128 (6.4%)
TSH, mU/L 0.11-3.06 0.12-3.36 0.16-3.49 0.16-3.67 0.05-3.49
FT4, pmol/L 11.7-20.4 11.5-19.2 11.6-18.9 12.0-19.3 12.0-20.0
FT3, pmol/L 3.87-6.21 3.75-5.87 3.70-5.80 3.69-5.98 3.89-6.03
TT4, nmol/L 87.8-166.7 82.5-164.3 85.0-164.7 79.0-158.5 81.0-174.3
TT3, nmol/L 1.35-2.87 1.29-2.81 1.28-2.93 1.27-2.96 1.30-2.86
The subgroup of women with UIC ≥ 500 µg/L (N=38, 1.9%) was too small for reliable calculations and there-
fore omitted. UIC, urinary iodine concentration.
Supplementary Table 3 Association between the natural log of UI/Creat and thyroid functions test in TPOAb-
negative women.
N β ± SE P value
TSH 1747 0.065 ± 0.029 0.025
FT4 1739 -0.086 ± 0.073 0.24
FT3 1736 -0.033 ± 0.021 0.11
FT4/FT3 ratio 1738 -0.002 ± 0.016 0.91
TT4 1733 -1.713 ± 0.794 0.031
TT3 1730 -0.025 ± 0.016 0.11
TT4/TT3 ratio 1733 -0.134 ± 0.370 0.72
Analyses were performed by multivariable linear regression analyses, adjusted for TPOAb, hCG, gestational 
age, maternal age, maternal ethnicity, maternal education, parity, maternal BMI, smoking status based on the 
serum cotinine concentration, and child sex. UI/Creat, TSH, TPOAb were log transformed. BMI, body mass 
index; hCG, human chorionic gonadotropin.
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Supplementary Table 4 Association between UI/Creat and thyroid auto-antibodies according to quartiles of 
UI/Creat.
UI/Creat, quartiles N median UI/Creat (range), µg/g
TPOAb positivity,
N (%)
TgAb positivity,
N (%)
quartile 1 503 50 (20-61) 58 (11.6) 46 (9.2)
quartile 2 502 72 (61-85) 55 (11.0) 36 (7.2)
quartile 3 501 103 (85-132) 52 (10.4) 42 (8.4)
quartile 4 503 191 (132-1368) 39 (7.8) 34 (6.8)
TPOAb positivity and TgAb positivity were defined as > 34 IU/mL and >115 IU/mL, respectively.
Supplementary Table 5 Association between urinary iodine concentration and thyroid auto-antibodies
UIC, µg/La
TPOAb positivity TgAb positivity
positive/negative (%) OR (95% CI), P positive/negative (%) OR (95% CI), P
<150b 172/1404 (10.9) 1.78 (1.06–3.00), 0.030 129/1442 (8.2) 1.22 (0.72-2.04), 0.45
150-249 17/247 (6.4) 1.00 (ref) 18/245 (6.8) 1.00 (ref)
250-499 11/117 (8.6) 1.29 (0.55–3.02), 0.56 6/122 (4.7) 0.58 (0.22–1.56), 0.28
≥ 500 4/34 (10.5) 2.20 (0.60–7.98), 0.23 5/33 (13.2) 2.27 (0.72–7.12), 0.16
Analyses were performed by multivariable logistic regression analyses, adjusted for hCG, gestational age, 
maternal age, maternal ethnicity, maternal education, parity, maternal BMI, smoking status based on the serum 
cotinine concentration, and child sex. TPOAb positivity and TgAb positivity were defined as > 34 IU/mL and 
>115 IU/mL, respectively.
a  The total number (%) of women with a UIC <150, 150-249, 250-499, and ≥500 µg/L in the total study 
population is 1579 (78.6), 264 (13.1), 128 (6.4), and 38 (1.9%), respectively.
b  Stratified sub-analysis TPOAb positivity: UIC <50 µg/L, OR 1.20 (95% CI 0.56-2.58), P=0.64; 50-99 µg/L, 
OR 2.0 (1.18-3.44), P=0.010; 100-149 µg/L, OR 1.55 (0.84-2.86), P=0.16. Stratified sub-analysis TgAb 
positivity: UIC <50 µg/L, OR 1.37 (95% CI 0.67-2.80), P=0.38; 50-99 µg/L, OR 1.32 (0.77-2.24), P=0.31; 
100-149 µg/L, OR 0.83 (0.44-1.58), P=0.58.
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Abstract
Context: Although the consequences of severe iodine deficiency are beyond doubt, the ef-
fects of mild to moderate iodine deficiency in pregnancy on child neurodevelopment are less 
well established.
Objective: To study the association between maternal iodine status during pregnancy and 
child IQ and identify vulnerable time windows of exposure to suboptimal iodine availability.
Design: Meta-analysis of individual participant data from three prospective population-based 
birth cohorts: Generation R (Netherlands), INMA (Spain), and ALSPAC (United Kingdom); 
pregnant women were enrolled between 2002 and 2006, 2003 and2008, and 1990 and1992, 
respectively.
Setting: General community.
Participants: A total of 6180 mother-child pairs with measures of urinary iodine and creati-
nine concentrations in pregnancy and child IQ. Exclusion criteria were multiple pregnancies, 
fertility treatment, medication affecting the thyroid, and preexisting thyroid disease.
Intervention(s): None.
Main Outcome Measure: Child non-verbal and verbal IQ assessed at 1.5 to 8 years of age.
Results: There was a positive curvilinear association of urinary iodine/creatinine ratio (UI/
Creat) with mean verbal IQ only. UI/Creat <150 µg/g was not associated with lower non-
verbal IQ (-0.6 point; 95% CI: -1.7 to 0.4 points; P=0.246) or lower verbal IQ (-0.6 point; 
95% CI: -1.3 to 0.1 points; P=0.082). Stratified analyses showed that the association of UI/
Creat with verbal IQ was only present up to 14 weeks of gestation.
Conclusions: Fetal brain development is vulnerable to mild to moderate iodine deficiency, 
particularly in the first trimester. Our results show that in future randomized controlled trials 
investigating the effect of iodine supplementation on child neurodevelopment in women with 
mild to moderate iodine deficiency, such supplementation should begin no later than the first 
trimester.
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Introduction
Iodine is an essential trace element required for the production of thyroid hormones; optimal 
thyroid hormone availability is important for normal fetal brain development 1,2. During preg-
nancy, there is a higher demand for maternal iodine intake 3,4. This is due to i) the increased 
maternal thyroid hormone synthesis required to ensure adequate thyroid hormone availability 
to the fetus, ii) greater urinary iodine loss due to an increased glomerular filtration rate, and 
iii) placental transfer of iodine to the fetus to facilitate fetal thyroid hormone production. 
Although severe iodine deficiency is no longer common in Europe, mild to moderate iodine 
deficiency is still common, especially in pregnant women 5. Severe iodine deficiency in 
pregnancy results in a higher risk of goiter, hypothyroidism, and mental retardation in the 
offspring 6. However, the consequences of mild to moderate iodine deficiency in pregnancy 
on child neurodevelopment are less well established 4.
Mild to moderate iodine deficiency or low iodine intake during pregnancy has been as-
sociated with adverse child neurodevelopmental outcomes observed in some 7–13 but not all 
studies 14–16. Differences in results between studies may be related to methodological differ-
ences (e.g., measurement of iodine status, selected reference group, and available data on 
confounders), the age at assessment of the neurodevelopmental outcome of interest, the timing 
of the iodine measurements, and the relative severity of iodine deficiency in the population. 
Although the main focus in the literature has been on the effects of iodine deficiency, some 
studies have suggested adverse effects of supplementary intake or excess iodine on either 
maternal thyroid function 17,18, fetal thyroid function 19,20, or child neurodevelopment 10,15,16.
International health authorities have similar recommendations to ensure optimal iodine 
status in pregnancy 21–23. It is universally recognized that any necessary iodine supplementa-
tion should be commenced before or as early as possible in pregnancy to achieve adequate 
iodine intake, owing to the susceptibility of the fetal brain to iodine deficiency 23. However, 
whether the effect of iodine on child cognition varies during different stages of pregnancy is 
unknown. We therefore assessed the association between maternal iodine status in pregnancy 
and child IQ across three cohorts of differing iodine status and investigated potential effect 
modification by gestational age.
Material and Methods
Study design and populations
This study was embedded in three cohort studies: Generation R (the Netherlands), the IN-
fancia y Medio Ambiente Project (INMA; Spain, three regions), and the Avon Longitudinal 
Study of Parents and Children (ALSPAC; United Kingdom). The study designs have been 
described elsewhere 24–27; the ALSPAC study website contains details of all the data that 
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are available through a fully searchable data dictionary and variable search tool 28. For the 
current study, mother-child pairs were included if a measure of urinary iodine and creatinine 
concentration during pregnancy and child IQ scores were available. Exclusion criteria were 
multiple pregnancies, fertility treatment, medication affecting the thyroid, and preexisting 
thyroid disease. Ethical approval was obtained from the Medical Ethical Committee of the 
Erasmus Medical Center (Generation R); the Ethical Committee of the Municipal Institute 
of Medical Investigation and the Ethical Committee of the hospitals involved in the study 
(INMA); and the ALSPAC Ethics and Law Committee and local research ethics committees; 
approval was given by participants and/or parents or guardians of the children by signed 
informed consent form.
Maternal iodine status
Urinary iodine concentration (UIC) and creatinine concentration were measured in spot urine 
samples stored at -20°C after collection. As part of this study, additional urine samples were 
analyzed for iodine and creatinine concentrations, and existing measurements from each 
cohort 7,19,29 were also included. The additional measurements were performed in the same 
laboratories where the existing measurements were performed. The laboratories were reg-
istered with EQUIP and used certified reference materials (Seronorm Urine Levels one and 
two; Nycomed, Norway) for the verification of results. In Generation R, UIC was measured 
by the Sandell-Kolthoff method. In INMA, UIC was measured using paired-ion reversed-
phase, high-performance liquid chromatography with electrochemical detection at a silver 
working electrode (Waters Chromatography, Milford, MA). In ALSPAC, UIC was measured 
on a dynamic reaction cell inductively coupled plasma mass spectrometer. Urinary creatinine 
concentration was determined by the Jaffe rate method in all cohorts. More information 
on the measurement methods and the variability between assays can be found in an online 
repository 30.
In a subset of women, repeated measures of urinary iodine and creatinine were available; 
we used the earliest available sample as an indicator of iodine status. The urinary iodine/
creatinine ratio (UI/Creat) was used as a measure of iodine status. Because of possible con-
tamination of UIC by the use of iodine-containing test strips in ALSPAC 31, UIC >500 µg/L 
and/or UI/Creat >700 µg/g was excluded from the analyses in this cohort (N=363). These 
cutoffs were based on previous work in ALSPAC and from other studies of pregnant women 
in the United Kingdom 7,32,33. We grouped women’s results by UI/Creat as follows: (i) <150 
µg/g, (ii) 150 to < 500 µg/g, and (iii) ≥500 µg/g; according to the World Health Organiza-
tion classification, these groups broadly relate to iodine deficiency, sufficiency, and excess, 
respectively.
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Maternal thyroid function
TSH and free thyroxine (FT4) were measured according to different methodologies between 
cohorts, which are described in detail elsewhere 34–36. For the analysis, FT4 and TSH con-
centrations were logarithmically transformed, and cohort-specific SD scores were calculated 
with a mean of 0 and an SD of 1 based on the data of thyroid peroxidase antibody (TPOAb)-
negative women (TPOAb measurements were available in Generation R and ALSPAC). 
TPOAb titres ≥ 60 IU/mL and ≥ 6 IU/mL were considered positive in Generation R and 
ALSPAC, respectively. These cutoffs were determined by the assay manufactures.
Non-verbal and verbal IQ
In Generation R, non-verbal IQ was assessed at a median age of 5.9 years using a subset of the 
Snijders Oomen Nonverbal Intelligence Test (2.5-7-Revised) 37, and verbal IQ was estimated 
by the short form of the McArthur Communicative Development Inventory 38 at a median age 
of 1.5 years. In INMA, non-verbal and verbal IQ scores were assessed at a median age of 4.6 
years using McCarthy Scales of Children´s Abilities 39. In ALSPAC, non-verbal and verbal 
IQ scores were assessed at a median age of 8.6 years using the Wechsler Intelligence Scale 
for Children, third UK edition 40. Except for verbal IQ ascertainment in Generation R, which 
involved a parental questionnaire, all other measurements were performed by psychologists or 
trained staff. To homogenize the different scores, raw cohort-specific scores were standardized 
to a mean of 100 and an SD of 15. Children with IQ scores <50 or >150 (n=3) were considered 
as outliers and excluded from analyses. Suboptimal IQ was defined as an IQ score <85.
Potential confounding variables
Information on maternal age, educational level (low, middle, high), ethnicity/country of birth 
(cohort-specific categories), parity (zero, one, two or more), pre-pregnancy body mass index, 
and smoking during pregnancy (never smoked, smoked in the beginning or until pregnancy 
confirmed, continued smoking) was collected by questionnaires administered during preg-
nancy. Gestational age at urine sampling was defined using ultrasonography or last menstrual 
period. Child sex and age at time of the IQ assessment was obtained during the study visits.
Statistical analyses
UI/Creat was not normally distributed and was therefore transformed using the natural loga-
rithm; back-transformed values are shown in plots for better interpretation. We studied the 
associations of UI/Creat with child non-verbal and verbal IQ by using one-step and two-step 
approaches. In the one-step approach, data from the cohorts were pooled, and we performed 
standard multivariable linear regression models with and without a quadratic term to investi-
gate the possible non-linear nature of the associations. Non-linearity was also investigated by 
using ordinary least squares linear regression models with restricted cubic splines with three 
knots. With ANOVA, we tested the null hypothesis that child mean IQ was similar across 
86 Chapter 4.1
the full range of the natural logarithm of UI/Creat. The decision for linear regression models 
instead of multilevel models for the one-step analyses was made because we found no differ-
ence between multilevel models with random intercepts and/or slope per cohort vs standard 
linear regression correcting for cohort (e.g., cohort-specific variable ethnicity/country of 
birth) when assessed using the Akaike information criterion and log-likelihood tests. In the 
two-step approach we first studied the associations of UI/Creat < 150 µg/g and UI/Creat ≥ 
500 µg/g with child IQ by using linear regression models in each cohort separately. In these 
analyses, the reference group consisted of women with UI/Creat of 150 to 500 µg/g. We then 
combined the cohort-specific effect estimates using random-effects meta-analyses.
Potential effect modification according to gestational age was analyzed by adding a product 
interaction term between UI/Creat and gestational age to the one-step approach models. Be-
cause of the known constraints of statistical power for interaction analyses, a P value <0.15 
for interaction terms was used to screen for potential relevant modification 41. We further 
quantified potential relevant differences by performing stratified analyses by tertiles of gesta-
tional age (≤12 weeks, >12 to ≤14 weeks, and >14 weeks). We also studied associations with 
suboptimal IQ (score <85) by combining cohort-specific estimates from logistic regression 
models into random-effects meta-analyses.
Sensitivity analyses were designed to study i) the associations of UI/Creat with verbal IQ 
score in mother-child pairs from INMA and ALSPAC only, as verbal IQ was assessed at a 
preschool age in Generation R; ii) the association between UI/Creat and maternal TSH and 
FT4 SD scores within the ± 4 SD range around the mean, as TSH and FT4 values outside this 
range were considered outliers (n=19 for TSH; n=5 for FT4); and iii) whether the association 
between UI/Creat and IQ score could potentially be explained by maternal thyroid function 
by adjusting for FT4 and TSH in the models.
 Heterogeneity between cohorts was assessed using the Cochran Q test and the I2 statistic 42. 
All models were adjusted for potential confounding variables. However, because of collinear-
ity between maternal ethnicity/country of birth, child age at IQ ascertainment, and cohort, we 
only adjusted for maternal ethnicity/country of birth in the one-step approach models.
We applied inverse probability weighting to take into account the potential differential 
loss to follow-up (Supplemental Table 1) 30 (i.e., to account for selection bias that potentially 
arises when only the population with available data on iodine status and child IQ is included 
compared with a full initial cohort recruited at pregnancy 43). Briefly, we used information 
available for all participants at recruitment to predict the probability of participation in the 
study and used the inverse of these probabilities as weights in the analyses so that results 
would be representative of the initial populations of the cohorts. In addition, missing values 
in potential confounding variables were imputed using chained equations 44. A total of 25 
datasets were generated. A P value <0.05 was defined as statistically significant. Statistical 
analyses were performed in STATA (version 14.0; StataCorp, College Station, TX) and R 
statistical software (version 3.3.2, package rms).
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Results
The fi nal study population consisted of 6180 mother child-pairs (Fig. 1). The median UIC 
(UI/Creat) was 159 µg/L (214 µg/g) in Generation R (adequate intake), 128 µg/L (152 µg/g) 
in INMA (mild defi ciency), and 96 µg/L (124 µg/g) in ALSPAC (moderate defi ciency; Table 
1). Iodine status was determined at a median [interquartile range (IQR)] gestational age of 
13.1 (12.1,14.8) weeks, 13.0 (12.4,14.1) weeks, and 12.0 (8.0-16.0) weeks in Generation R, 
INMA, and ALSPAC, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Final study population
N=6180
Enrolled during pregnancy
N=26631
   20451 exclusions:
18761 no measures of urinary iodine and creatinine
363 possible contaminated samples in ALSPAC 
              (UIC>500 µg/L and/or UI/Creat >700 µg/g
1280 without child IQ data
47 twin pregnancy, thyroid interfering medication 
              usage and/or pre-existing thyroid disease
Subdivided by cohort
Generation R: N=1931
INMA: N=1269
ALSPAC: N=2980
Subdivided by outcome
Non-verbal IQ: N=5788
Verbal IQ: N=5864
Figure 1 Flowchart of selection of the study population.
Non-verbal IQ
Using pooled data in the one-step approach, we observed a positive linear association be-
tween the UI/Creat and mean non-verbal IQ [Fig. 2(a) and Supplemental Table 2 30], although 
this association was not statistically signifi cant. Using the two-step approach in which we 
combined cohort-specifi c eff ect estimates using random-eff ects meta-analysis, neither UI/
Creat <150 µg/g nor UI/Creat ≥500 µg/g was associated with non-verbal IQ (-0.6 point; 95% 
CI: -1.7 to 0.4 points; P=0.246 and -1.1 points, 95% CI: -4.2 to 2.0 points; P=0.478) [(Fig. 
2(b) and 2(c)]. UI/Creat was not associated with suboptimal non-verbal IQ (Supplemental 
Figure 1 30).
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Verbal IQ
Using the one-step approach, we observed a positive curvilinear association between UI/Creat 
and verbal IQ [Fig. 3(a) and Supplemental Table 2 30]. There was a positive linear association 
when measures in preschool children from Generation R were excluded. Using the two-step 
approach, neither UI/Creat <150 µg/g nor UI/Creat ≥500 µg/g was associated with verbal IQ 
(-0.6 point, 95% CI: -1.3 to 0.1 points; P=0.082 and -0.6 point, 95% CI: -2.6 to 1.4 points; 
P=0.552, respectively) [Fig. 3(b) and 3(c) or suboptimal verbal IQ; Supplemental Figure 1 30].
Effect modification according to gestational age
The continuous association of UI/Creat with non-verbal IQ did not differ according to gesta-
tional age at measurement (P for interaction term=0.306). By contrast, we identified possible 
effect modification by gestational age in the association with verbal IQ (P for interaction 
term=0.078). Stratification by tertile of gestational age showed a positive curvilinear associa-
tion of UI/Creat with mean child verbal IQ, with an overall effect of ~5 IQ points during the 
first 12 weeks of pregnancy [Fig. 4(a) and Supplemental Table 3 30]. Furthermore, there was 
a positive linear association between UI/Creat and mean child verbal IQ during the 12th to 
14th weeks of pregnancy, with an overall effect of ~3 IQ points [Fig. 4(b)]. This association 
was no longer present after the 14th week of pregnancy [Fig. 4(c)].
Table 1 Population characteristics.
Variable
Generation R
(n=1931)
INMA
(n=1269)
ALSPAC
(n=2980)
n values n values n values
Offspring neurodevelopment, no. (%)
Suboptimal non-verbal IQa 1540 175 (11.4) 1269 216 (17.0) 2979 479 (16.1)
Suboptimal verbal IQa 1618 279 (17.2) 1269 211 (16.6) 2977 480 (16.1)
Female sex, no. (%) 1931 963 (49.9) 1268 632 (49.8) 2980 1514 (50.8)
Iodine status 1931 1269 2980
UI/Creat, µg/g, median (IQR) 214 (143-308) 152 (96-258) 124 (82-199)
UI/Creat < 150 µg/g, no. (%) 531 (27.5) 623 (49.1) 1831 (61.4)
UI/Creat > 500 µg/g, no. (%) 97 (5.0) 52 (4.1) 81 (2.7)
UIC, µg/L, median (IQR) 159 (90-275) 128 (75-213) 96 (57-153)
Gestational age at urine sampling, wk 1931 1267 2980
Median (IQR) 13.1 (12.1-14.8) 13.0 (12.4-14.1) 12.0 (8.0-16.0)
Range (min-max) 6.1-30.5 8.6-39.4 1.0-42.0
>20th week of gestation, no. (%) 66 (3.4) 130 (10.2) 211 (7.1)
Maternal thyroid function
TSH, mIU/L, median (IQR) 1719 1.29 (0.79-1.95) 1227 1.25 (0.85-1.80) 1102 0.97 (0.64-1.38)
FT4, pmol/L, median (IQR) 1728 14.6 (12.9-16.5) 1229 10.6 (9.7-11.6) 1108 16.2 (14.9-17.7)
TPOAb positivity, no. (%) 1737 98 (5.6) NA NA 1111 146 (13.1)
Gestational age, wk, mean (SD) 1733 13.3 (1.9) 1228 13.2 (1.4) 1118 10.3 (2.7)
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Iodine status and thyroid function
UI/Creat was not associated with TSH (0.007, 95 CI%: -0.044 to 0.058; P=0.789) or with FT4 
(-0.044, 95 CI%: -0.092 to 0.005; P=0.079). The association did not change between UI/Creat 
and child non-verbal or verbal IQ score after adjusting for TSH and/or FT4; there was also no 
sign of effect modification by TSH or FT4 (data not shown). There was no association of UI/
Creat with TSH and FT4 in TPOAb-negative women only.
Table 1 Population characteristics. (continued)
Variable
Generation R
(n=1931)
INMA
(n=1269)
ALSPAC
(n=2980)
n values n values n values
Educational level, no. (%) 1835 1265 2888
Low 154 (8.4) 270 (21.3) 573 (19.8)
Middle 760 (41.4) 525 (41.5) 1810 (62.7)
High 921 (50.2) 470 (37.2) 505 (17.5)
Maternal ethnicity/country of birth, no. (%) 1803 1266 2877
Spanish NA 1184 (93.5) NA
Latin-American NA 56 (4.4) NA
European/other NA 26 (2.1) NA
Dutch 1012 (53.2) NA NA
Indonesian 69 (3.6) NA NA
Cape Verdean 58 (3.1) NA NA
Moroccan 115 (6.0) NA NA
Surinamese 154 (8.1) NA NA
Turkish 170 (9.0) NA NA
Other, non-Western 150 (7.9) NA NA
Other, Western 174 (9.1) NA NA
Maternal ethnicity/country of birth, no. (%)
White NA NA 2841 (98.7)
Non-White NA NA 36 (1.3)
Maternal age, y, mean (SD) 1931 30.5 (4.8) 1257 31.6 (3.9) 2980 28.6 (4.5)
Parity, no. (%) 1931 1267 2877
0 1121 (58.1) 727 (57.4) 1346 (46.8)
1 564 (29.2) 458 (36.1) 992 (34.5)
≥2 246 (12.7) 82 (6.5) 539 (18.7)
Smoking during pregnancy, no. (%) 1744 1254 2926
Never 1319 (75.6) 870 (69.4) 2434 (83.2)
In the beginning of pregnancy 168 (9.6) 168 (13.4) 125 (4.3)
Continued 257 (14.7) 216 (17.2) 367 (12.5)
Pre-pregnancy BMI, kg/m2, median 
(IQR)
1694 22.6 (20.8-25.2) 1269 22.5 (20.8-25.0) 2713 22.2 (20.5-24.4)
Values are based on unimputed data.
 Abbreviations: BMI, body mass index; IQR, interquartile range; NA, not applicable.
a  Suboptimal defined as an IQ score <85.
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Figure 2 Association of maternal iodine status in pregnancy with child non-verbal IQ.
(a) Continuous association, depicted as the mean child non-verbal IQ (black line) with 95% confi dence interval 
(gray area) using pooled data. Models were adjusted for gestational age, child sex, maternal ethnicity/country 
of birth, maternal education, parity, maternal age, pre-pregnancy body mass index, and smoking during preg-
nancy. The P value was provided by an ANOVA test of the null hypothesis that child mean non-verbal IQ was 
similar across the whole range of the natural logarithm of UI/Creat. Forest plots of (b) UI/Creat <150 µg/g 
(“defi ciency”) and (c) UI/Creat ≥500 µg/g (“excess”) compared with the reference group of UI/Creat ≥150 to 
<500 µg/g (“suffi  cient”), depicted as eff ect estimate (dot) with 95% CI per cohort, and overall as estimated by 
random-eff ects meta-analysis (diamond). Abbreviation: Coef, coeffi  cient.
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Figure 3 Association of maternal iodine status during pregnancy with child verbal IQ.
(a) Continuous association, depicted as the mean child verbal IQ (black line) with 95% CI (gray area) using 
pooled data. Models were adjusted for gestational age, child sex, maternal ethnicity/country of birth, maternal 
education, parity, maternal age, pre-pregnancy body mass index, and smoking during pregnancy. The P value 
was provided by an ANOVA test of the null-hypothesis that child mean verbal IQ was similar across the whole 
range of the natural logarithm of UI/Creat. Forest plots of (b) UI/Creat <150 µg/g (“defi ciency”) and (c) UI/
Creat ≥500 µg/g (“excess”) compared with the reference group of UI/Creat ≥150 to <500 µg/g (“suffi  cient”), 
depicted as eff ect estimate (dot) with 95% CI per cohort and overall as estimated by random-eff ects meta-
analysis (diamond). Abbreviation: Coef, coeffi  cient.
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Discussion
This meta-analysis of individual participant data showed that a lower UI/Creat during preg-
nancy was associated with lower verbal IQ score. The association of UI/Creat with verbal 
IQ was only seen up to the start of the second trimester (up to the 14th week of gestation). 
In contrast, we observed no associations between IQ and UI/Creat <150 µg/g or ≥500 µg/g.
Only a few of the previous single-center studies (i.e., the Generation R and ALSPAC cohort 
studies) focused on child non-verbal IQ score 7,14. They found no association between UI/
Creat <150 µg/g and non-verbal IQ score. It was suggested that iodine deficiency in the 
Generation R cohort may not have been severe enough for an association to be identified 14. 
After combining these two cohorts of contrasting iodine status with a third mildly deficient 
population (INMA), there was still no effect of iodine deficiency on non-verbal IQ score.
Our meta-analysis using predefined cutoffs showed that UI/Creat <150 µg/g was not as-
sociated with lower verbal IQ score. The estimates we found for ALSPAC contrasted with 
the strong negative association of maternal UI/Creat <150 µg/g in the first trimester (defined 
as ≤13 weeks gestation) with child verbal IQ score found in a previously published study 
from that cohort (fully adjusted: -2.9, 95% CI: -5.0 to -0.8, P=0.006) 7. However, there are a 
few important differences between the studies. Compared with the previous publication, the 
ALSPAC data in our study included a larger number of mother-child pairs (2980 vs 958), 
fewer iodine-deficient women [1831 (61.4%) vs 646 (67.4%)], a study population with a 
higher UI/Creat [median UI/Creat (IQR): 124 (82 to 199) vs 110 (74 to 170)], and most 
notably, a higher number of mothers with iodine status measured after the first trimester [1135 
(38%) vs 0 (0%); median gestational age (IQR): 12 (8 to 16) weeks vs 10.0 (9 to 12) weeks]. 
In addition, we adjusted our analysis for a more stringent selection of variables. Comparison 
between study populations and additional analysis of the association between UI/Creat <150 
µg/g and a verbal IQ score in the bottom quartile in the whole cohort and in samples ≤13 
weeks’ gestation are described in Supplemental Table 4 and 5 30.
The importance of iodine status in the preconceptional stage for child IQ has recently been 
shown 45. In early pregnancy, the fetus is fully dependent on the placental transfer of thyroid 
hormone to support the crucial processes of brain development 2. There is a need for optimal 
iodine supply from the initiation of conception, implying that sufficient intrathyroidal iodine 
stores at the preconception stage may well be critical. Indeed, our results suggest that the fetus 
is particularly sensitive to suboptimal iodine status in the early stages of pregnancy (e.g., ≤14 
weeks of gestation) for optimal development of verbal IQ. Effects on verbal IQ could possibly 
be explained by the impact of mild iodine deficiency, via thyroid hormone, on the auditory 
system 13,46. In our study, we did not find evidence that the association between UI/Creat 
and verbal IQ was mediated via maternal thyroid function. Possible explanations could be 
that urinary iodine excretion is a highly volatile and crude measurement of individual iodine 
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status and/or a crude marker of thyroidal iodine availability. Alternatively, it is also possible 
that the effects are (in part) mediated via fetal thyroid function.
This study confirms that low iodine status is associated with a reduction in verbal IQ scores, 
putting these children at potential risk for poorer academic achievement 47. Furthermore, our 
findings may have implications on a national level (e.g., by negatively affecting economic 
growth) 48. However, there is still inconclusive evidence that supplementation in pregnant 
women with mild to moderate iodine deficiency is beneficial for child neurodevelopment 
11,15,16,49–53. A recent randomized, placebo-controlled trial showed no benefit on children’s non-
verbal or verbal IQ score with daily supplementation with 200 µg iodine (as potassium iodide) 
in women with mild iodine deficiency 52. In addition to the already mentioned limitations 
of that trial 54, our results provide an additional explanation for the null finding; the trial 
randomly assigned women at up to 14 weeks of gestation, whereas we showed that maternal 
iodine status is particularly important in the first trimester. Although our study needs replica-
tion, it suggests that the trial might have missed a critical period of vulnerability in women 
with iodine deficiency. Our results clearly suggest that additional randomized controlled trials 
should start with iodine supplementation early in the first trimester or preferably even before 
pregnancy.
The strengths of our study are as follows: A consistent approach to the analysis and harmo-
nization of potential confounding variables across cohorts optimized comparisons; advanced 
statistical methods were used to overcome selection bias due to loss to follow up and missing 
data; and UI/Creat was used as a marker of iodine status. The latter has been shown to be 
a more valid measure of iodine excretion when used in the same groups of age and sex 55, 
though we recognize that a single measure may not be reflective of overall iodine status in an 
individual. A limitation of the study is that the assessment of IQ was performed with different 
tools at different ages. Nevertheless, the tools measured the same construct (non-verbal or 
verbal IQ), and the standardization of IQ scores in each cohort facilitated comparison of re-
sults across cohorts. Sensitivity analysis in older children only (e.g., excluding children from 
Generation R, thus reducing the age range at which verbal IQ was assessed) confirmed the as-
sociation between UI/Creat and verbal IQ score. Another limitation is that UIC was measured 
in different laboratories using different assays; it is known that urinary iodine measurements 
vary between laboratories 56. We used laboratories that were registered with EQUIP, and the 
use of certified reference materials enabled us to ensure the accuracy of results.
In conclusion, this study confirms that iodine status in pregnancy is associated with child 
IQ scores, and results indicate that the development of verbal IQ of the fetus is particularly 
vulnerable to suboptimal iodine concentration during early pregnancy up until the start of 
second trimester. As such, our results suggest that iodine supplementation after the first 14 
weeks of pregnancy could be outside of the critical period during which iodine availability 
affects fetal brain development. However, further studies should replicate these data and 
investigate the effects of iodine supplementation.
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Supplemental material
Methods of urinary iodine measurements
In Generation R, urinary iodine was measured by the Sandell-Kolthoff method. Iodine 
calibration was performed using certified reference materials (CRM) Seronorm urine Levels 
one and two (Nycomed, Norway), and four EQUIP samples certified for urinary iodine 
concentration (Centers for Disease Control and Prevention, USA). At a level of 1.7 µmol/l 
iodine the within-assay CV was 5.1% and the between-assay CV was 14.3% (n= 30). In 
INMA, urinary iodine was measured using paired-ion reversed-phase, high-performance 
liquid chromatography (HPLC) with electrochemical detection at a silver working electrode 
(Waters Chromatography, Milford, MA). The accuracy of the results was verified using the 
CRM Seronorm urine Levels one and two (Nycomed, Norway), and internal quality control 
samples. Within run precision was 4.5% relative standard deviation (RSD) at 50 μg/L, 3.2% 
at 100 μg/L and 2.0% at 300 μg/L. Between run precision was 7.9% RSD at 50 μg/L, 3.5% 
at 100 μg/L and 2.5 % at 300 μg/L. In ALSPAC, iodine (127I) was measured on a dynamic 
reaction cell inductively-coupled plasma (ICP) mass spectrometer. The accuracy of the re-
sults was verified using the CRM Seronorm urine Levels one and two (Nycomed, Norway), 
and accuracy was also monitored by measurement of EQUIP samples at regular intervals 
throughout the analysis. Within run precision was 0.83% RSD at 42 µg/L, 2.47% at 84 µg/L, 
0.56% at 149 µg/L and 2.01% at 297 µg/L. Between run precision was 8.69% RSD at 42 
µg/L, 6.54% at 84 µg/L, 7.2% at 149 µg/L and 6.8% at 297 µg/L.
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Supplementary Table 2 Continuous analysis of the association of maternal iodine status during pregnancy 
with child non-verbal and verbal IQ using standard linear regression models.
Type of 
model
Non-verbal IQ verbal IQ
Variables in
the model Beta (95% CI) P-value Beta (95% CI) P-value
linear model UI/Creat 0.602 (-0.007 to 1.210) 0.053 1.061 (0.450 to 1.672) 0.001
non-linear 
model
UI/Creat 0.632 (-5.848 to 7.113) 0.848 10.011 (3.499 to 16.523) 0.003
UI/Creat^2 -0.003 (-0.651 to 0.644) 0.993 -0.898 (-1.549 to -0.247) 0.007
Reported beta and 95% CI are increase in mean child IQ per natural log increase in UI/Creat. UI/Creat^2 refers 
to the addition of a squared logtransformed UI/Creat variable in the model. Analyses were performed using 
linear regression models. Analyses were adjusted for gestational age at urine sampling, child sex, maternal 
ethnicity/country of birth, maternal education, parity, maternal age, pre-pregnancy BMI, and smoking during 
pregnancy.
Lower risk
nonverbal IQ <85
Higher risk
nonverbal IQ <85
Lower risk
nonverbal IQ <85
Higher risk
nonverbal IQ <85
UI/Creat < 150 µg/g(a) (b)
(c) (d)
Lower risk
verbal IQ <85
Higher risk
verbal IQ <85
UI/Creat < 150 µg/g
UI/Creat ≥500 µg/g
Lower risk
verbal IQ <85
Higher risk
verbal IQ <85
UI/Creat ≥500 µg/g
Generation R   
INMA                
ALSPAC          
Overall (I2= 70.2%, p=0.035)
Generation R   
INMA                
ALSPAC          
Overall (I2= 0.0%, p=0.428)
Generation R   
INMA                
ALSPAC          
Overall (I2= 63.2%, p=0.066)
Generation R   
INMA                
ALSPAC          
Overall (I2= 0.0%, p=0.849)
1.1 (0.8, 1.6)
1.8 (1.2, 2.5)
1.0 (0.8, 1.2)
1.2 (0.9, 1.7)
0.6 (0.1, 2,7)
0.6 (0.2, 1.8)
1.2 (0.7, 2.2)
1.0 (0.6, 1.6)
1.1 (0.9, 1.5)
1.5 (1.0, 2.1)
0.9 (0.7, 1.1)
1.1 (0.9, 1.4)
1.2 (0.3, 4.6)
0.9 (0.4, 2.2)
0.8 (0.4, 1.5)
0.9 (0.5, 1.4)
Cohort OR (95% CI) Cohort OR (95% CI)
Cohort OR (95% CI) Cohort OR (95% CI)
.11 .45       1              4.5      9 .11 .45       1              4.5      9
.11 .45       1              4.5      9 .11 .45       1              4.5      9
Supplemental Figure 1 Association of UI/Creat < 150 µg/g and UI/Creat ≥ 500 µg/g during pregnancy with 
child suboptimal non-verbal and verbal IQ.
Figure shows the association of UI/Creat <150 µg/g (“deficiency”) with a) non-verbal IQ score <85 and c) 
verbal IQ score <85, and UI/Creat >=500 µg/g (“excess”) with b) non-verbal IQ score <85 and d) verbal IQ 
score <85 as compared to the reference group (UI/Creat ≥150 to <500 µg/g). Associations are depicted as effect 
estimate (dot) with 95% CI per cohort and overall as estimated by random-effects meta-analysis (diamond). 
Models are adjusted for gestational age, child sex, maternal ethnicity/country of birth, maternal education, par-
ity, maternal age, pre-pregnancy BMI, smoking during pregnancy, child age and region in INMA.
100 Chapter 4.1
Supplemental Table 3 Continuous analysis of the association of maternal iodine status during pregnancy
with child verbal IQ stratified by tertile of gestational age using standard linear regression models.
Type of model Variables in the model Gestational age (weeks) Beta (95% CI) P-value
non-linear model
UI/Creat
≤12
18.276 (6.923 to 29.628) 0.002
UI/Creat^2 -1.786 (-2.953 to -0.620) 0.003
Linear model UI/Creat >12 and ≤14 1.333 (0.230 to 2.436) 0.018
Linear model UI/Creat >14 0.444 (-0.601 to 1.489) 0.405
Reported beta and 95% CI are increase in mean child verbal IQ per log increase in UI/Creat. UI/Creat^2 refers 
to the addition of a squared UI/Creat variable in the model. Analyses were performed using linear regression 
models. UI/Creat was transformed by the natural logarithm. Analyses were adjusted for gestational age at 
urine sampling, child sex, maternal ethnicity/country of birth, maternal education, parity, maternal age, pre-
pregnancy BMI, and smoking during pregnancy.
Supplemental Table 4 Comparison of the ALSPAC study population included in the current study and in the 
previous publication of Bath et al. 2013.
this study cohort this study cohort restricted
to ≤13 weeks gestation
Bath et al. 2013
No. 2980 1845 958
gestational age, median (IQR) 12 (8-16) 9 (7-11) 10 (9-12)
UI/Creat, µg/g, median (IQR) 124 (82-199) 108 (75-161) 110 (74-170)
UI/Creat < 150 µg/g , % 61.4 70.1 67.4
UIC, µg/L, median (IQR) 96 (57-153) 96.8 (60-149) 91.1 (53.8-143)
Supplemental Table 5 Association of maternal iodine status with a child verbal IQ score in the lowest quartile 
as studied in the current ALSPAC study population and as in the previous publication of Bath et al. 2013.
this study cohort this study cohort restricted
to ≤13 weeks gestation
Bath et al. 2013
OR (95% CI), P-value OR (95% CI), P-value OR (95% CI), P-value
1.13 (0.92 to 1.39), 0.259 1.42 (1.06 to 1.91), 0.019 1.58 (1.09 to 2.30), 0.02
Reported OR and 95% CI for a verbal IQ score in the bottom quartile when exposed to a maternal UI/Creat < 
150 µg/g vs ≥ 150 µg/g (reference group) during pregnancy. Analyses with un-imputed data were performed 
using logistic regression models and were adjusted as similarly as possible as compared to the fully adjusted 
model (model 3) as reported in the publication of Bath et al. Analyses were adjusted for preterm birth, birth-
weight, child sex, maternal education, paternal education, maternal ethnicity (instead of child ethnicity), parity, 
age at delivery, smoking, maternal alcohol intake, breastfeeding, iron intake, and omega-3 fatty acid intake 
estimated from the Food Frequency Questionnaire completed at 32 weeks’ of gestation. Missing information 
that was corrected for in model 3 of Bath et al but lacking in the analysis of this study cohort, were: mothers 
parenting score (seven-factor measure of cognitive stimulation at 6 months of age), home observation for 
measurement of environment (HOME) score (six-factor measure of the emotional and cognitive environment 
at 6 months of age), the family adversity index (18-factor measure of hardship during pregnancy), life-event 
score (exposure to 41 stressful events during pregnancy), maternal depression since birth, fish-oil supplements 
during pregnancy, housing status, and crowding.
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Abstract
Context: Low maternal free thyroxine (FT4) has been associated with poor child neurode-
velopment in some single-center studies. Evidence remains scarce for the potential adverse 
effects of high FT4 and whether associations differ in countries with different iodine status.
Objective: To assess the association of maternal thyroid function in early pregnancy with 
child neurodevelopment in countries with a different iodine status.
Design, Setting and Participants: Meta-analysis of individual participant data from 9,036 
mother-child pairs from three prospective population-based birth cohorts: INMA [INfancia y 
Medio Ambiente (Environment and Childhood project) (Spain)], Generation R (Netherlands) 
and ALSPAC (Avon Longitudinal Study of Parents and Children, United Kingdom). The 
exclusion criteria were multiple pregnancies, fertility treatments, thyroid interfering medica-
tion usage, and known thyroid disease.
Main outcomes: Child non-verbal IQ at 5 to 8 years of age, verbal IQ at 1.5 to 8 years of age, 
and autistic traits within the clinical range at 5 to 8 years of age.
Results: FT4 <2.5th percentile was associated with a 3.9-point (95% CI -5.7 to -2.2) lower 
non-verbal IQ and a 2.1-point (95% CI -4.0 to -0.1) lower verbal IQ. A suggestive association 
of hypothyroxinemia with a greater risk of autistic traits was observed. FT4 >97.5th percentile 
was associated with a 1.9-fold (95% CI 1.0 to 3.4) greater risk of autistic traits. No indepen-
dent associations were found with TSH.
Conclusions: Low maternal FT4 was consistently associated with lower IQ across the 
cohorts. Further studies are needed to replicate the findings of autistic traits and investigate 
the potential modifying role of maternal iodine status. FT4 seems a reliable marker of fetal 
thyroid state in early pregnancy, regardless of the type of immunoassay.
Maternal thyroid function, child IQ, and autistic traits 145
Introduction
Thyroid hormone regulates crucial processes of brain development, including the prolifera-
tion, migration, and differentiation of neuronal cells, as shown in animal studies 1,2. Because 
the fetal thyroid gland is not functionally mature until approximately week 18 of pregnancy 3, 
the fetus is dependent on placental transfer of maternal thyroid hormone during this period. 
Adequate maternal thyroid hormone concentrations during early pregnancy are therefore 
essential for optimal fetal brain development.
Previous studies focused mainly on the possible adverse effects of low maternal hormone 
availability on fetal brain development. In several studies, either overt hypothyroidism or low 
maternal free T4 (FT4) was associated with lower child IQ 4–8 and lower gray-matter volume 4, 
a greater risk of autistic traits 9, impaired psychomotor function 10, and schizophrenia 11. Al-
though the association of high maternal FT4 on child neurodevelopment has been less well 
studied, experimental evidence from rodents has indicated that high hormone availability 
may also have adverse effects 12–18. A recent study from the Netherlands has shown that high 
maternal FT4 is associated with lower IQ and gray matter volumes in the child 4. However, 
it is unclear whether these findings from an iodine-sufficient population in the Netherlands 19 
can be extrapolated to other countries with a different iodine status and whether high maternal 
FT4 is also associated with other adverse neurodevelopmental outcomes other than IQ.
Neither of the two randomized controlled trials that studied the effect of levothyroxine 
treatment in women with subclinical hypothyroidism or hypothyroxinemia on child IQ 
showed any benefit of treatment 20,21. However, these negative results could be ascribable to 
a relatively late start of treatment in both trials (13 weeks and 16 to 18 weeks, respectively), 
a relatively high dose was given that might have led to potential overtreatment 20, or a lack of 
power to detect the expected 3- to 4-point difference in IQ 21,22. Therefore, further studies are 
required to better quantify and replicate the potential effects of both low and high maternal 
thyroid hormone availability on fetal neurodevelopment. These studies can help improve the 
design of future controlled trials.
The aim of the present study was to investigate the association of maternal thyroid function 
in early pregnancy across the full range of FT4 and thyrotropin (TSH) concentrations with 
child’s IQ and autistic traits in three prospective birth cohorts.
Material and Methods
Study design and populations
For the present study, we used individual participant data from three prospective population-
based birth cohorts: INfancia y Medio Ambiente [INMA (Environment and Childhood 
project), Spain, three regions] 23, Generation R (the Netherlands) 24, and the Avon Longitu-
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dinal Study of Parents and Children (ALSPAC, United Kingdom) 25. In INMA, the eligible 
study participants were pregnant women with a singleton pregnancy residing in the regions 
of Valencia, Sabadell, and Gipuzkoa from November 2003 to January 2008. In Generation 
R, the eligible study participants were pregnant women living in the Rotterdam area with 
an expected delivery date from April 2002 to January 2006. In ALSPAC, the eligible study 
participants resided in a defined area in the southwest of England, with an expected date of 
delivery from April 1991 to December 1992 (the study website of ALSPAC contains details 
of all the data available through a fully searchable data dictionary 26). For the present study, 
eligible women were enrolled in the three cohorts during the first half of pregnancy (≤18th 
week of gestation). Women with multiple pregnancies or fertility treatment and/or using 
medication affecting the thyroid or having a known thyroid disease were excluded (Fig. 1). 
Ethical approval was obtained from the local ethical committees at the time of study enroll-
ment; all parents or guardians of the children provided informed consent.
Thyroid function
Thyroid function was measured in serum samples stored at -80°C (INMA and Generation 
R) or -20°C (ALSPAC). The samples were obtained at early pregnancy [ (mean ± SD) ges-
tational age: INMA, 13.1 ± 1.3 weeks; Generation R, 13.4 ± 2.0 weeks; ALSPAC, 11.0 ± 3.2 
weeks] (Table 1). Different assays were used to measure FT4 and TSH (Supplemental Table 
1). Although thyroid peroxidase antibody (TPOAb) was not measured in INMA, TPOAb 
measurements were available from Generation R and ALSPAC. The FT4 and TSH concentra-
tions were logarithmically transformed, and cohort-specific SD scores were calculated with a 
mean of 0 and a SD of 1 based on the data of TPOAb-negative women, as advocated by the 
guidelines when defining population-based reference ranges 27.
Hypothyroxinemia [normal (2.5th-97.5th percentile) TSH, low (<2.5th percentile) FT4], 
subclinical hypothyroidism [high (>97.5th percentile) TSH, normal FT4], and subclinical 
hyperthyroidism (low TSH, normal FT4) were defined according to the 2.5th and the 97.5th 
population-based percentiles of the whole study population in INMA, because TPOAb 
measurements were not available. Thyroid disease entities were defined using the same 
population-based percentiles in Generation R and ALSPAC. However, in these cohorts, the 
population-based percentiles were based on the results from TPOAb-negative women. The 
reference group consisted of euthyroid women (TSH and FT4 between the 2.5th and 97.5th 
percentiles). Additionally, to improve the statistical power, we identified thyroid disease enti-
ties using the 5th and the 95th population-based percentiles. The untransformed 2.5th and 
97.5th population-based percentiles. The untransformed 2.5th and 97.5th population-based 
percentiles based on TPOAb-negative women when possible were 0.14 and 3.86, 0.05 and 
4.13, and 0.07 and 2.58 mIU/L for TSH and 8.4 and 14.0, 10.4 and 22.1, and 12.6 and 22.5 
pmol/L for FT4 in INMA, Generation R, and ALSPAC, respectively.
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Non-verbal and verbal IQ
In INMA, non-verbal and verbal IQ were assessed by a psychologist at a median age of 4.6 
years using the McCarthy Scales of Children´s Abilities 28. In Generation R, non-verbal IQ 
was assessed by trained staff at a median age of 6.0 years using a subset of the Snijders Oomen 
Nonverbal Intelligence Test (2.5-7-Revised) 29, and verbal IQ was estimated by the parent-
reported short form of the McArthur Communicative Development Inventory 30 obtained at a 
median age of 1.5 years. In ALSPAC, non-verbal and verbal IQ were assessed by trained staff 
at a median age of 8.6 years using the Wechsler Intelligence Scale For Children, third UK 
edition 31. To homogenize the different scores, raw cohort-specific scores were standardized 
to a mean of 100 and a SD of 15 (new score = 100 + 15 x SD).
Enrolled during ≤18 weeks
N=13,881
TSH and FT4 measurement unavailable (mostly due to serum 
unavailability or measurement errors):                     N=1,157
IQ/autistic traits unavailable due to lack of follow-up: N=3,126 
Final study population
N=9,036
Subdivided by cohort
INMA: N=1,289
Generation R: N=4,660
ALSPAC: N=3,087
Subdivided by outcome
Nonverbal IQ: N=7,317
Verbal IQ N=7,280
Autistic traits N=7,773
Singleton pregnancies without thyroid disease or 
interfering thyroid medication usage
N=13,319
Exclusions:
Thyroid disease/medication:  N=214
IVF or multiple pregnancy:     N=348
Figure 1 Flowchart for the selection of the final study population. IVF, in vitro fertilization.
Autistic traits within the clinical range
Autistic traits are symptoms that represent subclinical deficits in social behavior, communica-
tion, and or restricted, repetitive patterns of behavior common to ASD but that do not meet 
clinical ASD diagnosis 32. Autistic traits within the clinical range were defined as the presence 
of an autistic traits score greater than the specific cutoff for each assessment tool, which had 
been previously validated in other studies to detect children at risk of ASD. In INMA, autistic 
traits were assessed with the Childhood Autism Spectrum Test (CAST) by a psychologist at a 
median age of 4.6 years, with a cutoff of ≥ 15 points to define autistic traits within the clinical 
range 33. In Generation R, autistic traits were assessed using the Pervasive Developmental 
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Problems subscale of the Child Behavior Checklist for Toddlers (CBCL1½–5) by the parents 
at a median age of 5.9 years, with a cutoff of ≥98th percentile to define autistic traits within 
the clinical range 34. In ALSPAC, autistic traits were assessed with the Social Communication 
Disorder Checklist (SCDC) by the parents at a median age of 7.6 years of age, with a cutoff 
of nine or more points to define autistic traits within the clinical range 35.
Potential confounding variables
A direct acyclic graph 36 facilitated decision making regarding which covariates should be 
adjusted for in the analysis. Information on maternal variables [age, educational level (low, 
medium, high), ethnicity (cohort-specific categories), parity (zero, one, two or more), pre-
pregnancy body mass index (BMI), and smoking during pregnancy (never smoked, smoked 
in the beginning or until pregnancy confirmed, continued smoking)] was collected during 
pregnancy using questionnaires. Gestational age at blood sampling was defined using ultra-
sonography or the last menstrual period. Child sex and age at IQ or autistic trait ascertainment 
were obtained during the study visits.
Statistical analyses
We used linear regression models to study the association of maternal FT4, TSH, and thyroid 
disease entities with child non-verbal or verbal IQ. We used logistic regression models to 
study the association of maternal FT4, TSH, and thyroid disease entities with child autistic 
traits within the clinical range.
We studied these associations using a one-step and a two-step approach. In the one-step 
approach, we assessed non-linearity between FT4 and TSH and each outcome using restricted 
cubic splines with three to five knots. An ANOVA test was used to report an overall P value 
for the null hypothesis that the mean IQ or probability of autistic traits within the clinical 
range was similar across the whole distribution of TSH or FT4. In the two-step approach, we 
combined cohort-specific effect estimates of the association between FT4, TSH, and thyroid 
disease entities and each outcome using random-effects meta-analyses. For this analysis, FT4 
and TSH concentrations were categorized as <2.5th, <5th, >95th, or >97.5th percentiles using 
women with values within the interquartile range (within the 25th and 75th percentile range) 
as the reference group. Compared with the one-step approach, the two-step approach allows 
for differences in participant characteristics between cohorts, and heterogeneity between 
cohorts can be calculated 37. Heterogeneity was assessed using the Cochran Q test and the I2 
statistic 38. All models were adjusted for maternal age, educational level, ethnicity, parity, pre-
pregnancy BMI, smoking, gestational age at blood sampling, and child sex. Because one-step 
approach models could not be adjusted for age at IQ or autistic trait ascertainment, cohort, 
and ethnicity at the same time owing to collinearity, we adjusted them only for ethnicity. The 
two-step approach models could be adjusted for these variables because the effect-estimates 
were calculated separately by cohort.
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Table 1 Distribution of maternal and child characteristics.
Variable INMA(n=1,289)
Generation R
(n=4,660)
ALSPAC
(n=3,087)
Maternal TSH, median (IQR), mIU/L 1.24 (0.84-1.81) 1.36 (0.85-2.03) 1.00 (0.64-1.46)
Maternal FT4, median (IQR), pmol/L 10.6 (9.7-11.6) 14.8 (13.2-16.7) 16.2 (14.8-17.7)
Thyroid disease entities,a n (%)
Hypothyroxinemia 32 (2.5) 111 (2.4) 61 (2.0)
Subclinical hypothyroidism 31 (2.4) 140 (3.0) 110 (3.6)
Subclinical hyperthyroidism 20 (1.6) 69 (1.5) 34 (1.1)
TPOAb positivity, n (%) NA 254 (5.8) 392 (12.8)
Gestational age at blood sampling, mean ± SD, wk 13.1 (1.3) 13.4 (2.0) 11.0 (3.2)
Maternal educational level, n (%)    
Low 281 (21.9) 353 (8.0) 736 (24.7)
Medium 537 (41.8) 1,904 (42.9) 1,828 (61.3)
High 468 (36.4) 2,179 (49.1) 416 (14.0)
Maternal ethnicity, n (%)    
Spanish 1,202 (93.4) NA NA
Latin-American 60 (4.7) NA NA
European/other 25 (1.9) NA NA
Dutch NA 2,606 (56.7) NA
Indonesian NA 150 (3.3) NA
Cape Verdean NA 170 (3.7) NA
Moroccan NA 225 (4.9) NA
Dutch Antilles NA 104 (2.3) NA
Surinamese NA 351 (7.6) NA
Turkish NA 356 (7.8) NA
Asian NA 51 (1.1) NA
Other, non-Western NA 162 (3.5) NA
Other, Western NA 418 (9.1) NA
White NA NA 2,924 (98.6)
Non-white NA NA 42 (1.4)
Maternal age, mean ± SD, y 31.5 (4.0) 30.3 (4.8) 28.0 (4.6)
Parity, n (%)    
0 731 (56.8) 2,721 (58.4) 1,410 (47.2)
1 472 (36.7) 1,386 (29.7) 1,033 (34.6)
≥2 84 (6.5) 553 (11.9) 543 (18.2)
Maternal smoking, n (%)    
Never smoked 883 (69.4) 3,085 (73.5) 2,391 (79.2)
Smoked at the beginning of pregnancy 174 (13.7) 396 (9.4) 142 (4.7)
Continued smoking 216 (17.0) 719 (17.1) 486 (16.1)
Pre-pregnancy BMI, median (IQR), kg/m2 22.5 (20.8-25.1) 22.6 (20.7-25.2) 22.1 (20.5-24.2)
Child female sex, n (%) 635 (49.3) 2,313 (49.6) 1,500 (48.6)
Child autistic traits within the clinical range, n (%) 16 (1.4) 117 (3.1) 206 (7.5)
Data might not sum to 100 because of rounding.
Abbreviations: BMI, body mass index; IQR, interquartile range; NA, not available.
a Based on the 2.5th and 97.5th population-based percentiles.
150 Chapter 5.1
As a sensitivity analysis, we adjusted the analyses of autistic traits for non-verbal IQ, a 
language- and culture-free measure of cognitive ability. Additionally, when we observed 
associations between maternal TSH and child IQ or autistic traits, we repeated the analysis 
stratifying by low-, mid-, and high-normal FT4. Finally, all analyses were repeated in the 
TPOAb-negative women only.
We applied inverse probability weighting to correct for potential differential loss to follow-
up 39. We performed multiple imputation using chained equations to account for missing 
values for the potential confounding variables 40. A total of 25 datasets were generated and 
analyzed using standard procedures for multiple imputation. Statistical analyses were per-
formed in STATA, version 14.0 (StataCorp, College Station, TX) and R statistical software, 
version 3.3.2, package rms and lme4 (R Foundation, Vienna, Austria).
Results
After exclusions, the final study population included 9036 mother-child pairs (Fig. 1), the 
characteristics of which are shown in Table 1. The mean maternal age varied across cohorts: 
31.5 years in INMA, 30.3 years in Generation R, and 28.0 years in ALSPAC. The percentage 
of mothers who continued smoking during pregnancy was similar among the cohorts (~ 16% 
to 17%). Autistic traits within the clinical range occurred in 1.4% of the children in INMA, 
3.1% in Generation R, and 7.5% in ALSPAC. The two most prevalent thyroid disease entities 
were hypothyroxinemia (2.0% to 2.5% across the cohorts) and subclinical hypothyroidism 
(2.4% to 3.6% across the cohorts). Compared with the final study population, the women not 
included in the analysis had a lower level of education, were less often native or white, and 
were younger in all three cohorts (Supplemental Table 2).
Non-verbal IQ
We observed a statistically significant nonlinear association between maternal FT4 and mean 
non-verbal IQ (Fig. 2). FT4 ≤2.5th percentile was associated with a 3.9-point (95% CI -5.7 
to -2.3; P<0.001) lower non-verbal IQ. Similar results were observed when using the fifth 
percentile cut-off. A high FT4 was not associated with the non-verbal IQ. TSH ≥97.5th and 
≥95th percentile was associated with a statistically non-significant slightly greater non-verbal 
IQ (1.5 points; 95% CI, -0.3 to 3.3; P=0.100; and 1.2 points, 95% CI, -0.1 to 2.5; P=0.063, 
respectively; Supplemental Fig.1). However, the sensitivity analysis showed that this as-
sociation was driven by women with a FT4 concentration in the mid- or high-normal range 
(Supplemental Table 3). No heterogeneity was observed among the cohorts. Results remained 
similar after excluding TPOAb-positive women.
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Verbal IQ
A statistically non-significant linear association was found between maternal FT4 and mean 
verbal IQ (Fig. 3). FT4 ≤2.5th percentile was associated with a 2.1-point (95% CI, -4.0 to -0.1; 
P=0.039) lower verbal IQ. In contrast, the association of FT4 at the fifth percentile or less was 
associated with a statistically non-significant slightly lower verbal IQ (-1.4 points; 95% CI 
-2.9 to 0.2; P=0.078). A high FT4 was not associated with verbal IQ. A low TSH was also not 
associated with verbal IQ (Supplemental Fig. 2). TSH ≥97.5th percentile was associated with 
a greater verbal IQ (1.9 points; 95% CI, 0.1 to 3.7; P=0.039). However, no association was 
found for TSH ≥95th percentile. The sensitivity analysis showed that the positive association 
of a high TSH ≥97.5th percentile with verbal IQ was driven by women with a FT4 concentra-
tion in the mid- or high-normal range (Supplemental Table 4). No heterogeneity was observed 
among the cohorts. The results remained similar after excluding TPOAb-positive women.
Autistic traits
No continuous association was found for maternal FT4 with child autistic traits (Fig.4). FT4 
≤2.5th percentile was not associated with autistic traits, but FT4 ≤5th percentile was associ-
ated with a statistically non-significant slightly higher risk of autistic traits [odds ratio (OR), 
1.5; 95% CI, 1.0 to 2.3; P=0.080). FT4 ≥97.5th percentile was associated with a 1.9-fold 
(95% CI, 1.0 to 3.4; P=0.043) greater risk of autistic traits. A similar association was found 
after adjusting for non-verbal IQ (data not shown). FT4 ≥95th percentile was not associated 
with autistic traits. TSH was not associated with autistic traits (Supplemental Fig. 3). No 
heterogeneity was observed among the cohorts. The results remained similar after excluding 
TPOAb-positive women.
Clinical disease entities
Highly similar results were obtained when FT4 and TSH were combined into clinical disease 
entities. Hypothyroxinemia, based on the 2.5th and 97.5th population-based percentiles, 
was associated with a 3.8-point (95% CI, -5.7 to -2.0; P<0.001) lower non-verbal IQ and a 
2.8-point (95% CI, -4.8 to -0.7; P=0.007) lower verbal IQ (Supplemental Fig. 4) but was not 
associated with autistic traits. For hypothyroxinemia, based on the 5th and 95th population-
based percentiles, similar results were found with non-verbal and verbal IQ, with a 1.8-fold 
(95% CI, 1.1 to 2.8; P=0.011) greater risk was found with autistic traits (Supplemental Fig. 
4), which remained after adjusting for non-verbal IQ (data not shown).
Subclinical hypothyroidism, based on the 2.5th and 97.5th population-based percentiles, was 
associated with a 1.9-point (95% CI, 0.1 to 3.6; P=0.037) greater non-verbal IQ but not with 
verbal IQ or autistic traits (Supplemental Fig. 5). When defining subclinical hypothyroidism 
using the 5th and 95th population-based percentiles, the association with non-verbal IQ became 
statistically non-significant (1.3 points; 95% CI -0.2 to 2.9; P=0.096). Subclinical hyperthyroid-
ism was not associated with non-verbal IQ, verbal IQ or autistic traits (Supplemental Fig. 6).
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Figure 2 Association of maternal FT4 during early pregnancy with child non-verbal IQ.
Association shown as a) a continuous association depicted as the mean child non-verbal IQ (black line) with 
95% CI (gray area) and by cohort-specifi c maternal FT4 concentrations in the (b) <2.5th percentile, (c) >97.5th 
percentile, (d), <5th percentile, and (e) >95th percentile compared with interquartile range (between 25th and 
75th percentiles), depicted as eff ect estimate (dot) with the 95% CI per cohort and overall as estimated by ran-
dom-eff ects meta-analysis (diamond). The I2 for each model is as follows: for FT4<2.5th percentile, I2=0.0%; 
for FT4>97.5th percentile, I2=48.5%; for FT4<5th percentile, I2=0.0%; for FT4>95th percentile, I2=37.8%.
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Figure 3 Association of maternal FT4 during early pregnancy with child verbal IQ.
Association shown as (a) a continuous association depicted as the mean child verbal IQ (black line) with 95% 
CI (gray area) and by cohort-specifi c maternal FT4 concentrations in the (b) <2.5th percentile, (c) >97.5th per-
centile, (d) <5th percentile, and (e) >95th percentile compared with interquartile range (between 25th and 75th 
percentiles), depicted as eff ect estimate (dot) with the 95% CI per cohort and overall as estimated by random-
eff ects meta-analysis (diamond). The I2 for each model is as follows: for FT4<2.5th percentile, I2=0.0%; for 
FT4>97.5th percentile, I2=0.0%; for FT4<5th percentile, I2=0.0%; for FT4>95th percentile, I2=0.0%.
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Figure 4 Association of maternal FT4 during early pregnancy with child autistic traits within the clinical range.
Association shown as (a) a continuous association depicted as the mean risk of child autistic traits within the 
clinical range (black line) with 95% CI (gray area) and by cohort-specifi c maternal FT4 concentrations in 
the (b) <2.5th percentile (c) >97.5th percentile, (d) <5th percentile, and (e) >95th percentile compared with 
interquartile range (between 25th and 75th percentile), depicted as eff ect estimate (dot) with 95% CI per co-
hort and overall as estimated by random-eff ects meta-analysis (diamond). The I2 for each model is as follows: 
for FT4<2.5th percentile, I2=7.4%; for FT4>97.5th percentile, I2=0.0%; for FT4<5th percentile, I2=0.0%; for 
FT4>95th percentile, I2=0.0%.
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Discussion
To the best of our knowledge, the present study is the first individual participant data meta-
analysis. We have demonstrated that low maternal FT4 in early pregnancy is associated with 
lower non-verbal and verbal child IQs. We also found a suggestive association between ma-
ternal hypothyroxinemia and high FT4 with a greater risk of autistic traits within the clinical 
range. In contrast to FT4, maternal TSH was not independently associated with non-verbal, 
verbal IQ, or autistic traits within the clinical range.
The association between low maternal FT4 and child IQ, specifically non-verbal IQ, was 
highly similar among the three cohorts, convincingly replicating the results of previous obser-
vational studies 4–9. A recent randomized controlled trial studied the effects of levothyroxine 
treatment for women with subclinical hypothyroidism or hypothyroxinemia on child full IQ 21. 
Although levothyroxine treatment of hypothyroxinemia or subclinical hypothyroidism started 
in mid-pregnancy (week 16 to 18), a statistically non-significant 3 points greater median 
child IQ was found after levothyroxine treatment compared with placebo. The associations 
of hypothyroxinemia with a 3.8- and 2.8-point lower non-verbal and verbal IQ, respectively, 
found in our study compared with euthyroid women might seem small on an individual level. 
However, on a population level, this might have effects on educational achievements and 
capita per income, among others 41.
The consistent association of low maternal FT4 with adverse child neurocognitive out-
comes, specifically lower non-verbal IQ in three independent cohorts, is particularly relevant 
given that all three cohorts used a different immunoassay to measure FT4. The value of an 
FT4 measurement during pregnancy has been under debate, because the absolute values 
of FT4 might have been under- or overestimated when measured using immunoassays in 
pregnancy, especially in the third trimester 42–44. However, these results suggest that FT4 is a 
reliable clinical marker of the fetal thyroid state in early pregnancy, a period when maternal 
FT4 is the sole source of thyroid hormones for the fetus and influences the developmental 
processes, including proliferation, migration, and differentiation of neuronal cells in various 
parts of the brain 45. No conclusions about the use of FT4 assays during the later stages of 
pregnancy, when the fetal thyroid is fully functional, should be drawn from these data.
In our study, the effect estimates for non-verbal IQ were larger than for those for verbal IQ. 
Non-verbal IQ is a language- and culture-free measure of cognitive ability that is less depen-
dent on the learning stimulus received by the child during the first years of life. Therefore, it 
might be a better neurodevelopmental outcome for detecting the effects of maternal exposures 
in early pregnancy, such as thyroid hormone levels.
Our results did not show an association between high maternal FT4 and non-verbal or verbal 
IQ across the three cohorts, although we confirmed the previously reported association with 
the Generation R data 4. The discrepancies in the association of high FT4 and non-verbal IQ 
among the cohorts might have resulted from population differences such as maternal iodine 
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status, which differed considerably among the cohorts. Pregnant women in Generation R had 
an adequate iodine status according to the World Health Organization (median urinary iodine 
concentration, 229.6 μg/L 19). In contrast, mild to moderate iodine insufficiency was present 
in the INMA and ALSPAC cohorts (median, 94 to 168 μg/L depending on the region and 91.1 
μg/L, respectively 46,47). Although mild-to-moderate iodine deficiency has been associated 
with adverse neurodevelopmental outcomes, such as lower verbal IQ, worse language skills, 
reduced educational outcomes, impaired executive function, more behavior problems, and 
worse fine motor skills, this was not found in iodine-deficient women in a iodine sufficient 
population 19,48–50. It is unclear how much of the association of iodine deficiency with child 
neurocognitive outcomes can be attributed to impaired thyroid function in the mother or to 
impaired thyroid function in the fetus. Further studies should elucidate the mediating role 
of maternal and fetal thyroid function in the association between maternal iodine status and 
child neurodevelopment.
To date, only two studies have explored the association between maternal thyroid func-
tion and ASD diagnosis or autistic traits. The Danish study was based on registry linkage 
information and showed that maternal diagnosed or treated hypothyroidism was associated 
with a greater risk of a diagnosed ASD (hazard ratio, 1.30, 95% CI, 1.11 to 1.53) 51. The Dutch 
study from the Generation R cohort found that severe hypothyroxinemia, defined as maternal 
FT4 ≤5th percentile with normal TSH, was associated with a greater risk of autistic traits 9. In 
the present meta-analysis, including data from Generation R, we also found an association 
between hypothyroxinemia using the FT4 fifth percentile or less cutoff and a greater risk of 
autistic traits. However, when using the FT4 ≤2.5th percentile cutoff, no greater risk of autistic 
was found, suggesting the possibility of a chance finding. Likewise, high FT4 was associ-
ated with a greater risk of autistic traits, although only when the more stringent cutoff was 
used (i.e., FT4 ≥97.5th percentile). Considering the crucial role of thyroid hormones in key 
processes in the pathophysiology of ASD, including neuronal cell migration, synaptogenesis, 
synapse maintenance, neuronal activity, and fetal growth 52,53, it is biologically plausible that 
nonoptimal levels of maternal FT4 during early pregnancy are related to a greater risk of 
ASD. However, the inconsistent results across cohorts or cutoffs limited us from drawing firm 
conclusions regarding this potential association. Further studies focusing on autistic traits or 
ASD diagnosis are therefore needed to replicate and better understand the full extent of these 
results.
TSH is frequently used as a marker of thyroid status during pregnancy. Subclinical hypo-
thyroidism has been associated with a greater risk of miscarriage and preterm delivery, and 
the beneficial effects of levothyroxine treatment for hypothyroid women have been shown in 
some trials, especially in TPOAb-positive women 54–57. Therefore, the current international 
guidelines recommend screening for TSH first, either directly in combination with TPOAb 
status 27 or determining TPOAb status and FT4 only when TSH is elevated 58. The results from 
the present study call into question the use of TSH as the only first-line parameter to screen 
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maternal thyroid status in early pregnancy. First, elevated human chorionic gonadotropin 
concentrations stimulate the thyroid directly to produce thyroid hormone, which induces a 
decrease in TSH in early pregnancy 59. Therefore, TSH might not be the best marker for 
maternal thyroid status in this time window. Second, in our study, maternal TSH was not 
independently associated with non-verbal IQ, verbal IQ, or autistic traits, in contrast to FT4. 
However, owing to the absence of available randomized trials demonstrating the benefit of 
levothyroxine treatment for maternal hypothyroxinemia, screening for FT4 cannot be advo-
cated.
One strength of the present study was that we investigated the association of maternal 
thyroid function with child neurodevelopmental outcomes in a prospective manner using a 
large dataset with detailed data on non-verbal IQ, verbal IQ, and autistic traits, assessed using 
validated tools. Furthermore, by combining data from three different countries, we were able 
to perform an external replication of previous studies and assess potential differences related 
to iodine status, after adjusting for many potential confounding variables. We also used ad-
vanced statistical methods, including multiple imputation combined with inverse probability 
weighting, to reduce possible selection bias.
One limitation of the present study was that the child neurodevelopmental outcomes were 
assessed with different tools at different ages. This might be, for example, reflected in the 
different prevalence of children with autistic traits within the clinical range across cohorts. 
The varying occurrence might have resulted from the different ages at the assessment and/or 
the different types of evaluator but most likely resulted from the different set of questions for 
assessing autistic traits. For instance, the CAST 33 contains 31 items and is therefore a more 
extensive questionnaire compared with the CBCL1½–5, with 13 items 34, and the SCDC, 
with 12 items 35. The CAST and CBCL1½–5 cover questions on all three domains of ASD. 
In contrast to the CAST and CBCL1½–5, the SCDC was designed to assess deficits in social 
and communications skills but does not assess the ASD domain of restricted and repetitive 
behaviors and interests. To account for the differences as best as possible, we standardized 
all outcome scores and adjusted all analyses for child age at the IQ or autistic traits ascertain-
ment. We observed little heterogeneity among the cohorts. Another limitation was the low 
prevalence children with autistic traits within the clinical range, which caused, especially 
in INMA, issues with statistical power. Furthermore, we only had a single thyroid function 
measurement available from early pregnancy. Hence, the results should not be generalized 
to thyroid function in late pregnancy, and the potential effects of individual variations in 
maternal thyroid hormone availability could not be studied.
In conclusion, the results from the present study have confirmed that a low FT4 is consis-
tently associated with a lower child IQ. We also found a suggestive association of maternal 
hypothyroxinemia and high FT4 with a greater risk of autistic traits within the clinical range. 
FT4 seemed a reliably marker of the fetal thyroid state in early pregnancy, regardless of 
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the type of immunoassay. Further studies should replicate the findings of autistic traits and 
investigate the potential modifying role of maternal iodine status.
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Supplemental material
Supplemental Table 1 Type of immunoassay used by the cohorts.
Cohort Assay TPOAb positivitya
INMA
AutoDEL-FIA (PerkinElmer Life and Analytical Sciences, Wallac 
Oy, Turku, Finland) and a lanthanide metal europium (Eu) label.
NA
Generation R
Vitros ECI immunodiagnostic (Ortho Clinical Diagnostics, 
Rochester, NY, USA)
≥60 IU/ml
ALSPAC Abbott Architect i2000 ≥6 IU/ml
a Assay cut-off. NA: not available
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Supplemental Fig. 1 Association of maternal TSH during early pregnancy with child non-verbal IQ.
Association shows as (a) a continuous association depicted as the child non-verbal IQ (black line) with 95% 
CI (gray area) and by cohort-specifi c maternal TSH concentrations in the (b) <2.5th percentile, (c) >97.5th per-
centile, (d) <5th percentile, and (e) >95th percentile compared with interquartile range (between 25th and 75th 
percentiles), depicted as eff ect estimate (dot) with the 95% CI per cohort and overall as estimated by random-
eff ects meta-analysis (diamond). The I2 for each model is as follows: for TSH<2.5th percentile, I2=57.5%; for 
TSH>97.5th percentile, I2=4.8%; for TSH<5th percentile, I2=0.0%; for TSH>95th percentile, I2=0.0%.
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Supplemental Table 3 Association of maternal TSH with child non-verbal IQ stratified by FT4.
 β (95% CI) P-value P heterogeneity I2
High TSH (>P95) vs. normal TSH (P25-P75) 1.2 (-0.1 to 2.5) 0.063 0.503 0.0
in low FT4 group (<P25) 0.9 (-1.3 to 3.0) 0.421 0.522 0.0
in medium FT4 group (P25-P75) 2.1 (0.1 to 4.0) 0.038 0.343 6.5
in high FT4 group (>P75) 1.0 (-2.6 to 4.6) 0.578 0.926 0.0
Supplemental Table 4 Association of maternal TSH with child verbal IQ stratified by FT4.
 β (95% CI) P-value P heterogeneity I2
High TSH (>P97.5) vs. normal TSH (P25-P75) 1.9 (0.1 to 3.7) 0.039 0.388 0.0
in low FT4 group (<P25) 0.8 (-2.0 to 3.6) 0.565 0.780 0.0
in medium FT4 group (P25-P75) 1.7 (-1.0 to 4.5) 0.219 0.432 0.0
in high FT4 group (>P75) 3.3 (-5.0 to 11.6) 0.438 0.103 55.9
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Supplemental Fig. 2 Association of maternal TSH during early pregnancy with child verbal IQ.
Association shown as (a) a continuous association depicted as the child verbal IQ (black line) with 95% CI 
(gray area); and by cohort-specifi c maternal TSH concentrations in the (b) <2.5th percentile, (c) >97.5th per-
centile, (d) <5th percentile, and (e) >95th percentile compared with interquartile range (between 25th and 75th 
percentiles), depicted as eff ect estimate (dot) with the 95% CI per cohort and overall as estimated by random-
eff ects meta-analysis (diamond). The I2 for each model is as follows: for TSH<2.5th percentile, I2=0.0%; for 
TSH>97.5th percentile, I2=0.0%; for TSH<5th percentile, I2=0.0%; for TSH>95th percentile, I2=0.0%.
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Supplemental Fig. 3 Association of maternal TSH during early pregnancy with child autistic traits within the 
clinical range.
Association shown a (a) a continuous association depicted as the child autistic traits within the clinical range 
(black line) with 95% CI (gray area) and by cohort-specifi c maternal TSH concentrations in the (b) <2.5th per-
centile, (c) >97.5th percentile, (d) <5th percentile, and (e) >95th percentile compared with interquartile range 
(between 25th and 75th percentiles), depicted as eff ect estimate (dot) with the 95% CI per cohort and overall 
as estimated by random-eff ects meta-analysis (diamond). The I2 for each model is as follows: for TSH<2.5th 
percentile, I2=0.0%; for TSH>97.5th percentile, I2=0.0%; for TSH<5th percentile, I2=0.0%; for TSH>95th 
percentile, I2=0.0%.
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Supplemental Fig. 4 Association of maternal hypothyroxinemia during early pregnancy with child non-verbal 
IQ, verbal IQ, and autistic traits within the clinical range.
Figure shows the association of maternal hypothyroxinemia during early pregnancy with child non-verbal 
IQ (a,b), verbal IQ (c,d), and autistic traits within the clinical range (e,f), defi ned using the cohort-specifi c 
2.5th and 97.5th population-based percentiles (a,c,e) or the 5th and 95th population-based percentiles (b,d,f), 
depicted as eff ect estimate (dot) with the 95% CI per cohort and overall as estimated by random-eff ects meta-
analysis (diamond). The reference group consisted of euthyroid women. The I2 for each model is as follows: for 
a, I2=0.0%; for b, I2=64.6%; for c, I2=0.0%; for d, I2=0.0%; for e, I2=0.0%; for f, I2=0.0%.
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Supplemental Fig. 5 Association of maternal subclinical hypothyroidism during early pregnancy with child 
non-verbal IQ, verbal IQ, and autistic traits within the clinical range.
Figure shows the association of maternal subclinical hypothyroidism during early pregnancy with child non-
verbal IQ (a,b), verbal IQ (c,d), and autistic traits within the clinical range (e,f), defi ned using the cohort-
specifi c 2.5th and 97.5th population-based percentiles (a,c,e) or the 5th and 95th population-based percentiles 
(b,d,f), depicted as eff ect estimate (dot) with the 95% CI per cohort and overall as estimated by random-eff ects 
meta-analysis (diamond). The reference group consisted of euthyroid women. The I2 for each model is as fol-
lows: for a, I2=0.0%; for b, I2=26.8%; for c, I2=0.0%; for d, I2=17.1%; for e, I2=0.0%; for f, I2=0.0%.
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Supplemental Fig. 6 Association of maternal subclinical hyperthyroidism during early pregnancy with child 
non-verbal IQ, verbal IQ, and autistic traits within the clinical range.
Figure shows the association of maternal subclinical hyperthyroidism during early pregnancy with child non-
verbal IQ (a,b), verbal IQ (c,d), and autistic traits within the clinical range (e), defi ned using the cohort-specifi c 
2.5th and 97.5th population-based percentiles (a,c) or the 5th and 95th population-based percentiles (b,d,e), 
depicted as eff ect estimate (dot) with the 95% CI per cohort and overall as estimated by random-eff ects meta-
analysis (diamond). The reference group consisted of euthyroid women. The I2 for each model is as follows: 
for a I2=60.5%; for b, I2=0.0%; for c, I2=0.0%; for d, I2=0.0%; for e, I2=0.0%.
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Abstract
Background: Thyroid hormone is essential for optimal fetal brain development. Evidence 
suggests that both low and high maternal thyroid hormone availability may have adverse 
effects on child neurodevelopmental outcomes, but the effect on behavioral problems remains 
unclear. We studied the association of maternal thyrotropin (TSH) and free thyroxine (FT4) 
concentrations during the first 18 weeks of pregnancy with child attention-deficit hyperactiv-
ity disorder (ADHD).
Methods: A total of 7669 mother-child pairs with data on maternal thyroid function and 
child ADHD were selected from three prospective population-based birth cohorts: INfancia 
y Medio Ambiente (INMA; N=1073, Spain), Generation R (N=3812, the Netherlands), and 
Avon Longitudinal Study of Parents and Children (ALSPAC; N=2784, United Kingdom). 
Exclusion criteria were multiple pregnancy, fertility treatment, usage of medication affecting 
the thyroid, and pre-existing thyroid disease. We used logistic regression models to study the 
association of maternal thyroid function with the primary outcome, ADHD, assessed via the 
Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria by 
parents and/or teachers at a median child age of 4.5 to 7.6 years, and with the secondary out-
come, an ADHD symptom score above the 90th percentile. Effect modification by gestational 
age and sex was tested with interaction terms and stratified analyses.
Results: Overall, 233 (3%) children met the criteria for ADHD. When analyzed continu-
ously, neither FT4 nor TSH was associated with a higher risk of ADHD [odds ratio (OR) 1.1, 
95% confidence Interval (95% CI 1.0-1.3), p=0.060 and OR 0.9, (95% CI 0.9-1.1), p=0.385, 
respectively] or with high symptom scores. When investigating effect modification by ges-
tational age, a higher FT4 was associated with symptoms above the 90th percentile but only 
in the first trimester [for FT4 per 1 SD: OR 1.2 (95% CI 1.0-1.4), p=0.027]. However, these 
differential effects by gestational age were not consistent. No significant effect modification 
by sex was observed.
Conclusions: We found no clear evidence of an association between maternal thyroid func-
tion and child ADHD.
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Introduction
Thyroid hormone regulates important brain developmental processes including early neuronal 
proliferation and migration 1. Until mid-gestation, fetal thyroid hormone availability largely 
depends on the supply of maternal thyroid hormone via the placenta 2. Relatively mild deficits 
in thyroid hormone availability have been associated with adverse child neurodevelopmental 
outcomes, such as lower IQ, lower psychomotor development scores, and lower gray matter 
and cortex volume 3–5. Evidence from mainly animal studies also suggests that high-normal 
thyroid hormone availability may have similar adverse effects on neurodevelopmental out-
comes 5–11. However, whether mild changes in thyroid hormone concentrations also play a 
role in the etiology of child behavioral problems is less well established.
 Attention-deficit hyperactivity disorder (ADHD) is a “persistent pattern of inattention and/
or hyperactivity-impulsivity that is more frequently displayed than is typically observed in 
individuals at a comparable level of development” 12 and occurs in ~ 5.9-7.1 percent of chil-
dren and adolescents 13. The exact cause of ADHD is unknown, but susceptibility is thought 
to depend on genetic predisposition, environmental factors and their interactions 14,15. There 
is some indication that high thyroid hormone availability may increase the risk of ADHD. Pa-
tients with resistance to thyroid hormone beta (RTHβ), in which a defective thyroid hormone 
receptor beta (TRβ) results in lifelong exposure to a high thyroid hormone concentration in 
tissues that predominantly express thyroid hormone receptor alfa (TRα) such as the brain, 
have a higher risk of ADHD 16. Furthermore, individuals with ADHD have a delay in cortical 
maturation, reduced neuronal activity, and brain volume 17–19 compared with healthy controls; 
some of the same abnormalities are also seen in the offspring of mothers with gestational 
thyroid dysfunction 5,20–22. However, further studies are required to clarify whether too low 
and/or too high thyroid hormone availability in pregnancy is consistently associated with the 
development of ADHD.
So far, evidence from epidemiological studies is inconsistent with regard to an association 
of maternal thyroid function with child ADHD 23–31. Some studies indicated that the effects of 
maternal thyroid function on ADHD may be more prominent in girls 23,31, but further studies 
are needed to replicate and further clarify sex-specific effects. In addition, it would be relevant 
to investigate whether there are differential effects by gestational age, as the relatively late start 
of levothyroxine therapy in women with subclinical hypothyroidism or hypothyroxinemia in 
two randomized control trials has been suggested to be a reason for the negative findings for 
those trials 32,33. We therefore combined data from three prospective birth cohorts to study the 
association between free thyroxine (FT4) and thyrotropin (TSH) in early pregnancy and the 
risk of ADHD, as well as the effect modification by child sex and gestational age.
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Material and Methods
Study design and populations
We used data from three population-based birth cohort studies: INfancia y Medio Ambi-
ente (INMA; Spain, sub-cohorts of Valencia, Sabadell, and Gipuzkoa), Generation R (the 
Netherlands), and the Avon Longitudinal Study of Parents and Children (ALSPAC, United 
Kingdom). Information on the designs of the three cohort studies can be found elsewhere 34–37; 
the ALSPAC study website contains details of all the data that is available through a search-
able data dictionary and variable search tool 38. Briefly, all three cohorts were designed 
to understand the role of environmental exposures and/or genetic characteristics for child 
growth, development, and health from fetal life until (young) adulthood. The INMA Project is 
a network of seven birth cohorts in Spain with different recruitment periods. Pregnant women 
included in the Valencia (N=855), Sabadell (N=657), and Gipuzkoa (N=638) cohorts enrolled 
from November 2003 until June 2005, July 2004 until July 2006, and April 2006 until January 
2008, respectively. In Generation R, 9778 mothers with a delivery date from April 2002 until 
January 2006 were enrolled in the study. In ALSPAC, pregnant women resident in Avon, 
UK with expected dates of delivery between April 1991 and December 1992 were invited 
to take part in the study. The initial number of pregnancies enrolled was 14541, of which 
13998 children were alive at the first year of age. For the current study, mother-child pairs 
were eligible if they had a thyroid measurement in the first half of pregnancy (≤18 weeks) 
and had data on an assessment of ADHD symptoms during childhood. Exclusion criteria were 
multiple pregnancy, fertility treatment, usage of medication affecting thyroid function during 
pregnancy, and pre-existing thyroid disease. Ethical approval was obtained before recruit-
ment and during the follow-up waves of data collection from a number of bodies: the Ethical 
Committee of the Municipal Institute of Medical Investigation, the Ethical Committees of 
the hospitals involved in the study (INMA; reference numbers G03/176, 2005/2106/I, and 
2009/3432/I), the Medical Ethical Committee of the Erasmus Medical Center (Generation R; 
reference numbers: MEC 198.782.2001.31, MEC-2007-413), the ALSPAC Ethics and Law 
Committee, and the Local Research Ethics Committees (ALSPAC; reference numbers avail-
able elsewhere 39); approval by parents or guardians of the children was given by a signed 
informed-consent form.
Maternal thyroid function
The procedures and methodologies by which maternal thyroid function was measured 
differed among cohorts. In INMA, serum samples were collected at a mean [± standard 
deviation (SD)] gestational age of 13.1 ± 1.3 weeks and stored at -80°C after collection. FT4 
and TSH were measured using a solid-phase, time-resolved sandwich fluoro-immunoassay 
(AutoDEL-FIA, PerkinElmer Life and Analytical Sciences, Wallac Oy, Turku, Finland) and 
a lanthanide metal europium (Eu) label. Thyroid peroxidase antibodies (TPOAbs) were not 
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measured. In Generation R, serum samples were collected at a mean ± SD age of 13.4 ± 1.9 
weeks, centrifuged, and stored at -80°C after collection. FT4 and TSH were measured using 
the Vitros ECI immunodiagnostic (Ortho clinical Diagnostics, Rochester, NY). Maternal 
TPOAbs were measured using the Phadia 250 immunoassay (Phadia AB, Uppsala, Sweden), 
and a TPO titre ≥ 60 IU/mL was considered as positive. In ALSPAC, serum samples were 
collected at a mean ± SD age of 11.0 ± 3.2 weeks and stored at -20°C. FT4, TSH, and TPOAb 
measurements were performed using Abbott Architect i2000. A TPO titre ≥ 6 IU/mL was 
considered as positive. Additional information about the serum measurements is provided in 
the Supplementary Material.
ADHD symptoms
In INMA, ADHD symptoms were assessed by teachers at a median age of 4.5 years [inter-
quartile range (IQR) 4.4-5.7 years] using the ADHD Criteria of Diagnostic and Statistical 
Manual of Mental Disorders, fourth edition (ADHD-DSM-IV) list 12. The DSM criteria are 
a valid tool for diagnosing ADHD, already at a pre-school age 40. The DSM-IV consists 
of questions on nine inattention symptoms and nine hyperactivity-impulsivity symptoms on 
a 4-point Likert scale (never or rarely, sometimes, often, or very often), designed to score 
ADHD symptoms present in the last six months before the assessment. A symptom was de-
fined as present if the question was answered with “often” or “very often”. The total symptom 
score consisted of the sum of all the inattention and hyperactivity-impulsivity symptoms. 
Based on the symptom criteria of the DSM-IV, an ADHD diagnosis was given when the child 
had at least six inattention and/or six hyperactivity-impulsivity symptoms.
 In Generation R, parents assessed their child’s behavior in the last two months at a median 
age of 6.0 years (IQR 5.9-6.2 years) using the Child Behavior Checklist 1½–5 (CBCL/1½–5) 41. 
From this 99-item questionnaire, the sum score of six questions on a 3-point Likert scale (not 
true, somewhat or sometimes true, very true or often true) made up the total ADHD symptom 
score. In addition, the computer-assisted Diagnostic Interview Schedule for Children - Young 
Child version 42, which is a DSM-IV based interview, was administered by research assistants 
at a median age of 6.6 years (IQR 6.3-7.1 years) to the parents or caregivers of a selected 
group of children. This subgroup consisted of a random selection of negative controls and 
children with a high probability of a psychiatric disorder, e.g., children who scored in the 
top 15th percentile of the CBCL1½–5 total problem score and/or in the top 2% of the syn-
drome scale scores. Algorithms provided by the developers of this tool were used to derive 
a DSM-IV diagnosis based on the symptom criteria of the DSM-IV. More information on 
the procedures and assessment is described elsewhere 43. In our study, the reference group 
consisted of children that were not identified as having ADHD and children who did not have 
data on the Diagnostic Interview Schedule-Young Child version, but did have data on ADHD 
symptoms as assessed with the CBCL/1½–5 (e.g., mostly children with a low probability of 
a psychiatric disorder).
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 In ALSPAC, the Development and Well-Being Assessment (DAWBA) was used to evalu-
ate child psychological disorders at a median age of 7.6 years (IQR 7.6-7.7 years) 44. This 
validated tool consists of questions based on the diagnostic criteria described in the Interna-
tional Classification of Diseases, Tenth Edition (ICD-10) or the DSM-IV. A semi-structured 
interview was administered to parents relating to inattention and hyperactivity symptoms 
present in the six months before the assessment. Teachers in the geographically defined study 
area were also requested to fill out the DAWBA questionnaire on all children with a birth 
date between April 1991 and December 1992. The completion rate by teachers was 37% for 
ALSPAC children 45. Clinical raters reviewed all available ratings on ADHD symptoms and 
assigned an ADHD diagnosis using the DSM-IV criteria as if in clinical settings.
Covariates
During pregnancy, questionnaires were used to collect information on maternal age, parity 
(zero, one, and two or more), Snijders Oomen Nonverbal Intelligence Test body mass index, 
smoking during pregnancy (never, smoked in the beginning or until pregnancy confirmed, 
continued smoking), ethnicity/country of birth (cohort-specific categories), and maternal edu-
cational level (low, middle, and high). Gestational age at blood sampling was defined using 
ultrasound and/or last menstrual period. Information on sex of the child was obtained from 
community midwives, obstetricians, hospital registries, clinical records, or questionnaires. 
Age at ADHD assessment was obtained during the study visit.
Statistical analyses
Owing to the differences in assays, the absolute values of TSH and FT4 across the cohorts 
cannot be compared. We therefore calculated cohort-specific SD scores with a mean of 0 
and a SD of 1 using logarithmically transformed values of FT4 and TSH based on TPOAb-
negative women when possible. Values outside the mean ± 4 SD range were considered as 
outliers and excluded from further analyses. We assessed the association of maternal TSH and 
FT4 SD scores within the mean ± 4 SD range with child ADHD by performing multivariable 
logistic regression models using pooled data. We used the same model to study the associa-
tion with our secondary outcome, an ADHD symptom score above the 90th percentile, which 
was generated in each cohort separately. This extra harmonized cut-off was chosen a priori 
to increase statistical power owing to the low prevalence of children meeting the criteria of 
ADHD and has been used previously to define children at risk 46,47. Negative binomial regres-
sion models were used to assess the association of FT4 and TSH with total ADHD symptom 
scores on a continuous scale per cohort. We could not analyze these associations using pooled 
data since the symptom scores did not share a common metric between cohorts and therefore 
were not comparable.
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We tested for non-linearity by adding a quadratic term to our models and we assessed mul-
ticollinearity between covariates by the variance inflation factor. All cohort-specific models 
were adjusted for all the mentioned covariates. However, in the pooled analyses, we could not 
adjust for child age at ADHD ascertainment, maternal ethnicity/country of birth, and cohort 
simultaneously. The categories or the range of these variables did not overlap i.e., they were 
cohort-specific, and adjusting for several of these variables at the same time causes multicol-
linearity. Therefore, in the pooled analyses, we chose to adjust for maternal ethnicity/country 
of birth because it is known that there are ethnic differences in maternal thyroid parameters 
during pregnancy 48–50, and race/ethnicity is intertwined with social economic status, which 
has been associated with behavioral problems 51 and ADHD 13,52. We investigated whether 
adjusting for cohort instead of ethnicity/country of birth yielded different results. Because 
the results were similar, we chose to show the results based on the ethnicity/country of birth 
adjustment. We decided to present standard logistic regression models after comparison with 
multilevel models using the Akaike information criterion.
We performed several sensitivity analyses. First, we tested for heterogeneity between 
cohorts using the Cochran Q test and the I2 statistic (Supplementary Fig. 1; 53). Second, we 
also compared the effect estimates before and after excluding TPOAb-positive women in 
mother-child pairs, of which TPOAb status was known, e.g., Generation R and ALSPAC, 
since TPOAb positivity was associated with a higher risk of ADHD irrespective of maternal 
TSH 54. Third, we tested for possible effect modification by sex and/or gestational age at 
blood sampling by adding product terms into the models. To identify potential relevant ef-
fect modifiers, we screened for interaction terms with a p-value of <0.15 and subsequently 
performed stratified analyses to verify and quantify any relevant differences. For gestational 
age, analyses were stratified by tertiles based on pooled data (< 11.8 weeks, ≥ 11.8 to ≤ 13.5 
weeks, and > 13.5 weeks).
The percentage of missing covariate data ranged from 0% to 15.6% (Table 1). Before pool-
ing the cohort data, missing values in these covariates were imputed using chained equations, 
generating 25 data sets. Additionally, to alleviate the potential bias that arises when only the 
population with available data on maternal thyroid function and child ADHD symptoms is 
included, we applied inverse probability weighting 55. Briefly, we used data on characteristics 
available for all participants at recruitment to predict the probability of participation in the 
study, and an inverse of those probabilities as weights in the analyses so that results would be 
representative for the initial populations of the cohorts. Statistical analyses were performed 
in STATA (version 15.0; Stata Corporation, College Station, TX).
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Table 1 Distribution of maternal and child characteristics.
INMA
(N=1073)
Generation R
(N=3812)
ALSPAC
(N=2784) p-value
ADHD, % 5.3 3.2 2.0 <0.001
ADHD symptoms > P90, % 10.4 10.3 10.3 0.990
Maternal TSH, median (IQR), mIU/L 1.25 (0.82-1.82) 1.38 (0.87-2.07) 1.02 (0.64-1.49) <0.001
Maternal FT4, median (IQR), pmol/L 10.6 (9.7-11.5) 14.8 (13.2-16.7) 16.1 (14.8-17.6) <0.001
TPOAb positivity, % NA 5.8 12.8 <0.001
Gestational age at blood sampling, mean (SD), 
weeks a
13.1 (1.3) 13.4 (1.9) 11.0 (3.2) <0.001
Maternal educational level, %a    <0.001
Low 20.8 6.2 24.0
Medium 42.5 40.8 61.6
High 36.6 53.0 14.4
Maternal ethnicity/country of birth, % a    <0.001
Spanish 93.8 NA NA
Other, non-Spanish 6.2 NA NA
Dutch NA 60.6 NA
Indonesian NA 3.3 NA
Cape Verdean NA 3.0 NA
Turkish NA 6.9 NA
Other, non-Western NA 17.0 NA
Other, Western NA 9.2 NA
White NA NA 98.6
Non-white NA NA 1.4
Maternal age, mean (SD), years 31.6 (3.9) 30.7 (4.6) 28.1 (4.6) <0.001
Parity, % a    <0.001
0 57.0 59.6 47.9
1 36.7 29.9 34.7
≥2 6.3 10.5 17.4
Smoking during pregnancy, % a    <0.001
Never 70.2 74.9 79.6
At the beginning of pregnancy 12.9 9.6 4.5
Continued smoking 16.9 15.5 15.9
Pre-pregnancy BMI, median (IQR), kg/m2 a 22.5 (20.8-25.0) 22.5 (20.8-25.1) 22.1 (20.5-24.2) <0.001
Child female sex, % a 48.9 50.1 48.5 0.410
p-value for differences was calculated using the Chi‐square test for categorical variables, one-way ANOVA for 
continuous normal‐distributed variables, and Kruskal‐Wallis test for continuous non‐normal distributed variables.
a  Values do not take into account missing data (0%, 0.2%, and 0% for gestational age; 0.3%, 3.2%, and 2.5% 
for maternal education; 0.1%, 0%, and 2.9% for maternal ethnicity/country of birth; 0.2%, 0%, and 2.9% for 
parity; 1.4%, 9.0%, and 1.7% for smoking; 0%, 15.6%, and 8.8% for pre-pregnancy BMI; 0.1%, 0%, and 0% 
for child sex in INMA, Generation R, and ALSPAC, respectively). ADHD, attention-deficit hyperactivity 
disorder; ALSPAC, Avon Longitudinal Study of Parents and Children; ANOVA, analysis of variance; BMI, 
body mass index; FT4, free thyroxine; INMA, INfancia y Medio Ambiente; IQR, interquartile range; NA, 
not available; SD, standard deviation; TPOAb, thyroid peroxidase antibody; TSH, thyrotropin.
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Results
After exclusions, data for a total of 7669 mother-child pairs were available for analyses 
(Fig. 1). An overview of the characteristics of the study population is given in Table 1. The 
prevalence of ADHD was 5.3% (n=57) in INMA, 3.2% (n=121) in Generation R, and 2.0% 
(n=55) in ALSPAC. Compared with the study population, women who were not included 
in the analysis had a lower education level, were less often native or Caucasian, and were 
younger in all three cohorts (Supplementary Table 1). There were similar diff erences in char-
acteristics when comparing mothers whose children had an ADHD symptom score and those 
whose children did not undergo an ADHD assessment (Supplementary Table 2). No clinically 
relevant diff erences were found in TSH and FT4 concentrations between these two groups.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Flowchart of the selection of the study population.
TSH: thyrotropin; FT4: free thyroxine; SD: standard deviation; ADHD: Attention Deficit Hyperactivity 
Disorder; INMA: INfancia y Medio Ambiente; ALSPAC: Avon Longitudinal Study of Parents and Children
Enrolled ≤18 weeks of gestation
N=13881
No assessment of maternal thyroid function
N=1187
Data on maternal thyroid function
N=12694
No assessment of child ADHD
N=4669
Data on child ADHD 
N=8025
Final study population:
N=7669
INMA:            N=1073
Generation R: N=3812
ALSPAC:         N=2784
Multiple pregnancy, fertility treatment, thyroid interfering
medication usage, or pre-existing thyroid disease
N=350
Both TSH and FT4 outside the range of mean ± 4SD
N=6
Figure 1 Flowchart of the selection of the study population.
ADHD, attention-defi cit hyperactivity disorder; ALSPAC, Avon Longitudinal Study of Parents and Children; 
FT4, free thyroxine; INMA, Infancia y Medio Ambiente; SD, standard deviation; TSH, thyrotropin.
Attention-defi cit hyperactivity disorder
FT4 was not associated with ADHD [odds ratio (OR) 1.1, 95% confi dence interval (95% CI 
1.0 to 1.3), p=0.060; Table 2 and Supplementary Fig.1]. The eff ect estimate remained similar 
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after excluding TPOAb-positive women. There was no effect modification by gestational age 
(p for interaction term=0.581). While there was no indication of significant effect modifica-
tion by child’s sex (p for interaction term=0.144), we did observe a significant association 
in girls only [OR 1.3 (95% CI 1.0 to 1.7), p=0.042; for boys: OR 1.1 (95% CI 0.9 to 1.3), 
p=0.352]. The association in girls became stronger after excluding TPOAb-positive women 
from mother-child pairs, of which TPOAb status was known [from OR 1.2 (95 % CI 0.9 to 
1.7), p=0.187 to OR 1.5 (95% CI 1.1 to 2.1), p=0.020], while the effect estimate remained 
similar in boys.
TSH was not associated with ADHD [OR 0.9 (95% CI 0.8 to 1.1), p=0.385; Table 2 and 
Supplementary Fig. 1) and the effect estimate remained similar after excluding TPOAb-
positive women. There was no effect modification by gestational age (p for interaction term= 
0.757; Table 3) or child sex (p for interaction term= 0.474).
Table 2 Association of maternal FT4 and TSH concentrations during pregnancy with child ADHD and with an 
ADHD symptom score ≥90th percentile
ADHD ADHD symptoms score ≥90th percentile
n/Na OR (95% CI) p-value n/Nb OR (95% CI) p-value
FT4
Pooled 232/7355 1.1 (1.0-1.3) 0.060 779/6768 1.0 (0.9-1.1) 0.554
INMA 57/1016 1.3 (0.9-1.7) 0.126 111/952 1.3 (1.0-1.6) 0.040
Generation R 121/3658 1.0 (0.8-1.3) 0.747 390/3384 1.0 (0.8-1.1) 0.420
ALSPAC 54/2681 1.2 (0.9-1.7) 0.225 278/2432 1.1 (0.9-1.3) 0.294
TSH
Pooled 230/7299 0.9 (0.8-1.1) 0.385 777/6712 0.9 (0.9-1.0) 0.073
INMA 56/1009 0.9 (0.7-1.3) 0.562 110/945 0.8 (0.7-1.0) 0.114
Generation R 119/3633 0.9 (0.8-1.1) 0.323 388/3359 1.0 (0.9-1.1) 0.943
ALSPAC 55/2657 0.9 (0.7-1.2) 0.641 279/2408 0.9 (0.8-1.0) 0.046
1.2 (1.0-1.4)c 0.027
Reported OR’s and 95% CIs are increase in odds per SD of log-transformed FT4 or TSH. Analyses were 
performed using logistic regression and adjusted for gestational age at blood sampling, maternal education, 
maternal ethnicity/country of birth, age, parity, smoking during pregnancy, pre-pregnancy body mass index, 
and child sex. Cohort-specific estimates were also adjusted for child age at ADHD ascertainment and sub-
cohort in INMA.
a n=children with ADHD, N=children without ADHD
b n=children with a symptom score ≥90th percentile, N=children with a symptom score < 90th percentile.
c A quadratic term (TSH SD score2) was added to the model, indicating a non-linear association.
CI, confidence interval; OR, odds ratio.
ADHD symptom score above the 90th percentile
There was no association of FT4 with an ADHD symptom score above the 90th percentile 
[OR 1.0 (95% CI 0.9 to 1.1), p=0.554, respectively; Table 2 and Supplementary Fig. 1] and no 
indication of effect modification by child’s sex. We did identify a possible effect modification 
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by gestational age for the association of FT4 with symptoms above the 90th percentile (p for 
interaction term: 0.013); a higher FT4 was associated with a significant 1.2-fold higher risk 
of ADHD symptoms above the 90th percentile in the early-pregnancy FT4 measurements 
(95% CI 1.0 to 1.4, p=0.027; < 11.8 weeks), while a higher FT4 was associated with a lower 
risk in mother-child pairs with relatively late-pregnancy FT4 measurements [OR 0.9 (95% CI 
0.7 to 1.0), p=0.045; Table 3]. The effect estimates remained similar after excluding TPOAb-
positive women.
 There was no association of TSH with an ADHD symptom score above the 90th percentile 
[OR 0.9 (95% CI 0.9 to 1.0), p=0.073, respectively; Table 2 and Supplementary Fig. 1] and no 
indication of effect modification by child’s sex. We identified a possible effect modification 
by gestational age for the association of TSH with symptom scores above the 90th percentile 
(p for interaction term: 0.082). Stratified analyses by tertile of gestational age showed that a 
higher TSH was associated with a significant 0.8-fold lower risk of ADHD symptoms above 
the 90th percentile in the relatively early-pregnancy TSH measurements (95% CI 0.7 to 
0.9, p=0.006; Table 3; < 11.8 weeks). The effect estimates remained similar after excluding 
TPOAb-positive women.
ADHD symptoms on a continuous scale
No associations were identified between FT4 or TSH across the full range and the total ADHD 
symptom score as investigated in each cohort separately (Supplementary Table 3 and 4).
Table 3 Pooled association of maternal FT4 and TSH concentrations during pregnancy with child ADHD and 
with an ADHD symptom score above the 90th percentile, stratified by tertile of gestational age.
ADHD ADHD symptoms abovethe 90th percentile
gestational age
median (range) N
% with
ADHD
OR
(95% CI) p-value N
% score
>P90
OR
(95% CI) p-value
FT4
Tertile 1 10.0 (4.0-11.8) 2523 2.4 1.1 (0.9-1.5) 0.356 2503 9.8 1.2 (1.0-1.4) 0.027
Tertile 2 12.6 (11.8-13.5) 2580 3.5 1.2 (1.0 -1.6) 0.064 2580 11.1 1.0 (0.9-1.2) 0.884
1.1 (1.0-1.2)a 0.027
Tertile 3 15.1 (13.5-18.0) 2480 3.2 1.0 (0.8-1.3) 0.799 2470 10.1 0.9 (0.7-1.0) 0.045
TSH
Tertile 1 10.0 (4.0-11.8) 2500 2.4 0.9 (0.7-1.2) 0.510 2480 9.9 0.8 (0.7-0.9) 0.006
Tertile 2 12.6 (11.8-13.5) 2562 3.5 1.0 (0.8-1.2) 0.836 2562 11.1 0.9 (0.8-1.1) 0.284
Tertile 3 15.1 (13.5-18.0) 2461 3.2 0.9 (0.7-1.2) 0.436 2451 10.1 1.0 (0.9-1.2) 0.595
Reported ORs and 95% CIs are increase in odds per SD of log-transformed FT4 or TSH. Analyses were 
performed using logistic regression and adjusted for gestational age at blood sampling, maternal education, 
maternal ethnicity/country of birth, age, parity, smoking during pregnancy, pre-pregnancy body mass index, 
and child sex.
a A quadratic term (FT4 SD score2) was added to the model, indicating a non-linear association.
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Discussion
We did not identify an association between FT4 and TSH and ADHD in the overall study 
population. There was inconsistent evidence that the associations investigated were different 
depending on gestational age.
While both low and high-normal maternal FT4 concentrations have been associated with 
adverse outcomes related to fetal brain development 3–11, the role of thyroid hormone in the 
development of ADHD is unknown. Exposure to high thyroid hormone concentrations might 
contribute to the etiology of this disorder, since individuals with generalized resistance to 
thyroid hormone were shown to be more prone to meet the criteria for ADHD than subjects 
without this mutation 16. Fetuses without the mutation but born to a mother with RTHβ have 
reduced sensitivity to thyroid hormone compared with fetuses born to mothers without 
RTHβ 56. The reduced sensitivity to thyroid hormone was explained by increased deiodinase 
3 (D3) expression in the anterior pituitary. Other studies have also shown that untreated 
hyperthyroidism during pregnancy may lead to persistent changes in the thyroid function 
of the child 57,58. In addition, children born to mothers with RTHβ were found to have lower 
birth weight 59. Lower birth weight and small size for gestational age, which has been already 
shown to be associated with a higher FT4 concentration in pregnancy in Generation R and 
INMA 60,61, could be on the causal pathway to ADHD symptomatology 62.
Thus far, the results of studies on the association between maternal thyroid function and 
child ADHD are inconsistent. While one study reported a positive association between FT4 
and ADHD symptoms (26), other studies either report no association 23,24,28,30 or a negative 
association 27,29,31. Likewise for TSH, studies show either a positive association between TSH 
and attention problems or ADHD symptoms 23–25, no association 26–29,31, or a possible protec-
tive effect of a higher TSH concentration 30. There may be different explanations as to why 
some studies found an association between FT4 or TSH and ADHD, while others did not. 
First of all, although FT4 and TSH both reflect thyroid status, TSH is a more sensitive reflec-
tion of thyroid autoimmunity, which is associated with ADHD 54. Second, the inconsistent 
study results may also be explained by several methodological points. ADHD symptoms 
were assessed differently between studies, with some earlier studies using tools that did not 
include an extensive set of items as the DSM-IV uses to classify ADHD. In addition, ADHD 
was defined differently across studies – by medical diagnosis 26,31, symptoms on a continuous 
scale 24,27,30, or by ADHD or inattention symptom cut-offs 23,25,28,29 – hence the comparability 
between studies is limited. The latter studies did not use a symptom score above the 90th 
percentile, as used in our study. Third, iodine status may also explain part of the heterogeneity 
between studies 63. Results in a small study population showed that ADHD prevalence was 
higher in an iodine-deficient area than in an iodine-sufficient area 64.
The importance of maternal thyroid hormone for the fetal brain changes throughout preg-
nancy. Before the fetal thyroid is functionally mature at 18-20 weeks gestation, the fetus 
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depends on thyroid hormone from the mother 1. During the second half of pregnancy, the 
maternal thyroid remains an important source, but to a lesser extent as considerable amounts 
of thyroid hormone are produced by the fetus itself 2. We investigated whether the effect of 
maternal thyroid hormone on ADHD (symptoms) differed by gestational age. The proportion 
of mother-child pairs were not equally distributed across the different groups of gestational 
age; in roughly the first 12 weeks of gestation, two thirds of the mother-child pairs were from 
the ALSPAC cohort. Stratified analyses showed that the association of higher FT4 with a 
higher risk of symptom score above the 90th percentile was prominent in roughly the first 12 
weeks of gestation, but not thereafter. Given these findings and the physiologically interrela-
tion between FT4 and TSH, we could also observe that a higher TSH was associated with a 
lower risk of symptom scores above the 90th percentile only in the first trimester. However, 
there was no significant interaction with gestational age in the association of FT4 or TSH with 
ADHD. From our analyses, we therefore have no strong evidence for differential effects by 
gestational age.
Interestingly, in the current study, a higher maternal FT4 concentration during pregnancy 
was associated with a higher risk of ADHD in girls only. Differential effects of thyroid hor-
mone on brain-development-related outcomes by sex have been reported previously 23,31, and 
it is well known that ADHD is more often diagnosed in males. While it remains unclear why 
this association may be sex-specific, it is known that child sex modifies the thyroidal response 
to human chorionic gonadotropin (hCG); women pregnant with a female fetus have a higher 
thyroidal response to high hCG concentrations, resulting in lower TSH and higher FT4, than 
those with a male fetus 65. However, our results have to be interpreted with caution as no 
significant interaction with sex was found. Further studies are needed to replicate if there are 
sex-specific effects of thyroid hormone on brain development.
Observational studies showed that both low and high maternal thyroid function are as-
sociated with lower child IQ and lower gray matter volume 3,5,25. Randomized trials thus 
far failed to show a benefit of levothyroxine treatment in pregnant women with subclinical 
hypothyroidism or hypothyroxinemia on child IQ 32,33, but these trials have been limited by a 
suboptimal timing and dose of treatment 66. Behavioral problems such as ADHD could also 
be considered an outcome that may reflect suboptimal fetal brain development during preg-
nancy. Our study shows no association between maternal thyroid function and child ADHD. 
However, owing to the observational design of this study, we cannot make statements on what 
the potential effects of this treatment on behavior problems in children would be.
We were able to combine data from three large cohorts, enabling us to investigate as-
sociations between thyroid function and ADHD in a large number of mother-child pairs. 
All three cohorts used the DSM, internationally applied, diagnostic criteria, which are the 
most used clinically for diagnosing psychiatric disorders. Using individual-participant data 
instead of aggregate data facilitated the use of consistent inclusion and exclusion criteria 
and standardized statistical analyses across cohort studies. Combining individual participant 
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data into a meta-analysis offers further advantages over individual studies. Irrespective of a 
replication of findings as found in individual studies, findings from meta-analyses enriches 
our knowledge on the theory tested and increases confidence in generalization.
In our study, ADHD occurred in only 3% of children, which may have been a low proportion 
in which to detect an association. This prevalence was lower than that reported in children and 
adolescents in a systematic review 13. The prevalence of ADHD in Generation R was lower 
than previously reported due to a different sample size, and we did not report a weighted 
prevalence to represent the full sample with CBCL1½–5 data 43. Prevalence estimates are 
known to vary widely by individual studies. Part of this variability may be explained by the 
diagnostic criteria used to define ADHD, the method used to assess ADHD symptoms, the 
incorporation of functional impairments as part of the definition of ADHD, and possibly 
also by social economic status of the population 13. In our study, mother-child pairs with a 
lower social economic status (e.g., lower maternal educational level and less often native or 
Caucasian) were more likely to be lost to follow-up. We accounted for potential differential 
loss to follow-up by applying inverse probability weighting. To increase statistical power, we 
used the highest 10% of ADHD symptoms as a secondary outcome. It should be noted that 
this extra cut-off was arbitrarily chosen and has not been validated.
A limitation of this study is that ADHD symptoms were assessed at different ages us-
ing different methods, including inconsistency in the type of assessor used by the different 
cohorts, which may have contributed to heterogeneity in results. The heterogeneity by the 
latter was shown by a recent study showing that maternal thyroid function was associated 
with teacher-rated ADHD symptoms, but not with parental ratings 29. Due to low-to-moderate 
agreement between teacher and parental observations, multi-informant assessment has been 
recommended in order to understand the behavior of a child in different settings 67,68; this 
was most closely adhered to in ALSPAC. We did not have the opportunity to re-score the 
data that was collected of a sample of children using the three methods. In addition, we had 
no data on clinical diagnosis of ADHD by a physician, which may have caused outcome 
misclassification.
In conclusion, the results of the current study do not show an association between maternal 
thyroid function and ADHD in the overall study population. As the etiology of ADHD as 
well as the potential role of thyroid hormone availability remains poorly understood, further 
studies are warranted.
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Supplemental material
Serum measurements
In INfancia y Medio Ambiente (INMA), the between-assay coefficients of variation for low, 
medium, and high hormone concentrations were 6.1%, 4.1%, and 4.0% for free thyroxine 
(FT4) respectively, and 3.0%, 3.1%, and 2.6% for thyrotropin (TSH). The intra-assay coef-
ficients of variation were 3.7%. 3.0%, and 3.3% for FT4, and 7.7%, 2.1%, and 1.7% for 
TSH, respectively (for AutoDEL-FIA, PerkinElmer Life and Analytical Sciences, Wallac Oy, 
Turku, Finland). In Generation R, the intra- and interassay coefficients of variation were 
<5.4% for FT4 with a range of 14.3-25.0 pmol/L and <4.1% for TSH with a range of 3.97-
22.7 mIU/L (for Vitros ECI immunodiagnostic; Ortho Clinical Diagnostics, Rochester, NY). 
In ALSPAC, FT4, TSH, and thyroid peroxidase antibody measurements were performed 
using Abbott Architect i2000 with functional sensitivity of 0.05 mIU/L or less. Inter- and 
intra-assay coefficients of variation were <5% for all analytes.
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Supplementary Fig. 1 Association of maternal FT4 and TSH concentrations during pregnancy with child 
ADHD and with an ADHD symptom score ≥90th percentile.
Associations shown as effect estimate (dot) with the 95% CI per cohort and overall as estimated by a random-
effects meta-analysis (diamond). Statistical heterogeneity was explored and quantified using the Cochran Q 
test and the I2 statistic, which is the proportion of total variation in the estimates that is due to heterogeneity 
between studies. The models were adjusted for maternal age, parity, pre-pregnancy body mass index, smoking 
during pregnancy, ethnicity/country of birth, maternal educational level, gestational age at blood sampling, 
child sex, and subcohort in INMA. (a) FT4 and ADHD, (b) TSH and ADHD, (c) FT4 and symptom score ≥90th 
percentile, (d) TSH and symptom score ≥90th percentile. ADHD, attention-deficit hyperactivity disorder; AL-
SPAC, Avon Longitudinal Study of Parents and Children; CI, confidence interval; FT4, free thyroxine; INMA, 
Infancia y Medio Ambiente; OR, odds ratio; TSH, thyrotropin.
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Supplementary Table 3 Association of maternal FT4 during early pregnancy with child ADHD
symptom scores on a continuous scale.
n IRR (95% CI) p-value
INMA 1063 1.05 (0.98 to 1.14) 0.187
Generation R 3657 0.98 (0.95 to 1.01) 0.204
ALSPAC 2710 0.99 (0.92 to 1.06) 0.692
Reported IRR and 95% CIs represent the change in ADHD symptoms per SD of log-transformed FT4 in terms 
of a percentage increase or decrease, with the precise percentage determined by the amount the IRR is either 
above or below 1. Analyses were performed using negative binomial regression models and adjusted for gesta-
tional age at blood sampling, maternal education, maternal ethnicity/country of birth, age, parity, smoking dur-
ing pregnancy, pre-pregnancy body mass index, child sex, child age, and sub-cohort in INMA. CI, confidence 
interval; IRR, incidence rate ratio.
Supplementary Table 4 Continuous association of maternal TSH during early pregnancy with child
ADHD symptom scores on a continuous scale.
n IRR (95% CI) p-value
INMA 1055 0.94 (0.87 to 1.02) 0.144
Generation R 3630 1.00 (0.97 to 1.03) 0.928
ALSPAC 2687 0.97 (0.91 to 1.03) 0.282
Reported IRR and 95% CIs represent the change in ADHD symptoms per SD of log-transformed TSH in terms 
of a percentage increase or decrease, with the precise percentage determined by the amount the IRR is either 
above or below 1. Analyses were performed using negative binomial regression models and adjusted for gesta-
tional age at blood sampling, maternal education, maternal ethnicity/country of birth, age, parity, smoking dur-
ing pregnancy, pre-pregnancy body mass index, child sex, child age, and sub-cohort in INMA. CI, confidence 
interval; IRR, incidence rate ratio.
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Severe maternal iodine deficiency during pregnancy can lead to dwarfism and intellectual dis-
ability (i.e., cretinism). Despite increasing efforts to eliminate iodine deficiency and prevent 
thyroid-related diseases world-wide, mild-to-moderate iodine deficiency is still common, 
especially in pregnant women. The potential effects of mild-to-moderate iodine deficiency 
during pregnancy for thyroid function and child neurodevelopment are less well known. 
For this reason, the aims of this thesis were to explore the determinants of iodine status, to 
examine the association of maternal iodine status with thyroid function during pregnancy, and 
to investigate if maternal iodine status and thyroid function during pregnancy are associated 
with child neurodevelopment outcomes. In this chapter the main results will be discussed in 
light of methodological considerations, together with the clinical implications and sugges-
tions for further research.
Main findings and interpretation
Determinants of iodine status
In chapter 2, we demonstrated that younger women, with a higher pre-pregnancy BMI, and 
with low intake of milk and dairy products are more likely to have a low urinary iodine-to-
creatinine ratio (UI/Creat) during pregnancy. We also identified cohort-specific determinants 
of maternal UI/Creat, such as intake of fish and shellfish in INMA and ALSPAC, and intake 
of eggs and cereal products in Generation R. The cohort-specific associations may be a reflec-
tion of differences between populations in the consumption of dietary iodine sources (i.e., 
the average fish consumption is higher in INMA and ALSPAC than in Generation R), the 
availability of iodized salt (i.e., the estimated penetration rate of iodized salt in household is 
60-70% in the Netherlands, 16% in Spain, and 2% in the UK 1; eggs are assumed to be eaten 
with salt), and the implemented iodine fortification program in the specific countries (i.e., 
bread is fortified with iodized salt in the Netherlands, and therefore a great source of iodine in 
this population 2). These cohort-specific associations of maternal characteristics and dietary 
habits with iodine status suggest that public health interventions targeted to achieve iodine 
sufficiency in pregnancy probably need to be country-specific.
Iodine status and maternal thyroid function
In Chapter 3, we showed that in a population of 2009 pregnant women with a median UI/
Creat of 85 µg/g (indicating mild-to-moderate iodine deficiency during pregnancy), the 
clinical reference ranges of thyroid function tests were not meaningfully different among 
subgroups of women differing in iodine status. We therefore question the current recom-
mendation to calculate reference ranges for thyroid function during pregnancy solely in 
iodine sufficient populations. Furthermore, we examined the cross-sectional associations 
of maternal UI/Creat with TSH, FT4, FT3, TT4, TT3, TPOAb and TgAb positivity. Lower 
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iodine availability was associated with a slightly higher TT4 and a lower TSH, while women 
with adequate iodine intake (i.e., UI/Creat of 150-249 µg/g) had the lowest risk of TPOAb 
positivity. The latter results are in line with the current recommendations that define an iodine 
concentration between 150-249 µg/L as optimal during pregnancy 3. The lack of an associa-
tion of UI/Creat with the FT4/FT3 and TT4/TT3 ratios indicated that there was no increase 
in T3 over T4 secretion or higher peripheral deiodination of T4, both well-known adaptive 
mechanisms to chronic low iodine intake. The severity of iodine deficiency in this population 
may have been too mild to deplete the intra-thyroidal iodine storage and thus caused no shift 
in these ratios. Unfortunately, we could not study if the mild changes in thyroid function that 
were found in our study (i.e., higher TT4 and TPOAb positivity), were also associated with 
neurodevelopmental outcomes in the offspring from the SELMA cohort. Hence, we can only 
speculate about the clinical relevance of the observed associations. The association of TT4 
during pregnancy with child neurodevelopmental outcomes has not yet been studied in great 
detail, though research in the iodine sufficient Generation R cohort showed that TT4 was not 
associated with child IQ after correction for FT4 4. TPOAb positivity during pregnancy has 
been associated with pregnancy outcomes, such as preterm birth 5, and with a higher risk of 
ADHD 6, and a lower IQ score in the offspring 7. The latter was however only observed in the 
iodine sufficient population of Generation R but not in the mild-to-moderate iodine deficient 
population of ALSPAC.
Maternal iodine status and child neurodevelopment
In chapter 4.1, a pooled analysis of individual-participant data in 6180 mother-child pairs 
showed a positive curvilinear association of UI/Creat with mean verbal IQ. The results further 
suggested that particularly the first 14 weeks of gestation constitute a vulnerable period for 
fetal exposure to maternal iodine deficiency. This supports the notion that it is important 
for pregnant women to have adequate iodine stores in early or even before pregnancy. We 
were unable to show that the association of maternal iodine status with child verbal IQ was 
mediated through maternal thyroid function; UI/Creat was not associated with TSH or FT4. 
The absence of such an association might be explained through possible flaws of UI/Creat 
as a proxy for individual iodine status or thyroidal iodine availability, or suggest that the 
association is mediated by fetal thyroid function. Iodine “deficiency” (i.e., UI/Creat below 
150 µg/g) and iodine “excess” (i.e., UI/Creat above 150 µg/g) were not associated with lower 
verbal or non-verbal IQ. In chapter 4.2, we describe that there is no evidence for an associa-
tion between iodine deficiency during pregnancy and the child’s ADHD or autistic traits. The 
associations of maternal FT4 or TSH with ADHD or autistic traits did not depend on maternal 
iodine status.
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Maternal thyroid function and child neurodevelopment
In chapter 5.1, our meta-analysis of individual-participant data in 9036 mother-child pairs 
showed that low maternal FT4 in early pregnancy was associated with lower non-verbal 
and verbal child IQ scores. The association of low FT4 with the non-verbal IQ score was 
robust in all three cohorts, showing a 3.9-point lower non-verbal IQ score in children born to 
women with FT4 <2.5th percentile as compared with those born to women with FT4 between 
the 25th to 75th percentile range. We could not replicate the association of high FT4 with 
lower non-verbal IQ that had previously been demonstrated in the Generation R cohort 8. 
Firm conclusions about the association of maternal thyroid function with autistic traits could 
not be made due to the small number of children scoring within the clinical range and the 
inconsistency of the results when using different cut-off values in the extreme ends of the 
FT4 distribution. In chapter 5.2, we show that in 7669 mother-child pairs maternal TSH 
or FT4 was not associated with child ADHD or with high ADHD symptom scores. Further 
investigation of effect modification by gestational age showed no consistent differential effect 
across the two outcomes.
No association was observed between TSH and IQ, ADHD, or autistic traits in any of 
the studies published in chapter 5. We therefore question whether maternal FT4 is a better 
marker for fetal thyroid state than maternal TSH. However, recent analysis in the Generation 
R cohort showed that maternal TSH was associated with brain imaging by MRI, which is an 
objective reproducible measure of brain development 9.
While non-verbal IQ is a language- and culture-free measure of cognitive ability which is 
less dependent on the learning stimulus received by the child during the first years of life, it is 
somewhat surprising that maternal iodine status was not associated with child non-verbal IQ, 
considering that low FT4 was associated with lower child non-verbal IQ. Our results show 
an association of lower maternal UI/Creat with lower child verbal IQ instead, suggesting that 
maternal iodine status potentially affects child neurodevelopment in a specific manner. Why 
this would be the case, requires further investigation regarding the underlying mechanisms. 
We speculate that the association between maternal iodine status and child verbal IQ may 
be explained through effects of mild iodine deficiency, via thyroid hormone, on the auditory 
system 10,11, but this requires further study.
Methodological considerations
Exposure assessment
As a proxy measurement for thyroidal iodine availability, we have used one to four measure-
ments of urinary iodine concentration in pregnant women, which we divided by the creatinine 
concentration to take urine dilution into account. The urinary iodine concentration in a single 
spot urine sample is known to fluctuate based on diet, and reaches a peak concentration ap-
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proximately 4-5 hours after meals 12. In large populations, this day-to-day variation in iodine 
intake, and thus the random measurement error, is balanced out in a median value of spot 
urinary iodine concentration 13. The precision by which the iodine status of a population 
can be determined, increases with the number of individuals included. For instance, a study 
showed that the mean iodine excretion in a population can be estimated with a 5% or 2% 
precision range if from 489 or 3054 individuals a spot urine sample is collected, respectively 
14. Because the number of individuals included in the birth cohort studies in this thesis is 
large, it seems safe to say that we have estimated the iodine status of these populations with 
high precision. Another important factor in determining individual iodine status, is timing of 
urine collection. For example, early morning urine void tends to underestimate daily iodine 
excretion 15. In SELMA, early morning urine void was collected in all women, and in INMA 
(i.e., INMA Valencia) fasting urine samples were collected 16, but it is unsure whether these 
were overnight fasting samples. In Generation R and ALSPAC, urine was obtained at random 
moments during the day. It remains unsure whether potential timing of sampling significantly 
affected the population status, and whether this error was random or more common in sub-
groups of women that gave birth to children with lower IQ scores or neurodevelopmental 
problems.
In general, random measurement error in the exposure flattens the slope of the regression 
line, resulting in a regression coefficient biased towards the null 17. To minimize random 
measurement error in the exposure variable, one could obtain repeated measurements or use 
a biomarker, if available, that better reflects the exposure. For individual iodine status, more 
research should be performed into thyroglobulin, which is a protein from which thyroid hor-
mones are formed 18, as a biomarker for individual iodine status. In children, reference ranges 
of blood spot thyroglobulin have been made available in iodine-sufficient children, and a 
median blood spot thyroglobulin concentration above 40 Ig/L has been suggested to reflect 
adequate iodine status 19. In pregnant women, thyroglobulin may be a sensitive biomarker 
of individual iodine status 20, but references ranges have yet to be defined. Alternatively, 
individual iodine status can be determined by repeated measurements. Research suggests that 
if 10 or 55 urine spot samples were obtained from each individual over a period of time, we 
could calculate the mean iodine excretion for this individual with a 25% or 10% precision 
range (e.g., if the mean iodine excretion was 200 µg/L, then the true iodine excretion with 
a 25% precision range would be between 150-250 µg/L) 14. Determining individual iodine 
status by a limited number of repeated measurements is unlikely to be very precise (i.e., 1 to 
4 samples were obtained from mothers from the cohorts included in this thesis; the precision 
range would be approximately 40 to 50%).
Next, as a proxy of the fetal exposure to maternal thyroid hormone we used maternal serum 
TSH or FT4 concentrations measured before mid-gestation. FT4 was measured using im-
munoassays and may potentially have under- or overestimated the true concentration due 
to immunoassay interference 21–23. Owing to the use of different assays and reference ranges 
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between the cohorts, the absolute value of the thyroid function tests could not be compared 
across cohorts and standardization of both the TSH and FT4 concentration was necessary.
Outcome assessment
The assessment of the outcome is likely subject to measurement error. We have used IQ 
scores and child behavioral problems as outcomes related to fetal brain development. These 
outcomes were assessed with validated tests or questionnaires. While each child was ad-
ministered an IQ test, their behavior, i.e., ADHD symptoms and autistic traits, was assessed 
through questionnaires filled in by parents and/or teachers. The assessment of child behavior 
may be a more subjective dimension of health than IQ, because every informant may have 
different perspectives on behavior. This may be influenced by the behavior required in a 
particular setting. With regards to ADHD, the international DSM-IV criteria require that at-
tention and/or hyperactivity symptoms cause some impairment in at least two settings, e.g., 
at home, work, or school 24. Due to low-to-moderate agreement between teacher and parental 
observations, multi-informant assessment has been recommended in order to understand the 
behavior of a child more completely 25,26. However, ADHD symptoms were assessed by a 
single informant in the cohorts included in this thesis, with exception of a proportion of 
children in ALSPAC. Potentially, random error in the assessment of ADHD may therefore 
have been higher in INMA and Generation R than in ALSPAC. In general, random error in 
the outcome measurements may lead to wider confidence ranges as a result of higher standard 
error, and as such, there is a higher chance to obtain statistically non-significant associations. 
By increasing the sample size, precision of the estimates can be retained. Again, bias can only 
be introduced if the degree of random measurement error is uneven between the cases [i.e., 
those with ADHD or autistic traits above the (validated) cut-off] and the controls [i.e., those 
without ADHD or autistic traits below the (validated) cut-off]. However, due to the natural 
course of cohort studies, it is unlikely that the misclassification of children depended on the 
exposure status during pregnancy, since the exposure status was unknown to the assessors.
The accuracy of a meta-analysis
With the growing number of individual studies, meta-analyses are useful to summarize the 
existing evidence from often small studies into an overall pooled estimate. This may enhance 
evidence-based policy decisions, a re-evaluation of clinical practice guidelines, or be an 
incentive for further research. The individual studies that are used for a meta-analysis will, 
to some extent, be heterogeneous. The pregnant populations of INMA, Generation R, and 
ALSPAC differed in maternal and child characteristics, maternal iodine status, the assays 
that were used to measure iodine status and thyroid function, and in the outcome assess-
ment. Heterogeneity across studies can be minimized by using individual participant data, 
so that similar in- and exclusion criteria can be applied and the data and analyses can be 
harmonized. But even then, there will be some degree of heterogeneity. In this thesis, we 
210 Chapter 6
have performed random-effects meta-analyses instead of fixed-effects meta-analyses, because 
a random-effects meta-analysis does not assume that differences in effect estimates across 
cohorts is due to chance only. There are three types of heterogeneity: clinical (e.g., differ-
ences related to the population characteristics, interventions, and outcomes), methodological 
(e.g., differences in how the study was conducted and the risk of bias), and statistical. There 
are currently no criteria to check the degree of clinical and methodological heterogeneity 
27. In contrast, statistical heterogeneity can be assessed by the I2 statistic, which indicates 
the percentage of variability across studies due to heterogeneity rather than chance28. If the 
degree of heterogeneity is unknown, a high percentage of I2 (i.e., ≥75%) indicates that studies 
are highly heterogeneous and in the absence of strict criteria, it is up to the meta-analysist to 
decide whether the meta-analysis is meaningful or if it is better to present the cohort-specific 
effect estimates only27. While several meta-analyses included in this thesis showed moderate 
statistical heterogeneity (i.e., I2 ~ 50%), the only meta-analysis which showed a high I2 of 
77.7% was of the association of maternal UI/Creat with child autistic traits in those with at 
least one measure of UI/Creat in the first 14 weeks of pregnancy (chapter 4.2). This finding 
should therefore be interpreted with caution.
Clinical implications
Should we be concerned about mild-to-moderate iodine deficiency during 
pregnancy?
There has been increased international support for the elimination of iodine deficiency 
disorders since 1990, which led to the endorsement of universal salt iodization as the most 
cost-effective preventive measure in 1994. Although great improvement has been made in 
the last 2-3 decades, iodine deficiency is still common among pregnant women, even in 
countries with a mandatory or voluntary iodine fortification program 29–31. According to the 
global iodine status in 2017, 39 out of 72 countries (54.2%) reported insufficient iodine intake 
in pregnant women (i.e., median UIC < 150 µg/L) 31,32. Because this public health problem 
remains to exist, the EUthyroid consortium, and other signatories of the Krakow Declaration 
on Iodine, have called on governments, public health authorities, the food industry, scientists, 
and health professionals for what they think is needed towards the elimination of iodine 
deficiency disorders: obligatory universal salt iodization, harmonized monitoring and evalua-
tion of fortification programs across countries, and public information campaigns 33.
The results of this thesis indicate that mild-to-moderate iodine deficiency during pregnancy 
is associated with a higher risk of TPOAb positivity, but not with meaningful alterations in 
other thyroid function tests. Lower iodine status in the first 14 weeks of gestation was associ-
ated with lower mean child verbal IQ scores. Our research therefore suggests that adequate 
iodine intake in early pregnancy is important for fetal brain development. One of the means 
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of achieving adequate iodine intake in pregnancy, is iodine supplementation. In the United 
Kingdom, a country without an iodine fortification program or supplementation recommen-
dation, universal iodine supplementation before, during, and right after pregnancy has been 
estimated to hypothetically increase child IQ with 1.2 IQ points 34. However, randomized 
controlled trials have thus far failed to show any benefit of daily iodine supplementation dur-
ing pregnancy for child IQ. The most recent randomized, placebo-controlled trial conducted 
in Thailand and India, showed no statistical difference in child non-verbal or verbal IQ scores 
at a mean age of 5.4 years of daily supplementation with 200 µg iodine as potassium iodide 
of mildly iodine-deficient women 35. It should be noted however that pregnant women from 
India included in this trial were not iodine deficient at baseline (i.e., median UIC of 188 μg/L) 
and that treatment only started at a mean gestational age of 10.7 weeks 36. Two other random-
ized trials also showed no benefit of treatment, but these were underpowered 37,38. Several 
non-randomized trials in mild-to-moderate iodine deficient regions showed mixed results for 
benefits of iodine supplementation for neurodevelopment 39–41. Two of the studies suggest 
benefits of a maternal intake of 200 or 300 µg of iodine supplements for child neurodevelop-
ment up to 2 years of age 39,40. Another study, without placebo group, found no difference in 
child neurodevelopmental outcomes if the mother used iodized salt or took iodine containing 
supplements of either 150 µg or 230 µg per day 41.
If a future randomized placebo controlled trial were to be designed, then our results indicate 
that supplementation should not start later than the first trimester. Iodine supplementation 
may even need to be started before conception, as there is evidence that a late start of iodine 
supplementation (i.e., between week 13-20 of gestation) is associated with a lower FT4 con-
centration than when supplementation is initiated preconceptionally 42, and pre-pregnancy 
iodine status has been associated with child IQ 43. A future randomized placebo controlled 
trial should be performed in a country which has not yet introduced iodine supplementation 
recommendations.
Should mild maternal thyroid dysfunction be treated?
Our results clearly indicate that mild maternal thyroid dysfunction, particularly low FT4, is 
associated with lower IQ scores in the offspring. From an individual point of view, lower IQ 
may lead to poorer academic achievements. From a public health perspective, IQ loss in a 
population may have economic implications. A loss of 5 IQ points has been estimated to cost 
$30 billion per year in Canada and $275 billion to $326 billion per year in the United States 
44. In clinical practice, TSH, but not FT4, is used as the first line parameter to screen maternal 
thyroid status at the first prenatal consultation. Even though our results suggest that screening 
for FT4 may need to be considered, evidence is first needed from randomized controlled trials 
on the benefits of screening and subsequent levothyroxine treatment of women with mild 
thyroid dysfunction during pregnancy for child neurodevelopment.
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Randomized controlled trials have yet to show benefit of treatment. The CATS trial was 
the first to investigate the treatment effect of levothyroxine (LT4) administration in pregnant 
women with subclinical hypothyroidism or hypothyroxinemia on child neurodevelopment 
45. Women with these mild types of thyroid dysfunction were randomized to either standard 
care (control group) or treatment with 150 µg of levothyroxine per day, which was initiated 
at a median gestational age of 13 weeks and 3 days. The offspring of these women underwent 
neuropsychological testing when they were 3 and 9.5 years of age 45,46. This trial found no 
statistical significant difference in IQ score between the control and treatment group at both 
time points in childhood. One of the explanations for the absence of effect may be that the 
dose of levothyroxine was not optimal. During the course of pregnancy, the dose had to be 
lowered or increased in 10% and 5% of women due to signs of side-effects, respectively. 
In two other randomized controlled trials, women with subclinical hypothyroidism were 
randomized to placebo or instructed to take 100 µg of levothyroxine daily, while women 
with hypothyroxinemia were randomized to placebo or treatment with a dose of 50 µg of 
levothyroxine per day 47. The primary outcome was the child IQ score at the age of 3 or 5 
years. Though a 3-point difference in IQ was observed in both trials between the treatment 
and the placebo group, this difference did not reach statistical significance. The absence of 
a statistical difference may have to do with the fact that these trials were only powered to 
detect a difference of 5 IQ points; an expected effect size which was based on the 7 IQ point 
difference between children born to treated or untreated women with overt hypothyroidism 48. 
Another concern was that treatment was started relatively late - week 16 and 4 days of gesta-
tion for subclinical hypothyroidism and week 18 for hypothyroxinemia. This may have been 
too late to result in a beneficial effect because adequate maternal thyroid hormone transfer to 
the fetus is especially important for fetal brain development during the period when the fetal 
thyroid is not functionally mature yet (i.e., before mid-gestation).
How could observational studies help to design future randomized clinical 
trials?
Observational studies can inform on what is a realistic IQ difference between the treated and 
untreated group. A realistic expected effect size is essential for adequate power calculations. 
The study in chapter 5.1 showed that hypothyroxinemia during pregnancy is associated with 
a 2 to 4 point IQ difference, depending on the cut-off values used and the type of IQ score. 
As a consequence, a marked difference of 5 IQ points or higher may not be a realistic aim 
for studies that investigate the effect of treatment of mild gestational thyroid dysfunction. In 
addition, observational studies can help to identify vulnerable periods for exposure to inad-
equate thyroid hormone concentrations. This can provide more insight into the optimal timing 
of treatment. The most vulnerable periods could be investigated by testing for differential ef-
fects by gestational age. If thyroid function tests are performed repeatedly during pregnancy, 
observational studies can also provide a better understanding of how the duration of thyroid 
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dysfunction is associated with offspring neurodevelopmental outcomes. Unfortunately, most 
cohorts only have a single measurement available. To our knowledge, a study with repeated 
thyroid function measurements in relation to child neurocognitive outcomes has only been 
performed once and showed that low a FT4 concentration at week 12, but which increased 
during pregnancy, was associated with better mental and motor function scores at the age of 2 
years than when FT4 remained low at week 24 and week 32 of gestation 49.
Future research
The urinary iodine concentration is commonly used as a marker for iodine status of popula-
tions. However, due to high day-to-day variability of urinary iodine concentrations 14,50,51, 
a reliable marker of individual iodine status is currently missing. Future studies should 
investigate whether thyroglobulin (and possible other new potential biomarkers) could be 
used during pregnancy as a marker for individual iodine status. Studies need to examine the 
dose-dependent effects of iodine or levothyroxine supplementation on thyroid function to 
investigate the optimal dose for treatment and examine if treatment during pregnancy, well 
before the fetal thyroid is fully functional (i.e., at mid-gestation), would be beneficial for child 
neurodevelopment.
Conclusion
The results of this thesis suggest:
• that public-health interventions focusing on improving the dietary iodine intake of preg-
nant women need to follow a country-specific approach, taking into account differences 
in dietary habits.
• that mild-to-moderate deficiency are not associated with meaningful variation in clinical 
reference ranges of thyroid function tests.
• that mild-to-moderate iodine deficiency may not be severe enough to evoke adaptive 
mechanisms to chronic low iodine intake (e.g., preferential production of T3).
• that maternal iodine status in particularly the first 14 weeks of gestation constitute a 
vulnerable period for fetal exposure to maternal iodine deficiency.
• that there is consistent evidence for a role of maternal thyroid hormone in normal brain 
development.
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Summary
Chapter 1 provides a brief background about the importance of thyroid hormone for fetal 
brain development and the role of severe iodine deficiency therein. The regulation of thyroid 
hormone production through the hypothalamic-pituitary-thyroid axis is explained as well as 
the scientific evidence underlying the guidelines for the management of thyroid dysfunction 
during pregnancy. Relevant knowledge gaps concerning the potential effects of mild-to-
moderate iodine deficiency for maternal thyroid function during pregnancy and fetal brain 
development are mentioned. Lastly, the aims of the thesis, the setting, and the outline of the 
thesis are described.
In chapter 2, we explore what are the determinants of maternal iodine status during 
pregnancy and whether these are similar across mild-to-moderate iodine deficient and iodine 
sufficient pregnant populations. We show that younger women, with a higher pre-pregnancy 
BMI, and with low intake of milk and dairy products were more likely to have low urinary 
iodine excretion during pregnancy. Cohort-specific determinants were also identified, such 
as the intake of fish and shellfish in INMA and ALSPAC (mild-to-moderate iodine deficient 
populations), and the intake of eggs and cereal products in Generation R (iodine sufficient 
population). These cohort-specific associations of maternal characteristics and dietary habits 
with urinary iodine excretion suggest that public health interventions targeted at achieving 
iodine sufficiency in pregnancy may need to be country-specific.
In chapter 3, we investigate the association between maternal iodine status and maternal 
thyroid function in a mild-to-moderate iodine deficient population and determine whether 
there is variation in thyroid function reference ranges according to iodine status. We show that 
lower iodine availability is associated with a slightly higher total thyroxine (TT4) and a lower 
thyroid stimulating hormone (TSH) concentration, while women with adequate iodine intake 
have the lowest risk of thyroid peroxidase antibody positivity. The lack of an association of 
iodine status with the free T4/free triiodothyronine (FT4/FT3) and TT4/TT3 ratios indicate no 
evidence for an increase in T3 secretion or higher peripheral de-iodination of T4, which are 
adaptive mechanisms to chronic low iodine intake. The clinical reference ranges of thyroid 
function tests are found not to be meaningfully different in subgroups of women differing in 
iodine status.
In chapter 4, we study the association between maternal iodine status and child neurode-
velopmental outcomes. Chapter 4.1 shows that in a pooled analysis of individual-participant 
data, lower iodine availability is associated with a lower mean child verbal IQ score. Also dif-
ferential effects by gestational age are detected, suggesting that the first 14 weeks of gestation 
potentially constitute a vulnerable period for fetal exposure to maternal iodine deficiency. In 
chapter 4.2, we describe that we find no evidence for an association between iodine deficiency 
during pregnancy and a greater risk of offspring ADHD or autistic traits. The associations of 
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the maternal FT4 or TSH concentrations with ADHD or autistic traits did not depend on 
maternal iodine status.
In chapter 5, we examine the association of maternal thyroid function with child neurode-
velopmental outcomes. In chapter 5.1, our meta-analysis of individual-participant data shows 
that a low maternal FT4 concentration in early pregnancy is associated with lower mean 
child verbal and non-verbal IQ scores; the latter association being robust in mild-to-moderate 
iodine deficient and iodine sufficient populations. Firm conclusions about the association of 
maternal thyroid function with autistic traits could not made. In chapter 5.2, we show that the 
maternal TSH or FT4 concentrations during pregnancy are not associated with child ADHD.
Chapter 6 provides a general discussion of the main results and their interpretation, meth-
odological considerations, clinical implications, and suggestions for further research.
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Samenvatting
Hoofdstuk 1 geeft een korte achtergrond over het belang van schildklierhormoon voor de 
ontwikkeling van de foetale hersenen en de rol die ernstige jodium deficiëntie daarin speelt. 
De regulatie van de schildklierhormoon balans door de hypothalamus-hypofyse-schildklier-
as wordt uitgelegd, evenals het wetenschappelijk bewijs dat ten grondslag ligt aan de richt-
lijnen voor de behandeling van schildklierafwijkingen tijdens de zwangerschap. Relevante 
ontbrekende kennis wordt genoemd met betrekking tot de potentiële effecten van milde tot 
matige jodium deficiëntie voor de schildklierfunctie van de moeder tijdens de zwangerschap 
en de ontwikkeling van de foetale hersenen. Ten slotte worden de doelen en de opzet van het 
proefschrift besproken.
In hoofdstuk 2 onderzoeken we wat de determinanten zijn van de jodiumstatus van zwan-
gere populaties en of deze vergelijkbaar zijn in populaties die gemiddeld mild tot gematigd 
jodium deficiënt of jodium sufficiënt zijn. We laten zien dat jongere vrouwen, met een 
hogere BMI vóór de zwangerschap en met een lage inname van melk en zuivelproducten, 
een grotere kans hadden om tijdens de zwangerschap een lage urine-excretie van jodium te 
hebben. Cohort-specifieke determinanten werden ook geïdentificeerd, zoals de inname van 
vis en schaaldieren in INMA en ALSPAC (mild tot matig jodium deficiënte populaties), en de 
inname van eieren en graanproducten in Generation R (jodium sufficiënte populatie). Deze 
cohort-specifieke associaties van maternale kenmerken en voedingsgewoonten met urine-
excretie van jodium suggereren dat interventies gericht op het bereiken van jodium sufficiënte 
tijdens de zwangerschap mogelijk per land moeten verschillen.
In hoofdstuk 3 onderzoeken we het verband tussen maternale jodiumstatus en maternale 
schildklierfunctie in een milde tot matige jodium deficiënte zwangere populatie en bepalen 
we of er verschillen zijn in de schildklier referentiewaarden op basis van de jodiumstatus. We 
laten zien dat een lagere urine-excretie van jodium geassocieerd is met een iets hogere totale 
thyroxine concentratie (TT4) en een lagere concentratie van schildklier stimulerend hormoon 
(TSH), terwijl vrouwen met een adequate jodiuminname het laagste risico op positieve 
schildklierautoantistoffen hebben. Het ontbreken van een verband tussen de jodiumstatus en 
de vrije T4 tot vrije trijodothyronine (FT4 / FT3) verhouding of de TT4 tot TT3 verhouding 
duiden niet op aanwijzingen voor een toename in de T3-productie of een hogere perifere 
dejodinatie van T4, wat adaptieve mechanismen zijn bij een chronische lage jodiuminname. 
De klinische referentiewaarden van schildklierfunctietests blijken niet erg anders te zijn in 
subgroepen van vrouwen met een verschillende jodiumstatus.
In hoofdstuk 4 bestuderen we de associatie tussen maternale jodiumstatus en neurolo-
gische uitkomsten van het kind. Hoofdstuk 4.1 laat zien dat in een gepoolde analyse van 
gegevens van individuele deelnemers, lagere urine-excretie van jodium geassocieerd is met 
een lager gemiddeld verbale IQ score van kinderen. Deze associatie lijkt afhankelijk te zijn 
van de week van de zwangerschap, want de resultaten suggereren dat de eerste 14 weken 
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van de zwangerschap mogelijk een kwetsbare periode vormen voor foetale blootstelling aan 
maternale jodiumdeficiëntie. In hoofdstuk 4.2 beschrijven we dat we geen bewijs vinden voor 
een verband tussen jodiumtekort tijdens de zwangerschap en een groter risico op ADHD of 
autistische trekken bij het kind. De associaties van de maternale FT4 of TSH concentraties 
met ADHD of autistische trekken waren niet afhankelijk van de jodiumstatus van de moeder 
tijdens de zwangerschap.
In hoofdstuk 5 onderzoeken we de associatie van maternale schildklierfunctie met neu-
rologische uitkomsten van het kind. In hoofdstuk 5.1 laat onze meta-analyse van gegevens 
van individuele deelnemers zien dat een lage maternale FT4 concentratie in de vroege zwan-
gerschap geassocieerd is met een lager gemiddeld verbale en non-verbale IQ score van het 
kind, waarbij de laatste associatie robuust is in milde tot matige jodium-deficiënte en jodium 
sufficiënte populaties. Harde conclusies over de associatie van maternale schildklierfunctie 
met autistische trekken konden niet worden getrokken. In hoofdstuk 5.2 laten we zien dat 
de maternale TSH of FT4 concentraties tijdens de zwangerschap niet geassocieerd zijn met 
ADHD van het kind.
In hoofdstuk 6, de discussie van het proefschrift, worden de belangrijkste resultaten en 
hun interpretatie besproken, als ook enkele methodologische overwegingen, de klinische 
implicaties en suggesties voor toekomstig onderzoek.
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